Heterocyclic compounds, compositions thereof, and methods of treatment thereof
By providing a specific heterocyclic compound, the KRAS G12V mutant protein can be selectively inhibited, and the problem of difficult inhibition of KRAS G12D and G12V mutant proteins in the prior art is solved, and effective treatment or prevention of KRAS-dependent cancers is achieved.
Patent Information
- Application Number
- CN202380028687.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-24
- Filing Date
- 2023-03-23
- Publication Date
- 2024-11-05
AI Technical Summary
The prior art is difficult to selectively inhibit the activity of KRAS G12D and G12V mutant proteins, resulting in limited therapeutic effects on pancreatic cancer and other KRAS-dependent cancers.
Provided is a heterocyclic compound that inhibits its activity by contacting KRAS mutant proteins, and is used to treat or prevent cancer caused by KRAS mutations. The specific compound structure is a compound with a specific ring structure and substituent group, which is selective. Inhibiting KRAS G12V mutant protein.
This compound can effectively inhibit the activity of KRAS mutant proteins and provides a potential therapeutic strategy for KRAS-dependent cancers, especially for pancreatic cancers.
Smart Images

Figure CN118900838A_ABST
Abstract
Description
Technical Field
[0001] Provided herein are heterocyclic compounds useful for treating cancer, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer or disorders that can be treated or prevented by inhibiting KRAS G12V activity, the methods comprising administering an effective amount of the compound to a subject in need thereof. Background Art
[0002] Ras is a family of proteins associated with the cell membrane through its C-terminal membrane targeting region, and is well known as a molecular switch in the intracellular signaling network (Cox AD, Der CJ. Ras history: The saga continues. Small GTPases. 2010; 1 (1): 2-27). Ras protein binds to GTP or GDP and switches between "on" and "off" states. When Ras protein binds to GDP, it is in a closed (or inactive) state. And when Ras is turned on by certain growth-promoting stimulants such as growth factors, Ras protein will be induced to exchange its bound GDP for GTP and become an open (or active) state (Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003; 3 (6): 459-465). By switching to an activated state, Ras proteins can interact with different downstream proteins and activate related signaling pathways (Berndt N, Hamilton AD, Sebti SM. Targeting protein prenylation for cancer therapy. Nat Rev Cancer. 2011; 11(11): 775-791). The Ras superfamily contains different subfamilies, including Ras, Ral, Ra p, Rheb, Rad, Rit, and Miro (Wennerberg K, Rossman KL, Der CJ. The Ras superfamily at a glance. J Cell Sci. 2005; 118(Pt 5): 843-846). HRas, NRas, and KRas are the most studied proteins in the Ras family because these proteins are the most common oncogenes in human cancers (O'Bryan JP. Pharmacological targeting of RAS: Recent success with direct inhibitors. Pharmacol Res. 2019; 139: 503-511).
[0003] KRas is one of the most common mutated genes in human cancer. Based on data from the Catalog of Somatic Mutations (COSMIC) database, KRas mutations can be found in about 20% of human cancers, including pancreatic cancer, colorectal cancer, lung cancer, skin cancer, etc. (O'Bryan JP.Pharmacological targeting of RAS: Recent success with direct inhibitors.Pharmacol Res.2019; 139: 503-511). By blocking the GTP hydrolysis activity stimulated by the GTPase activating protein (GAP) of KRas, the most common KRas mutations were found at positions G12 and G13 (Wang W, Fang G, Rudolph J. Ras inhibition via direct Ras binding--is there a path forward?. Bioorg Med Chem Lett.2012; 22 (18): 5766-5776). This leads to overactivation of KRas protein, and ultimately leads to uncontrolled cell proliferation and cancer.
[0004] Among different cancers, pancreatic cancer is considered to be the most KRas-dependent cancer type. KRas mutations were found in 94.1% of pancreatic ductal adenocarcinomas (PDAC). KRas G12D (41%) and G12V (34%) mutations are the two most common mutations in all KRas-mutated PDACs (Waters AM, Der CJ. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med. 2018; 8 (9): a031435). In vivo data generated by mouse models have shown that the progression and maintenance of pancreatic cancer is highly dependent on the constitutive activation of KRas downstream signals (Siveke JT, Schmid RM. Chromosomal instability in mouse metastatic pancreatic cancer--it's Kras and Tp53 after all. Cancer Cell. 2005; 7 (5): 405-407). This suggests that mutant KRas proteins are attractive drug targets for pancreatic cancer and other cancers with KRas mutations. Since WT KRas proteins also play a key role in the function of normal tissues, and WT KRas function has been shown to be necessary for adult hematopoiesis (Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003; 3(6): 459-465), it is very worthwhile to find a potential drug molecule that can selectively inhibit mutant KRas proteins in cancer cells and retain their WT partners in normal cells.
[0005] Therefore, KRas G12D and G12V mutations are highly attractive targets for pancreatic cancer and other cancers with this mutation. Therefore, small molecule therapeutics that can selectively bind to KRas G12D and / or G12V and inhibit their function would be considered an attractive strategy for targeting cancers with this mutation.
[0006] Citation or identification of any reference in this section shall not be construed as an admission that such reference is prior art to the present application. Summary of the invention
[0007] Provided herein are compounds having the following formula (I):
[0008]
[0009] and pharmaceutically acceptable salts, tautomers, stereoisomers, enantiomers, atropisomers, isotopomers and prodrugs thereof,
[0010] in:
[0011] Ring A is
[0012] X is N or CR 2 ;
[0013] Y is N or C-CN;
[0014] Z is N or CR 3 ;
[0015] W is N or CR 5 ;
[0016] V is N or CR 7 ;
[0017] R 1 Yes - NR 1a R 1b ;
[0018] R 2 is halogen, or unsubstituted or substituted alkyl;
[0019] R 3 is halogen, or unsubstituted or substituted alkyl;
[0020] R 4 is halogen, -NO2, or unsubstituted or substituted alkyl;
[0021] R 5 is hydrogen, halogen or -CN;
[0022] R 7 is hydrogen, halogen or -CN;
[0023] R 8 , R 9 and R 10 Each of is independently hydrogen, halogen, unsubstituted or substituted alkyl or -OH;
[0024] R 1a and R 1b are each independently hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocyclylalkyl, provided that R 1a and R 1b Not all hydrogen; or
[0025] R 1a and R 1bTogether with the nitrogen atom to which they are attached they form an unsubstituted or substituted heterocyclic group.
[0026] In one embodiment, the compound of formula (I) is wherein Ring A is In one embodiment, Y is N. In one embodiment, Y is C-CN. In one embodiment, X is CR 2 In one embodiment, R 2 is halogen or unsubstituted or substituted alkyl; preferably Cl or CF3; more preferably CF3. In one embodiment, R 1 Yes - NHR 1a In one embodiment, R 1a is an unsubstituted or substituted cycloalkyl group, or an unsubstituted or substituted heterocyclic group, wherein R 1a At least one ring of is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; preferably cyclopropyl.
[0027] In one embodiment, the compound of formula (I) is wherein Ring A is In one embodiment, X is CR 2 In one embodiment, R 2 is halogen, or alkyl which is unsubstituted or substituted by halogen; preferably Cl or CF3; more preferably Cl. 8 is methyl, ethyl, Cl, -CN or -CCH; preferably -CCH. In one embodiment, R 9 is hydrogen or F. In one embodiment, R 10 In one embodiment, R 1 Yes - NHR 1a In one embodiment, R 1a is an unsubstituted or substituted cycloalkyl group, or an unsubstituted or substituted heterocyclic group, wherein R 1a At least one ring of is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; preferably cyclopropyl. In one embodiment, R 1a It is cyclopropyl.
[0028] In one embodiment, the compound of formula (I) is wherein Ring A is In one embodiment, X is CR 2 In one embodiment, R 2 It is halogen, or alkyl which is unsubstituted or substituted by halogen; preferably Cl or CF3; more preferably Cl.
[0029] In one embodiment, Ring A is In one embodiment, R 1a and R1b Together with the nitrogen atom to which they are attached they form an unsubstituted or substituted heterocyclic group.
[0030] In one embodiment, the compound of formula (I) is wherein Ring A is And R 1 yes In one embodiment, ring A is
[0031] In one embodiment, the compound of formula (I) is wherein Ring A is and X is N. In one embodiment, ring A is In one embodiment, R 1 Yes - NHR 1a In one embodiment, R 1a is an unsubstituted or substituted cycloalkyl group, or an unsubstituted or substituted heterocyclic group, wherein R 1a At least one ring of is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; preferably cyclopropyl.
[0032] In one embodiment, Ring A is
[0033] In one embodiment, Ring A is
[0034] In one embodiment, R 1a and R 1b Together with the nitrogen atom to which they are attached, they form an unsubstituted or substituted monocyclic heterocyclyl or an unsubstituted or substituted spiro heterocyclyl containing 0, 1 or 2 additional heteroatoms selected from oxygen, nitrogen or optionally oxidized sulfur; preferably, R 1 is an unsubstituted or substituted heterocyclic group selected from unsubstituted or substituted azetidinyl, unsubstituted or substituted pyrrolidinyl, unsubstituted or substituted piperidinyl, unsubstituted or substituted morpholinyl or unsubstituted or substituted
[0035] In one embodiment, the compound of formula (I) is a compound wherein R 1a and R 1b Together with the nitrogen atom to which they are attached, they form an unsubstituted or substituted heterocyclyl; and the heterocyclyl is an unsubstituted or substituted monocyclic heterocyclyl, an unsubstituted or substituted bicyclic heterocyclyl, an unsubstituted or substituted tricyclic heterocyclyl, an unsubstituted or substituted tetracyclic heterocyclyl, or an unsubstituted or substituted spirocyclic heterocyclyl.
[0036] In one embodiment, the compound is selected from Table 1, Table 2, and Table 3.
[0037] In one embodiment, provided herein is a method for inhibiting the activity of a KRAS mutant protein in a cell, comprising contacting the cell with an effective amount of a compound provided herein or a pharmaceutically acceptable salt, tautomer, isotopomer, stereoisomer or prodrug thereof, optionally wherein the KRAS mutant protein is a KRAS G12V mutant protein.
[0038] In one embodiment, provided herein is a method for treating or preventing cancer, the method comprising administering to a subject in need thereof an effective amount of a compound provided herein or a pharmaceutically acceptable salt, tautomer, isotopomer, stereoisomer or prodrug thereof, optionally wherein the cancer is mediated by a KRAS mutation; preferably a KRAS G12V mutation. DETAILED DESCRIPTION
[0039] definition
[0040] As used herein, "KRAS gene" refers to a gene selected from the group consisting of DIRAS1; DIRAS2; DIRAS3; ERAS; GEM; HRAS; KRAS; MRAS; NKIRAS1; NKIRAS2; NRAS; RALA; RALB; RAP1A; RAP1B; RAP2A; RAP2B; RAP2C; RASD1; RASD2; RASL10A; RASL10B; RASL11A; RASL11B; RASL12; REM1; REM2; RERG; RERGL; RRAD; RRAS; RRAS2, and mutants thereof.
[0041] As used herein, "KRAS protein" refers to a protein expressed by the KRAS gene or an isoform thereof (Scolnick EM, Papageoege AG, Shih TY (1979), "Guanine nucleotide-binding activity for src protein of rat-derived murine sarcoma viruses," Proc Natl Acad Sci USA. 76(5):5355–5559; Kranenburg O (November 2005) "The KRAS oncogene: past, present, and future," Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1756(2):81–2).
[0042] As used herein, "G12V mutation" refers to a mutation of the 12th amino acid residue located in the G domain of the KRAS protein from glycine to valine.
[0043] As used herein, "KRAS G12V" or "G12V" refers to a KRAS protein having a G12V mutation.
[0044] As used herein and in the specification and appended claims, the indefinite articles "a" and "an" and the definite article "the" include plural as well as singular referents unless the context clearly dictates otherwise.
[0045] As used herein, and unless otherwise indicated, the terms "about" and "approximately" when used in conjunction with the dose, amount, or weight percentage of an ingredient of a composition or dosage form, mean a dose, amount, or weight percentage that one of ordinary skill in the art considers to provide a pharmacological effect equivalent to that obtained from a specified dose, amount, or weight percentage. In certain embodiments, the terms "about" and "approximately" when used herein encompass doses, amounts, or weight percentages within 30%, 20%, 15%, 10%, or 5% of a specified dose, amount, or weight percentage.
[0046] As used herein and unless otherwise indicated, the terms "about" and "approximately" when used in connection with a value or range of values provided to characterize a particular solid form, e.g., a particular temperature or temperature range, such as describing melting, dehydration, desolvation, or glass transition temperature; a change in mass, such as a change in mass as a function of temperature or humidity; solvent or water content, e.g., in mass or percentage; or peak position, such as in analysis by, e.g., IR or Raman spectroscopy or XRPD; indicate that the value or range of values may deviate to an extent that is considered reasonable by one of ordinary skill in the art while still describing the solid form. Techniques used to characterize crystalline forms and amorphous solids include, but are not limited to, thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), single crystal X-ray diffraction, vibrational spectroscopy (e.g., infrared (IR) and Raman spectroscopy), solid-state and solution nuclear magnetic resonance (NMR) spectroscopy, optical microscopy, hot stage optical microscopy, scanning electron microscopy (SEM), electron crystallography and quantitative analysis, particle size analysis (PSA), surface area analysis, solubility studies, and dissolution studies. In certain embodiments, the terms "about" and "approximately" when used in this context indicate that a value or range of values may vary within 30%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1.5%, 1%, 0.5%, or 0.25% of the recited value or range of values. For example, in some embodiments, the value of an XRPD peak position may vary by as much as ±0.2° 2Θ (or ±0.2 degrees 2Θ) while still describing a specific XRPD peak.
[0047] An "alkyl" group is a saturated, partially saturated or unsaturated straight or branched acyclic hydrocarbon having 1 to 10 carbon atoms, typically 1 to 8 carbons, or in some embodiments 1 to 6, 1 to 4, or 2 to 6 carbon atoms. Representative alkyl groups include -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, and -n-hexyl; while saturated branched alkyl groups include -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, -neopentyl, tert-pentyl, -2-methylpentyl, -3-methylpentyl, -4-methylpentyl, -2,3-dimethylbutyl, and the like. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, allyl, -CH=CH(CH3), -CH=C(CH3)2, -C(CH3)=CH2, -C(CH3)=CH(CH3), -C(CH2CH3)=CH2, -C≡CH, -C≡C(CH3), -C≡C(CH2CH3), -CH2C≡CH, -CH2C≡C(CH3), and -CH2C≡C(CH7CH3), etc. The alkyl group may be substituted or unsubstituted. When alkyl groups described herein are referred to as "substituted," they may be substituted with any one or more substituents, such as those present in the exemplary compounds and embodiments disclosed herein, as well as halogen (chloro, iodo, bromo or fluoro); alkyl; hydroxy; alkoxy; alkoxyalkyl; amino; alkylamino; carboxyl; nitro; cyano; thiol; thioether; imine; imide; amidine; guanidine; enamine; aminocarbonyl; amido; phosphonate; phosphine; thiocarbonyl; sulfonyl; sulfone; sulfonamide; ketone; aldehyde; ester; urea; urethane; oxime; hydroxylamine; alkoxyamine; arylalkyloxyamine; N-oxide; hydrazine; hydrazide; hydrazone; azide; isocyanate; isothiocyanate; cyanate; thiocyanate; B(OH)2 or O(alkyl)aminocarbonyl.
[0048] "Cycloalkyl" group is a saturated, partially saturated or unsaturated cyclic alkyl group with 3 to 10 carbon atoms of a monocyclic or multiple condensed or bridged rings, which can be optionally substituted by 1 to 3 alkyl groups. In some embodiments, the cycloalkyl group has 3 to 8 ring members, and in other embodiments, the number of ring carbon atoms is in the range of 3 to 5, 3 to 6 or 3 to 7. The cycloalkyl containing more than one ring can be fused, spirocyclic or bridged, or a combination thereof. Such cycloalkyl groups include, for example, monocyclic structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 1-methylcyclopropyl, 2-methylcyclopentyl, 2-methylcyclooctyl, etc., or polycyclic or bridged ring structures such as 1-bicyclo [1.1.1] pentyl, bicyclo [2.1.1] hexyl, bicyclo [2.2.1] heptyl, bicyclo [2.2.2] octyl, adamantyl, etc. Examples of unsaturated cycloalkyl groups include cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl, hexadienyl, etc. The cycloalkyl group may be substituted or unsubstituted. Such substituted cycloalkyl groups include, for example, cyclohexanol, etc.
[0049] An "aryl" group is an aromatic carbocyclic group of 6 to 14 carbon atoms having a monocyclic ring (e.g., phenyl) or multiple fused rings (e.g., naphthyl or anthracenyl). In some embodiments, the aryl group contains 6-14 carbons, and in other embodiments, the ring portion of the aryl group contains 6 to 12 or even 6 to 10 carbon atoms. Specific aryl groups include phenyl, biphenyl, naphthyl, etc. The aryl group may be substituted or unsubstituted. The phrase "aryl group" also includes groups containing fused rings, such as fused aromatic-aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, etc.).
[0050] "Heterocyclyl" is an aromatic (also referred to as heteroaryl) or non-aromatic cycloalkyl group, wherein one to four ring carbon atoms are independently substituted by heteroatoms from the group consisting of O, S and N. In some embodiments, the heterocyclyl group includes 3 to 10 ring members, while other such groups have 3 to 5, 3 to 6 or 3 to 8 ring members. The heterocyclyl group can also be bonded to other groups at any ring atom (i.e., at any carbon atom or heteroatom of the heterocycle). The heterocyclyl group can be substituted or unsubstituted. The heterocyclyl group can include multiple fused rings, including but not limited to bicyclic, tricyclic and tetracyclic, and bridged or spirocyclic systems. The heterocyclyl group includes unsaturated, partially saturated and saturated ring systems, such as imidazolyl, imidazolinyl and imidazolidinyl (e.g., imidazolidin-4-one or imidazolidin-2,4-diketo). The phrase heterocyclyl includes fused ring species, including those containing fused aromatic and non-aromatic groups, such as 1-aminotetralin and 2-aminotetralin, benzotriazolyl (e.g., 1H-benzo[d][1,2,3]triazolyl), benzimidazolyl (e.g., 1H-benzo[d]imidazolyl), 2,3-dihydrobenzo[1,4]dioxinyl and benzo[1,3]dioxolyl. The phrase also includes bridged polycyclic ring systems containing heteroatoms, such as, but not limited to, quinuclidine. Representative examples of heterocyclyl groups include, but are not limited to, aziridinyl, azetidinyl, azepanyl, oxetanyl, pyrrolidinyl, imidazolidinyl (e.g., imidazolidin-4-one or imidazolidin-2,4-dione), pyrazolidinyl, thiazolidinyl, tetrahydrothienyl, tetrahydrofuranyl, dioxolyl, furanyl, thienyl, pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, benzisoxazolyl (e.g., benzo[d]isoxazolyl), thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, piperidinyl, piperazinyl (e.g., piperazin-2-one), morpholinyl, oxadiazolyl, pyrrolidyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, benzisoxazolyl (e.g., benzo[d]isoxazolyl), thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, piperidinyl, piperazinyl (e.g., piperazin-2-one), morpholinyl, oxadiazolyl, piperidinyl, piperazinyl (e.g., piperazin-2-one), morpholinyl, oxadiazolyl, pyrrolidyl, pyrrolidyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, linyl, thiomorpholinyl, tetrahydropyranyl (e.g., tetrahydro-2H-pyranyl), tetrahydrothiopyranyl, oxathiolanyl, dioxy, dithianyl, pyranyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, dihydropyridyl, dihydrodithienyl, dihydrodisulfide, 1,4-dioxaspiro[4.5]decyl, 2-oxo-1-oxa-3,8-diazaspiro[4.5]decane, 1-oxo-2,8-diazaspiro[4.5]decane, 3-oxo-2,8-diazaspiro[4.5]decane, 3-oxo-1-oxa-4,9-diazaspiro[5.5]undecane, 2-oxo-1-oxa-3,9-diazaspiro[5.5]undecane.5] undecane, homopiperazinyl, quinolyl, indolyl (e.g., indolyl-2-one or isoindolyl-1-one), indolyl, isoindolyl, isoindolyl, azaindolyl (pyrrolopyridinyl or 1H-pyrrolo[2,3-b]pyridinyl), indazolyl, indolizinyl, benzotriazolyl (e.g., 1H-benzo[d][1,2,3]triazolyl), benzimidazolyl (e.g., 1H-benzo[d][1,2,3]triazolyl), 1H-benzo[d]imidazolyl or 1H-benzo[d]imidazolyl-2(3H)-nonyl), benzofuranyl, benzothiophenyl, benzothiazolyl, benzoxadiazolyl, benzoxazininyl, benzodithiazinyl, benzothiazinyl, benzothiazinyl, benzoxazolyl (i.e., benzo[d]oxazolyl), benzothiazolyl, benzothiadiazolyl, benzo[1,3]dioxolanyl, pyrazolopyridinyl (e.g., 1H-pyrazolo[ 3,4-b]pyridinyl, 1H-pyrazolo[4,3-b]pyridinyl), imidazopyridinyl (e.g., azobenzimidazolyl or 1H-imidazo[4,5-b]pyridinyl), triazolopyridinyl, isoxazolopyridinyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolyl, isoquinolyl (e.g., 3,4-dihydroisoquinolin-1(2H)-one), quinolizinyl, quinoxalinyl, quinoline Representative non-aromatic heterocyclic groups include oxazolinyl, cinnolinyl, phthalazinyl, naphthyridinyl, pteridinyl, thienyl, dihydrobenzothiazinyl, dihydrobenzofuranyl, dihydroindolinyl, dihydrobenzodioxazinyl, tetrahydroindolinyl, tetrahydroindazolyl, tetrahydrobenzimidazolyl, tetrahydrobenzotriazolyl, tetrahydropyrrolopyridinyl, tetrahydropyrazolopyridinyl, tetrahydroimidazopyridinyl, tetrahydrotriazolopyridinyl, tetrahydropyrimidin-2(1H)-one, and tetrahydroquinolinyl groups. Representative non-aromatic heterocyclic groups do not include fused ring species containing fused aromatic groups. Examples of non-aromatic heterocyclic groups include aziridinyl, azetidinyl, azepanyl, pyrrolidinyl, imidazolidinyl (e.g., imidazolidin-4-one or imidazolidin-2,4-dione), pyrazolidinyl, thiazolidinyl, tetrahydrothienyl, tetrahydrofuranyl, piperidinyl, piperazinyl (e.g., piperazin-2-one), morpholinyl, thiomorpholinyl, tetrahydropyranyl (e.g., tetrahydro-2H-pyranyl), tetrahydrothiopyranyl, oxathianyl, dithianyl, 1,4-dioxaspiro[4.5]decyl, homopiperazinyl, quinuclidinyl, or tetrahydropyrimidin-2(1H)-one. Representative substituted heterocyclic groups may be monosubstituted or substituted more than once, such as, but not limited to, pyridinyl or morpholinyl, 2-substituted, 3-substituted, 4-substituted, 5-substituted, or 6-substituted, or disubstituted with various substituents, such as those listed below. .
[0051] A "heteroaryl" group is an aryl ring system having one to four heteroatoms as ring atoms in a heteroaromatic ring system, wherein the remaining atoms are carbon atoms. In some embodiments, the heteroaryl group contains 3 to 6 ring atoms, and in other embodiments, the ring portion of the group contains 6 to 9 or even 6 to 10 atoms. Suitable heteroatoms include oxygen, sulfur and nitrogen. In certain embodiments, the heteroaryl ring system is monocyclic or bicyclic. Non-limiting examples include, but are not limited to, groups such as pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, benzisoxazolyl (e.g., benzo[d]isoxazolyl), thiazolyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, benzothienyl, furanyl, benzofuranyl, indolyl (e.g., indol-2-one or isoindolin-1-one), azaindolyl (pyrrolopyridinyl or 1H-pyrrolo[2,3-b]pyridinyl), indazolyl, benzimidazolyl (e.g., 1H-benzo[d]imidazolyl) ), imidazopyridyl (e.g., azabenzimidazolyl or 1H-imidazo[4,5-b]pyridyl), pyrazolopyridyl, triazolopyridyl, benzotriazolyl (e.g., 1H-benzo[d][1,2,3]triazolyl), benzoxazolyl (e.g., benzo[d]oxazolyl), benzothiazolyl, benzothiadiazolyl, isoxazolopyridyl, thionaphthyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolyl, isoquinolyl (e.g., 3,4-dihydroisoquinolin-1(2H)-one), tetrahydroquinolyl, quinoxalinyl, and quinazolinyl.
[0052] As used herein, "spirocycle" refers to two or more rings in which adjacent rings are connected by a single atom. The individual rings within a spirocycle may be the same or different. Each ring in a spirocycle may be substituted or unsubstituted and may have a substituent that is different from each other ring within a set of spirocycles.
[0053] A "cycloalkylalkyl" group is a group of the formula: -alkyl-cycloalkyl, wherein the alkyl and cycloalkyl groups are as defined above. Substituted cycloalkylalkyl groups may be substituted at the alkyl, cycloalkyl, or both alkyl and cycloalkyl portions of the group. Representative cycloalkylalkyl groups include, but are not limited to, methylcyclopropyl, methylcyclobutyl, methylcyclopentyl, methylcyclohexyl, ethylcyclopropyl, ethylcyclobutyl, ethylcyclopentyl, ethylcyclohexyl, propylcyclopentyl, propylcyclohexyl, and the like.
[0054] An "aralkyl" group is a group of the formula: -alkyl-aryl, wherein the alkyl and aryl groups are as defined above. Substituted aralkyl groups may be substituted at the alkyl, aryl, or both the alkyl and aryl portions of the group. Representative aralkyl groups include, but are not limited to, benzyl and phenethyl groups and fused (cycloalkylaryl) alkyl groups, such as 4-ethyl-indanyl.
[0055] A "heterocyclylalkyl" group is a group of the formula: -alkyl-heterocyclyl, wherein the alkyl and heterocyclyl groups are defined above. Substituted heterocyclylalkyl groups may be substituted at the alkyl, heterocyclyl, or both alkyl and heterocyclyl portions of the group. Representative heterocyclylalkyl groups include, but are not limited to, 4-ethyl-morpholinyl, 4-propylmorpholinyl, furan-2-ylmethyl, furan-3-ylmethyl, pyridin-3-ylmethyl, tetrahydrofuran-2-ylethyl, and indol-2-ylpropyl.
[0056] "Halogen" is fluorine, chlorine, bromine or iodine.
[0057] A "hydroxyalkyl" group is an alkyl group as described above substituted with one or more hydroxy groups.
[0058] An "alkoxy" or "alkoxyl" group is an -O-(alkyl) group, wherein alkyl is as defined above.
[0059] An "alkoxyalkyl" group is a -(alkyl)-O-(alkyl) where alkyl is as defined above.
[0060] An "amino" group is a group of the formula: -NH2.
[0061] An "alkylamino" group is a group of the formula: -NH-alkyl or -N(alkyl)2 wherein each alkyl group is independently as defined above.
[0062] A "carboxy" group is a group of the formula: -C(O)OH.
[0063] An "aminocarbonyl" group is a group of the formula: -C(O)N(R # )2、-C(O)NH(R # ) or -C(O)NH2, where each R # and R is independently substituted or unsubstituted alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl or heterocyclic as defined herein.
[0064] An "acylamino" group is a group of the formula: -NHC(O)(R # ) or -N(alkyl)C(O)(R # ), wherein each alkyl group and R # Independently as defined above.
[0065] A "sulfonylamino" group is a group of the formula: -NHSO2(R # ) or -N(alkyl)SO2(R # ), wherein each alkyl group and R # As defined above.
[0066] A "urea" group is a group of the formula: -N(alkyl)C(O)N(R# )2, -N(alkyl)C(O)NH(R # )、-N(alkyl)C(O)NH2、-NHC(O)N(R # )2、-NHC(O)NH(R # ) or -NH(CO)NHR # , where each alkyl group and R # Independently as defined above.
[0067] When groups described herein (other than alkyl) are referred to as "substituted", they may be substituted with any suitable substituent or substituents. Illustrative examples of substituents are those found in the exemplary compounds and embodiments disclosed herein, as well as halogen (chlorine, iodine, bromine or fluorine); alkyl; hydroxyl; alkoxy; alkoxyalkyl; amino; alkylamino; carboxyl; nitro; cyano; thiol; thioether; imine; imide; amidine; guanidine; enamine; aminocarbonyl; acylamino; phosphonato; phosphine; thiocarbonyl; sulfonyl; sulfone; sulfonamide; ketone; aldehyde; ester; urea; carbamate; oxime; hydroxylamine; alkoxyamine; aralkyloxyamine; N-oxide; hydrazine; hydrazide; hydrazone; azide; isocyanate; isothiocyanate; cyanate; thiocyanate; oxygen (═O); B(OH)2, O(alkyl)aminocarbonyl; cycloalkyl , which may be a monocyclic or fused or non-fused polycyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), or a heterocyclic group, which may be a monocyclic or fused or non-fused polycyclic (e.g., pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or thiazinyl); a monocyclic or fused or non-fused polycyclic aryl or heteroaryl (e.g., phenyl, naphthyl, pyrrolyl, indolyl, furanyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridyl, quinolyl, isoquinolyl, acridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzimidazolyl, benzothienyl or benzofuranyl); aryloxy; aralkyloxy; heterocyclyloxy; and heterocyclylalkoxy.
[0068] As used herein, the term "one or more pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases (including inorganic acids and bases and organic acids and bases). Suitable pharmaceutically acceptable base addition salts of compounds of formula (I) include, but are not limited to, those well known in the art, see, for example, Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing, Easton PA (1990) or Remington: The Science and Practice of Pharmacy, 19th edition, Mack Publishing, Easton PA (1995).
[0069] Unless otherwise indicated, the term "stereoisomer" or "stereoisomerically pure" as used herein means that one stereoisomer of a compound is substantially free of other stereoisomers of the compound. For example, a stereoisomerically pure compound with one chiral center will be substantially free of the opposite enantiomer of the compound. A stereoisomerically pure compound with two chiral centers is substantially free of other diastereomers of the compound. A typical stereoisomerically pure compound contains greater than about 80% by weight of one stereoisomer of the compound and less than about 20% by weight of other stereoisomers of the compound, greater than about 90% by weight of one stereoisomer of the compound and less than about 10% by weight of other stereoisomers of the compound, greater than about 95% by weight of one stereoisomer of the compound and less than about 5% by weight of other stereoisomers of the compound, or greater than about 97% by weight of one stereoisomer of the compound and less than about 3% by weight of other stereoisomers of the compound. Compounds can have chiral centers and can appear as racemates, individual enantiomers or diastereomers and mixtures thereof. All such isomeric forms are included in the embodiments disclosed herein, including mixtures thereof.
[0070] The use of stereoisomerically pure forms of such compounds and the use of mixtures of these forms are encompassed in the embodiments disclosed herein. For example, a mixture of enantiomers of a particular compound containing equal or unequal amounts can be used in the methods and compositions disclosed herein. These isomers can be asymmetrically synthesized or split using standard techniques such as chiral columns or chiral splitting agents. See, for example, Jacques, J., et al., Enantiomers, Racemates and Resolutions (Wiley-Interscience, New York, 1981); Wilen, SH, et al., Tetrahedron 33: 2725 (1977); Eliel, EL, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, SH, Tables of Resolving Agents and Optical Resolutions, p. 268 (ELEliel, Univ. of Notre Dame Press, Notre Dame, IN, 1972).
[0071] It should also be noted that the compound may include E and Z isomers, or mixtures thereof, as well as cis and trans isomers, or mixtures thereof. In certain embodiments, the compound is separated into E or Z isomers. In other embodiments, the compound is a mixture of E and Z isomers.
[0072] As used herein and unless otherwise indicated, "atropisomer" refers to a stereoisomer resulting from hindered rotation about a single bond axis, where the barrier to rotation is sufficiently high to allow separation of the individual rotamers.
[0073] "Tautomers" refers to isomeric forms of a compound that are in equilibrium with each other. The concentrations of the isomeric forms will depend on the environment in which the compound is located, and may vary depending on, for example, whether the compound is a solid or in an organic or aqueous solution. For example, in aqueous solution, pyrazole may exhibit the following isomeric forms, which are referred to as tautomers of each other:
[0074]
[0075] It will be readily appreciated by those skilled in the art that various functional groups and other structures may exhibit tautomerism, and all tautomers of the compounds of formula (I) are within the scope of the present invention.
[0076] It should also be noted that a compound may contain unnatural proportions of atomic isotopes at one or more of its atoms. For example, a compound may contain an isotope such as tritium ( 3 H), iodine-125 ( 125 I), sulfur-35( 35 S) or carbon-14 ( 14 C), or can be radiolabeled with a radioactive isotope such as deuterium ( 2 H), carbon-13 ( 13 C) or nitrogen-15( 15 N) isotopically enriched. As used herein, an "isotopologue" is an isotopically enriched compound. The term "isotopically enriched" refers to an atom whose isotopic composition is different from the natural isotopic composition of the atom. "Isotopically enriched" can also refer to a compound containing at least one atom whose isotopic composition is different from the natural isotopic composition of the atom. The term "isotopic composition" refers to the amount of each isotope present in a given atom. Radiolabeled and isotopically enriched compounds can be used as therapeutic agents, such as cancer and inflammatory therapeutic agents; research reagents, such as binding assay reagents; and diagnostic agents, such as in vivo imaging agents. All isotopic variations of compounds as described herein (whether or not radioactive) are intended to be covered within the scope of the embodiments provided herein. In some embodiments, isotopologues of compounds are provided, for example, isotopologues are deuterium, carbon-13, or nitrogen-15 enriched compounds.
[0077] As used herein, "treating" refers to the complete or partial relief of a disorder, disease or condition, or one or more symptoms associated with a disorder, disease or condition, or to slow or stop the further progression or worsening of those symptoms, or to alleviate or eradicate the cause of the disorder, disease or condition itself. In some embodiments, "treating" means the complete or partial relief of a disorder, disease or condition, or to slow or stop the further progression or worsening of those symptoms. In another embodiment, "treating" means the complete or partial relief of a disorder, disease or condition, or symptoms associated with a disorder, wherein the disorder can be treated or prevented by inhibiting KRASG12V.
[0078] As used herein, "prevention" means a method of completely or partially delaying and / or hindering the onset, recurrence or spread of a disorder, disease or condition; a method of preventing a subject from developing a disorder, disease or condition; or a method of reducing the risk of a subject developing a disorder, disease or condition. In one embodiment, the disorder is a disorder that can be treated or prevented by inhibiting KRAS G12V.
[0079] The term "effective amount" with respect to a compound refers to an amount capable of treating or preventing a disorder, disease or condition disclosed herein, or a symptom thereof.
[0080] The term "subject" includes animals, including but not limited to animals such as cows, monkeys, horses, sheep, pigs, chickens, turkeys, quail, cats, dogs, mice, rats, rabbits or guinea pigs, in one embodiment mammals, in another embodiment humans.
[0081] Compound
[0082] Aspect 1: Provided herein are compounds having the following formula (I):
[0083]
[0084] and pharmaceutically acceptable salts, tautomers, stereoisomers, enantiomers, atropisomers, isotopomers and prodrugs thereof,
[0085] in:
[0086] Ring A is
[0087] X is N or CR 2 ;
[0088] Y is N or C-CN;
[0089] Z is N or CR 3 ;
[0090] W is N or CR 5 ;
[0091] V is N or CR 7 ;
[0092] R 1 Yes - NR 1a R 1b ;
[0093] R 2 is halogen, or unsubstituted or substituted alkyl;
[0094] R 3 is halogen, or unsubstituted or substituted alkyl;
[0095] R 4 is halogen, -NO2, or unsubstituted or substituted alkyl;
[0096] R 5 is hydrogen, halogen or -CN;
[0097] R 7 is hydrogen, halogen or -CN;
[0098] R 8 , R 9 and R 10 Each of is independently hydrogen, halogen, unsubstituted or substituted alkyl or -OH;
[0099] R 1a and R 1b are each independently hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocyclylalkyl, provided that R 1a and R 1b Not all hydrogen; or
[0100] R 1a and R 1b Together with the nitrogen atom to which they are attached they form an unsubstituted or substituted heterocyclic group.
[0101] Aspect 2: In one embodiment, the compound of formula (I) is wherein Ring A is of compounds.
[0102] In one embodiment, Y is N.
[0103] In one embodiment, Y is C-CN.
[0104] In one embodiment, X is CR 2 In one embodiment, R 2 It is halogen or unsubstituted or halogen-substituted alkyl; preferably Cl or CF3; more preferably CF3.
[0105] In one embodiment, R 1 Yes - NHR 1a In one embodiment, R 1a is an unsubstituted or substituted cycloalkyl group, or an unsubstituted or substituted heterocyclic group, wherein R 1a At least one ring of is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; preferably cyclopropyl. In one embodiment, R 1a is a cycloalkyl or heterocyclic group, wherein R 1a At least one ring of is cyclopropyl; and R 1a Optionally one or more C 1-4 Alkyl, C 1-4 Alkoxy, halogen, -CN, -OH or acetyl substitution, where C 1-4 Alkyl and C 1-4 Each of the alkoxy groups is independently optionally substituted with one or more halogens, -CN, -OH, or contains a carbon-carbon triple bond. 1a is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, spiro[3.3]hept-2-yl, 2-oxaspiro[3.3]hept-6-yl, bicyclo[1.1.1]pent-1-yl, 3-oxabicyclo[3.1.0]hex-6-yl, 1-(3-azabicyclo[3.1.0]hex-3-yl)ethan-1-one-6-yl or Preferably cyclopropyl; R 1a Optionally one or more C 1-4 Alkyl, halogen, -CN, -OH or C 1-4 Alkoxy substituted; and C 1-4 Alkyl and C 1-4 Each of the alkoxy groups is independently optionally substituted with one or more halogens, -CN, -OH, or contains a carbon-carbon triple bond. 1a yes
[0106] Aspect 3: In one embodiment, the compound of formula (I) is wherein Ring A is of compounds.
[0107] In one embodiment, X is CR 2 In one embodiment, R 2 It is halogen, or alkyl which is unsubstituted or substituted by halogen; preferably Cl or CF3; more preferably Cl.
[0108] In one embodiment, R 8 It is methyl, ethyl, Cl, -CN or -CCH; preferably -CCH.
[0109] In one embodiment, R 9is hydrogen or F.
[0110] In one embodiment, R 10 It is -OH.
[0111] In one embodiment, R 1 Yes - NHR 1a In one embodiment, R 1a is an unsubstituted or substituted cycloalkyl group, or an unsubstituted or substituted heterocyclic group, wherein R 1a At least one ring of is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; preferably cyclopropyl. In one embodiment, R 1a It is cyclopropyl.
[0112] In one embodiment, R 1 Yes - NR 1a R 1b , where R 1a and R 1b Together with the nitrogen atom to which they are attached, they form an unsubstituted or substituted monocyclic heterocyclyl or an unsubstituted or substituted spiro heterocyclyl. In some embodiments, the unsubstituted or substituted monocyclic heterocyclyl or unsubstituted or substituted spiro heterocyclyl contains one or two additional heteroatoms selected from oxygen, nitrogen or optionally oxidized sulfur. In one embodiment, R 1a and R 1b Together with the nitrogen atom to which they are attached, they form an unsubstituted or substituted heterocyclyl group selected from unsubstituted or substituted azetidinyl, unsubstituted or substituted pyrrolidinyl, unsubstituted or substituted piperidinyl, unsubstituted or substituted azepanyl, unsubstituted or substituted Unsubstituted or substituted Unsubstituted or substituted Unsubstituted or substituted or unsubstituted or substituted In one embodiment, the heterocyclyl is optionally substituted with one or more C 1-4 Alkyl, halogen, -CN, -OH, C 1-4 Alkoxy, cycloalkylalkyl or methylsulfonyl substituted, wherein C 1-4 Alkyl and C 1-4 Each of the alkoxy groups is independently optionally substituted with one or more halogen, -CN, -OH or C 1-4 Alkoxy substitution.
[0113] In one embodiment, R 1 is azetidin-1-yl, 2-methyl-azetidin-1-yl, 3-methyl-azetidin-1-yl, 2,2-Dimethyl-azetidin-1-yl, 3-Fluoro-azetidin-1-yl, 3,3-Difluoro-azetidin-1-yl, 3-cyano-azetidin-1-yl,
[0114]
[0115] Aspect 4: In one embodiment, the compound of formula (I) is wherein Ring A is of compounds.
[0116] In one embodiment, X is CR 2 .
[0117] In one embodiment, R 2 It is halogen, or alkyl which is unsubstituted or substituted by halogen; preferably Cl or CF3; more preferably Cl.
[0118] In one embodiment, Ring A is
[0119] In one embodiment, R 1a and R 1b Together with the nitrogen atom to which they are attached, they form an unsubstituted or substituted heterocyclic group selected from unsubstituted or substituted azetidinyl, unsubstituted or substituted pyrrolidinyl, unsubstituted or substituted piperidinyl, unsubstituted or substituted morpholinyl, unsubstituted or substituted In one embodiment, the heterocyclyl is optionally substituted with one or more C 1-4 Alkyl, halogen, -CN or -OH substitution.
[0120] In one embodiment, R 1 yes
[0121] Aspect 5: In one embodiment, the compound of formula (I) is wherein Ring A is And R 1 yes of compounds.
[0122] In one embodiment, Ring A is
[0123] Aspect 6: In one embodiment, the compound of formula (I) is wherein Ring A is and X is a compound of N.
[0124] In one embodiment, Ring A is
[0125] In one embodiment, R 1 Yes - NHR 1a .
[0126] In one embodiment, R 1a is an unsubstituted or substituted cycloalkyl group, or an unsubstituted or substituted heterocyclic group, wherein R 1a At least one ring of is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; preferably cyclopropyl.
[0127] In one embodiment, R 1a is a cycloalkyl or heterocyclic group, wherein R 1a At least one ring of is cyclopropyl; and R 1a Optionally one or more C 1-4 Alkyl substitution.
[0128] In one embodiment, R 1a is cyclopropyl, cyclobutyl, bicyclo[1.1.1]pentan-1-yl or 3-oxabicyclo[3.1.0]hexan-6-yl; preferably cyclopropyl; and R 1a Optionally one or more C 1-4 Alkyl substitution.
[0129] In one embodiment, R 1a yes Best
[0130] In one embodiment, R 1a and R 1b Together with the nitrogen atom to which they are attached, they form an unsubstituted or substituted heterocyclyl group, wherein at least one ring of the heterocyclyl group is piperidinyl or morpholinyl.
[0131] In one embodiment, R 1 Optionally one or more C 1-4 Alkyl, halogen, -CN or -OH substituted, where C 1-4 Each of the alkyl groups is independently optionally substituted with one or more halogen, -CN or -OH.
[0132] In one embodiment, R 1 yes
[0133] Best
[0134] In one embodiment, R 1 yes
[0135] In one embodiment, Ring A is
[0136] Aspect 7: In one embodiment, the compound of formula (I) is a compound wherein R 1a and R 1b Together with the nitrogen atom to which they are attached, they form an unsubstituted or substituted heterocyclyl; and the heterocyclyl is an unsubstituted or substituted monocyclic heterocyclyl, an unsubstituted or substituted bicyclic heterocyclyl, an unsubstituted or substituted tricyclic heterocyclyl, an unsubstituted or substituted tetracyclic heterocyclyl, or an unsubstituted or substituted spirocyclic heterocyclyl.
[0137] In one embodiment, R 1 Not unsubstituted or substituted piperazinyl.
[0138] In one embodiment, R 1 Not unsubstituted or substituted Unsubstituted or substituted Unsubstituted or substituted Unsubstituted or substituted Unsubstituted or substituted Unsubstituted or substituted or unsubstituted or substituted
[0139] In one embodiment, R 1 is not unsubstituted or substituted 3,8-diazabicyclo[3.2.1]octan-3-yl, or unsubstituted or substituted
[0140] Aspect 8: In one embodiment, the compound is selected from Table 1, Table 2 and Table 3.
[0141] Aspect 9: In one embodiment, provided herein is a pharmaceutical composition comprising an effective amount of a compound provided herein or a pharmaceutically acceptable salt, tautomer, isotopomer, stereoisomer or prodrug thereof and a pharmaceutically acceptable carrier, excipient or vehicle.
[0142] Aspect 10: In one embodiment, provided herein is a method for inhibiting the activity of a KRAS mutant protein in a cell, comprising contacting the cell with an effective amount of a compound provided herein or a pharmaceutically acceptable salt, tautomer, isotopomer, stereoisomer or prodrug thereof, optionally wherein the KRAS mutant protein is a KRAS G12D and / or G12V mutant protein.
[0143] Aspect 11: In one embodiment, provided herein is a method for treating or preventing cancer, the method comprising administering to a subject in need thereof an effective amount of a compound provided herein or a pharmaceutically acceptable salt, tautomer, isotopomer, stereoisomer or prodrug thereof, optionally wherein the cancer is mediated by KRAS mutations; preferably KRAS G12D and / or G12V mutations.
[0144] Aspect 12: Provided herein is a method for modulating KRAS G12D and / or G12V activity, comprising contacting the cell with an effective amount of a compound provided herein or a pharmaceutically acceptable salt, tautomer, isotopomer, stereoisomer or prodrug thereof.
[0145] Aspect 13: Provided herein is a method for treating or preventing cancer, the method comprising administering an effective amount of a compound provided herein to a subject in need thereof.
[0146] Aspect 14: Provided herein is a kit for treating cancer, the kit comprising (a) a pharmaceutical composition comprising a compound provided herein; and (b) instructions for administering an effective amount of a pharmaceutical composition comprising a KRAS G12D and / or G12V inhibitor provided herein to treat cancer in an individual.
[0147] A more complete understanding of the embodiments of the present invention may be obtained by referring to the detailed description and examples, which are intended to illustrate non-limiting embodiments.
[0148] Methods for preparing compounds
[0149] The compound can be prepared using conventional organic synthesis and commercially available starting materials. As an example and not limitation, the compound of formula (I) can be prepared as outlined in the schemes 1-3 shown below and in the examples described herein. It should be noted that those skilled in the art will know how to modify the procedures described in the illustrative schemes and examples to obtain the desired product. Common protecting groups can be used to prevent certain functional groups from undergoing undesirable reactions. Exemplary protecting groups are described in "Protective Groups in Organic Synthesis", 4th edition, PGM Wuts; TW Greene, John Wiley, 2007, and references cited therein.
[0150] Solution 1
[0151]
[0152] As shown in Scheme 1, in some embodiments, provided herein are methods for preparing compounds as defined in Formula (I). The halogen-substituted compound 1-1 (X1, X2, X3 are halogens) is converted to compound 1-2 under alkaline conditions (e.g., NaH, THF); compound 1-2 is then converted to compound 1-3 under alkaline conditions (e.g., Cs2CO3, 1,4-dioxane) or Buchwald coupling conditions (e.g., RuPhos Pd catalyst, Cs2CO3, 1,4-dioxane); compound 1-3 is further subjected to a metal-catalyzed cross-coupling reaction with A-M1, such as Suzuki or Stille coupling (e.g., Pd(dtbpf)Cl2, K3PO4, 1,4-dioxane, water for Suzuki coupling), wherein A may or may not contain a protecting group (PG2), to obtain compound 1-4, wherein M1 may be boronic acid, boronic ester, metal (such as Zn), tributyltin, etc.; by deprotecting compound 1-4 (e.g., when PG1 is Bn, 10% Pd / C, H2, EtOAc to deprotect the benzyl group) to prepare compound 1-5; convert compound 1-5 to 1-6 under substitution or coupling reaction conditions (e.g., BOP or PyBOP, DIPEA, MeCN); then deprotect compound 1-6 (e.g., when PG1 is Boc, TFA and DCM to deprotect the Boc group) to obtain a compound as defined in formula (I).
[0153] Solution 2
[0154]
[0155] As shown in Scheme 2, in some embodiments, provided herein is a method for preparing a compound as defined in formula (I). The halogen-substituted compound 2-1 (X1, X2, X3 are halogens) is converted to compound 2-2 under basic conditions (e.g., NaH, THF); then, the halogen-substituted compound 2-1 (X1, X2, X3 are halogens) is converted to compound 2-2 under basic conditions (e.g., Cs2CO3, 1,4-dioxane) or Buchwald coupling conditions (e.g., RuPhos Pd catalyst, Cs2CO3, 1,4-dioxane) to convert compound 2-2 to compound 2-3; compound 2-3 is further subjected to a metal-catalyzed cross-coupling reaction with A-M1, such as Suzuki or Stille coupling (e.g., Pd(dtbpf)Cl2, K3PO4, 1,4-dioxane, water for Suzuki coupling), wherein A may or may not contain a protecting group (PG2), to obtain compound 2-4, wherein M1 may be boronic acid, borate, metal (such as Zn), tributyltin, etc.; compound 2-5 is prepared by deprotecting compound 2-4 (e.g., when PG1 is Bn and PG2 is Boc, TFA deprotects benzyl and Boc); compound 2-5 is converted to a compound as defined in formula (I) under substitution or coupling reaction conditions (e.g., BOP or PyBOP, DIPEA, MeCN).
[0156] Solution 3
[0157]
[0158] As shown in Scheme 3, in some embodiments, provided herein is a method for preparing a compound as defined in formula (I). The halogen-substituted compound 3-1 (X1, X2, X3 are halogens) is converted to compound 3-2 under substitution or coupling reaction conditions (e.g., DIPEA, DCM); then compound 3-2 is converted to compound 3-3 under substitution conditions (e.g., KF, DMSO, wherein X4 is F); compound 3-3 is further subjected to a metal-catalyzed cross-coupling reaction with A-M1, such as Suzuki or Stille coupling (e.g., Pd(dppf)Cl2, K3PO4, THF, water for Suzuki coupling), wherein A may or may not contain a protecting group (PG2), to obtain compound 3-4, wherein M1 may be boronic acid, boronic ester, metal (such as Zn), tributyltin, etc.; compound 3-5 is prepared by modifying compound 3-4 (e.g., I2, Ag2SO4 and DMF for iodination; for example, CuI, methyl 2,2-difluoro-2-(fluorosulfonyl)acetate, NMP for trifluoromethylation); compound 3-5 is converted into compound 3-6 under alkaline conditions (e.g., Cs2CO3, 1,4-dioxane) or Buchwald coupling conditions (e.g., RuPhos Pd catalyst, Cs2CO3, 1,4-dioxane); compound 3-6 is converted into a compound as defined in formula (I) under deprotection conditions (e.g., when PG2 is PMB, TFA deprotects the PMB group).
[0159] A more complete understanding of the embodiments of the present invention may be obtained by referring to the detailed description and examples, which are intended to illustrate non-limiting embodiments.
[0160] Example
[0161] The following examples are intended to be exemplary only and should not be considered to be limited in any way. Unless otherwise stated, the experimental methods in the embodiments described below are conventional methods. Unless otherwise stated, reagents and materials are all commercially available. All solvents and chemicals used are of analytical grade or chemical purity. Solvents are all redistilled before use. Anhydrous solvents are all prepared according to standard methods or reference methods. Silica gel (100-200 mesh) for column chromatography and silica gel (GF254) for thin layer chromatography (TLC) are commercially available from Qingdao Ocean Chemical Co., Ltd. or Yantai Chemical Co., Ltd. in China; unless otherwise stated, all are eluted with petroleum ether (60°C to 90°C) / ethyl acetate (v / v), and are developed by a solution of iodine or molybdophosphoric acid in ethanol. Unless otherwise stated, all extraction solvents are dried over anhydrous Na2SO4.
[0162] Unless otherwise noted, the reactions described below were performed under a positive pressure of nitrogen or argon or with a drying tube in anhydrous solvents; reaction flasks were equipped with rubber septa for introduction of substrates and reagents via syringe; glassware was oven-dried and / or heat-dried.
[0163] Unless otherwise stated, column chromatography purifications were performed on a Biotage system (manufacturer: Dyax Corporation) with silica gel columns or on silica SepPak cartridges (Waters), or on a Teledyne Isco Combiflash purification system using pre-packed silica gel cartridges.
[0164] Recorded on a Varian instrument operating at 400 MHz or 500 MHz 1 H NMR spectra were obtained using TMS (tetramethylsilane) as an internal standard using CDCl3, CD2Cl2, CD3OD, D2O, d6-DMSO, d6-acetone or (CD3)2CO as solvents and tetramethylsilane (0.00 ppm) or residual solvent (CDCl3: 7.25 ppm; CD3OD: 3.31 ppm; D2O: 4.79 ppm; d6-DMSO: 2.50 ppm; d6-acetone: 2.05; (CD3)2CO: 2.05) as reference standards. 1 H-NMR spectra. When peak multiplicities are reported, the following abbreviations are used: s (singlet), d (doublet), t (triplet), q (quartet), qn (quintet), sx (sextet), m (multiplet), br (broad), dd (double of doublets), dt (double of triplets). Coupling constants, when given, are reported in Hertz (Hz).
[0165] LC / MS data were recorded by using an Agilent 1100, 1200 high performance liquid chromatography-ion trap mass spectrometer (LC-MSD Trap) equipped with a diode array detector (DAD) detecting at 214 nm and 254 nm and an ion trap (ESI source). All compound names except reagents are from 19.1 generated.
[0166] In the following examples, the following abbreviations are used:
[0167]
[0168]
[0169]
[0170] Compound synthesis
[0171] Example 1a (common intermediate): 7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-ol
[0172]
[0173] Step 1: 7-Bromo-2,4-dichloro-8-fluoro-6-(trifluoromethyl)quinazoline
[0174]
[0175] To a stirred solution of 7-bromo-8-fluoro-6-(trifluoromethyl)quinazoline-2,4-diol (20.0 g, 61.2 mmol) in 120 mL of POCl3 was added N,N-diisopropylethylamine (40.0 mL), and the resulting mixture was stirred at 100 ° C for 2 hours. The cooled reaction mixture was evaporated under vacuum. The residue was purified by flash chromatography (PE / DCM=1 / 1) to give the title compound (16.5 g). MS (ESI, m / e) [M+H] + 364.7.
[0176] Step 2: 4-(Benzyloxy)-7-bromo-2-chloro-8-fluoro-6-(trifluoromethyl)quinazoline
[0177]
[0178] To a stirred solution of NaH (2.20 g, 54.4 mmol, 60%) in 50 mL THF was added BnOH (5.15 g, 47.6 mmol) at 0°C and stirred at 0°C for 30 minutes. Then, to a solution of 7-bromo-2,4-dichloro-8-fluoro-6-(trifluoromethyl)quinazoline (16.5 g, 45.3 mmol) in 150 mL THF was added the above mixture at -40°C and the reaction mixture was stirred at room temperature for 3 hours. The reaction was quenched with water and extracted with EtOAc, and the combined organic layers were dried over sodium sulfate and evaporated. The residue was purified by flash chromatography to give the title product (16.7 g). MS (ESI, m / e) [M+H] + 436.7.
[0179] Step 3: 4-(Benzyloxy)-7-bromo-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazoline
[0180]
[0181] To a stirred solution of 4-(benzyloxy)-7-bromo-2-chloro-8-fluoro-6-(trifluoromethyl)quinazoline (12.5 g, 28.7 mmol) in 120 mL of dioxane was added Cs2CO3 (23.4 g, 71.8 mmol) and ((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizine-7a(5H)-yl)methanol (6.85 g, 43.1 mmol), and the resulting mixture was stirred at 80°C overnight. The cooled reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (eluted with DCM / MeOH=20 / 1) to give the title product (13.1 g). MS (ESI, m / e) [M+H] + 557.8.
[0182] Step 4: tert-Butyl (4-(4-(benzyloxy)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-yl)carbamate
[0183]
[0184] To a 250 mL round-bottom flask were added 4-(benzyloxy)-7-bromo-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazoline (10.0 g, 17.9 mmol), (2-((tert-butoxycarbonyl)amino)-7-fluorobenzo[d]thiazol-4-yl)boronic acid (11.2 g, 35.8 mmol), K3PO4 (15.2 g, 71.6 mmol), Pd(dtbpf)Cl2 (1.17 g, 1.79 mmol), dioxane (120 mL) and H2O (24 mL), and the reaction mixture was stirred at 100°C for 3 hours. The resulting cooled mixture was concentrated and purified by flash column chromatography (DCM / MeOH=20 / 1) to give the title product (8.67 g). MS (ESI, m / e) [M+H] + 745.9.
[0185] Step 5: 7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-ol
[0186] To a 250 mL round bottom flask was added tert-butyl (4-(4-(benzyloxy)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-yl)carbamate (10.0 g, 13.4 mmol) and TFA (100 mL), and the resulting mixture was stirred at room temperature overnight. The reaction mixture was evaporated under vacuum. The residue was purified by preparative HPLC to give the title compound (6.1 g). MS (ESI, m / e) [M+H] + 556.3.
[0187] Example 1b (common intermediate): tert-butyl (7-fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-hydroxy-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-yl)carbamate
[0188]
[0189] Step 1: tert-Butyl (7-fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-hydroxy-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-yl)carbamate
[0190] To a stirred solution of tert-butyl (4-(4-(benzyloxy)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-yl)carbamate (8.67 g, 11.6 mmol) in 120 mL of EtOAc was added 10% Pd / C (2.90 g) under N2, and the resulting mixture was degassed 3 times with H2 and stirred at room temperature under H2 atmosphere for 5 hours. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (eluting with DCM / MeOH=10 / 1) to give the title product (6.54 g). MS (ESI, m / e) [M+1] + 656.3. 1 H NMR(500MHz,DMSO-d6)δ12.20(s,1H),8.18(s,1H),7.46–7.36(m,1H),7.25–7.3 5(m,1H),5.20–5.45(m,1H),2.80–3.23(m,4H),1.77–2.22(m,6H),1.47(s,9H).
[0191] Example 1: 4-(4-(cyclopropylamino)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0192]
[0193] Step 1: 4-(4-(Cyclopropylamino)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0194] To a solution of 7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizine-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-ol (25 mg, 0.04 mmol) in acetonitrile (5 mL) was added cyclopropylamine (5 mg, 0.09 mmol), (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (36 mg, 0.08 mmol) and 0.2 mL of N,N-diisopropylethylamine at room temperature. After addition, the mixture was stirred at room temperature for 16 hours. It was then diluted with dichloromethane and water. The organic layers were combined, dried over sodium sulfate and evaporated, and the residue was purified by preparative HPLC to give the title compound (6 mg). 1 H NMR(500MHz,CD3OD)δ8.44(s,1H),7.21-7.14(m,1H),6.99-6.92(m,1H),5.46-5.30(m,1H),4.51-4.35(m,2H),3.55-3.36 (m,3H),3.19-3.06(m,2H),2.53-2.18(m,3H),2.16-2.05(m,2H),2.01-1.92(m,1H),1.00-0.89(m,2H),0.82-0.74(m,2H). MS(ESI,m / e)[M+H] + 595.4.
[0195] Example 2: 7-Fluoro-4-(8-fluoro-4-(((1S,2R)-2-fluorocyclopropyl)amino)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0196]
[0197] Step 1: tert-Butyl (7-fluoro-4-(8-fluoro-4-(((1S,2R)-2-fluorocyclopropyl)amino)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-yl)carbamate
[0198]
[0199] To a solution of tert-butyl (7-fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-hydroxy-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-yl)carbamate (50 mg, 0.08 mmol) in 10 mL of N,N-dimethylformamide was added (1S,2R)-2-fluorocyclopropane-1-amine hydrochloride (17 mg, 0.15 mmol), ((1H-benzo[d][1,2,3]triazol-1-yl)oxy)tris(pyrrolidin-1-yl)phosphonium hexafluorophosphate (80 mg, 0.15 mmol) and 0.3 mL of N,N-diisopropylethylamine. The reaction was stirred at room temperature for 16 hours and then diluted with ethyl acetate and water. The combined organic layers were dried over sodium sulfate and evaporated. The residue was purified by silica gel chromatography to give the title compound (10 mg, 15%). MS (ESI, m / e) [M+H] + 713.4.
[0200] Step 2: 7-Fluoro-4-(8-fluoro-4-(((1S,2R)-2-fluorocyclopropyl)amino)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0201]
[0202] To a solution of tert-butyl (7-fluoro-4-(8-fluoro-4-(((1S,2R)-2-fluorocyclopropyl)amino)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizine-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazoline-7-yl)benzo[d]thiazol-2-yl)carbamate (10 mg, 0.015 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (1 mL) at room temperature. After addition, the mixture was stirred at room temperature for 4 hours. The solution was then evaporated, and the pH of the residue was adjusted to 11 with aqueous sodium carbonate solution, and the mixture was diluted with dichloromethane and water. The combined organic layers were dried over sodium sulfate and evaporated. The residue was purified by preparative HPLC to give the title compound (2 mg). 1 H NMR(500MHz,CD3OD)δ8.55(s,1H),7.22-7.16(m,1H),7.00-6.93(m,1H),5.50-5.33(m,1H),4.95-4.75(m,2H),4 .60-4.47(m,2H),3.73-3.45(m,3H),3.17-3.10(m,1H),2.58-2.22(m,3H),2.22-1.94(m,3H),1.42-1.28(m,2H). MS(ESI,m / e)[M+H] + 613.4.
[0203] Example 3: 7-Fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-((2-methylcyclopropyl)amino)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0204]
[0205] Example 3 was prepared by a procedure analogous to that described in Example 1, substituting 2-methylcyclopropane-1-amine for cyclopropylamine, to give the title product. 1 H NMR(500MHz,CD3OD)δ8.43(s,1H),7.22-7.15(m,1H),7.00-6.90(m,1H),5.50-5.30(m,1H),4.55-4.35 (m,2H),3.65-3.35(m,3H),3.23-3.13(m,1H),2.78-2.70(m,1H),2.53-1.91(m,6H),1.26-0.70(m,6H). MS(ESI,m / e)[M+H] + 609.6.
[0206] Example 4: 4-(4-(((trans-2-ethylcyclopropyl)amino)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0207]
[0208] Example 4 was prepared by a procedure analogous to that described in Example 1, substituting trans-2-ethylcyclopropane-1-amine for cyclopropylamine, to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.44(s,1H),7.19-7.13(m,1H),6.98-6.91(m,1H),5.43-5.27(m,1H),4.47-4.32(m,2H),3.50-3.33(m,4H),3.13-3.05 (m,1H),2.88-2.81(m,1H),2.45-1.89(m,6H),158-1.47(m,1H),1.45- 1.35(m,1H),1.15-1.05(m,3H),0.97-0.89(m,1H),0.79-0.70(m,1H). MS(ESI,m / e)[M+H] + 623.3.
[0209] Example 5: 7-Fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-(((trans)-2-phenylcyclopropyl)amino)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0210]
[0211] Example 5 was prepared by a procedure analogous to that described in Example 1, substituting trans-2-phenylcyclopropane-1-amine for cyclopropylamine, to provide the title product. 1 H NMR (500MHz, CD3OD) δ8.53–8.45(m,1H),7.41–7.06(m,6H),7.01–6.90(m,1H),5.45-5.25(m,1H),4.28–4. 00(m,2H),3.62–3.37(m,3H),3.18–2.99(m,1H),2.39–1.68(m,7H),1.66–1.50(m,1H),1.48–1.34(m,1H). MS(ESI,m / e)[M+H] + 671.5.
[0212] Example 6: 7-Fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-((2-methoxycyclopropyl)amino)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0213]
[0214] Example 6 was prepared by a procedure analogous to that described in Example 1, substituting 2-methoxycyclopropane-1-amine for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.54(s,1H),7.23-7.14(m,1H),7.00-6.92(m,1H),5.48-5.29(m,1H),4.55-4.38 (m,2H),3.64-3.40(m,4H),3.37-3.32(m,3H),3.24-3.15(m,2H),2.52-1.91(m,6H),1.19-1.08(m,2H). MS(ESI,m / e)[M+H] + 625.4.
[0215] Example 7: 4-(4-(((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)amino)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0216]
[0217] Example 7 was prepared by a procedure analogous to that described in Example 1, substituting (1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-amine for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.45(s,1H),7.20–7.15(m,1H),6.98-6.94(m,1H),5.50-5.39(m,1H),4.59-4.50(m,2H),4.10-4.08(m,2H),3.83-3.71 (m,2H),3.74–3.61(m,3H),3.27–3.23(m,1H),2.87-2.85(m,1H),2.57 –2.38(m,2H),2.33–2.25(m,1H),2.20-2.18(m,2H),2.11–1.98(m,3H). MS(ESI,m / e)[M+H]+ 637.4.
[0218] Example 8: 4-(4-(Bicyclo[3.1.0]hexan-6-ylamino)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0219]
[0220] Example 8 was prepared by a procedure analogous to that described in Example 1, substituting bicyclo[3.1.0]hexan-6-amine for cyclopropylamine, to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.48(s,1H),7.20–7.15(m,1H),6.99-6.93(m,1H),5.60-5.41(m,1H),4.72-4.55(m,2H),3.94–3.66(m,3H),3.42-3.34 (m,1H),2.85-2.78(m,1H),2.66–2.44(m,2H),2.40–2.23(m,3H),2.22 –1.95(m,3H),1.89–1.80(m,2H),1.74–1.58(m,3H),1.37–1.20(m,1H). MS(ESI,m / e)[M+H] + 635.4.
[0221] Example 9: 1-((1R,5S,6s)-6-((7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)amino)-3-azabicyclo[3.1.0]hexan-3-yl)ethan-1-one
[0222]
[0223] Example 9 was prepared by a procedure analogous to that described in Example 1, substituting 1-((1R,5S,6s)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl)ethan-1-one for cyclopropylamine to provide the title product. 1H NMR(500MHz,CD3OD)δ8.44(s,1H),7.25-7.06(m,1H),7.00-6.88(m,1H),5.51-5.33(m,1H),4.60-4.45(m,2H),3.98–3.86 (m,2H),3.85–3.74(m,1H),3.71–3.41(m,4H),3.28-3.22(m,2H),2.80-2.75(m,1H),2.59–2.23(m,3H),2.21–1.88(m,7H). MS(ESI,m / e)[M+H] + 678.4.
[0224] Example 10: 4-(4-(cyclobutylamino)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0225]
[0226] Example 10 was prepared by a procedure analogous to that described in Example 1, substituting cyclobutylamine for cyclopropylamine, to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.54(s,1H),7.20-7.15(m,1H),6.99-6.92(m,1H),5.46-5.30(m,1H),4 .41-4.36(m,2H),3.55-3.37(m,3H),3.18-3.08(m,2H),2.53-2.18(m,7H),2.16-1.81(m,5H). MS(ESI,m / e)[M+H] + 609.3.
[0227] Example 11: cis-3-((7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)amino)cyclobutan-1-ol
[0228]
[0229] Example 11 was prepared by a procedure analogous to that described in Example 1, substituting cis-3-aminocyclobutanol for cyclopropylamine, to provide the title product. 1H NMR(500MHz,CD3OD)δ8.61–8.54(m,1H),7.22–7.13(m,1H),7.02–6.89(m,1H),5.49–5.34(m,1H),4.55–4.38(m,2H),4.33–4.09(m,2H) ,3.66–3.49(m,3H),3.27–3.20(m,1H),2.94–2.83(m,2H),2.53–2.35(m,2H),2.31–2.23(m,1H),2.21–2.08(m,4H),2.05–1.94(m,1H). MS(ESI,m / e)[M+H] + 625.6.
[0230] Example 12: (trans)-3-((7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)amino)cyclobutan-1-ol
[0231]
[0232] Example 12 was prepared by a procedure analogous to that described in Example 1, substituting trans-3-aminocyclobutanol for cyclopropylamine, to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.61(s,1H),7.21–7.15(m,1H),7.00–6.93(m,1H),5. 55-5.40(m,1H),4.63-4.47(m,3H),3.85-3.63(m,3H),2.58-2.00(m,10H). MS(ESI,m / e)[M+H] + 625.5.
[0233] Example 13: 7-Fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-(((cis)-3-methoxycyclobutyl)amino)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0234]
[0235] Example 13 was prepared by a procedure analogous to that described in Example 1, substituting cis-3-methoxycyclobutylamine for cyclopropylamine, to provide the title product. 1H NMR(500MHz,CD3OD)δ8.60(s,1H),7.28–7.10(m,1H),7.11–6.84(m,1H),5.59–5.42(m,1H),4.70–4.55(m,2H),4.45–4.35(m,1H),3.96–3.70 (m,5H),3.43–3.37(m,2H),2.94–2.84(m,2H),2.68–2.64(m,1H),2.63 –2.49(m,2H),2.42–2.36(m,1H),2.33–2.24(m,2H),2.20–2.06(m,3H). MS(ESI,m / e)[M+H] + 638.2.
[0236] Example 14: 7-Fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-(((trans)-3-methoxycyclobutyl)amino)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0237]
[0238] Example 14 was prepared by a procedure similar to that described in Example 1, substituting trans-3-methoxycyclobutylamine for cyclopropylamine to give the title product. 1H NMR (500 MHz, CD3OD) δ 8.57 (s, 1H), 7.21-7.14 (m, 1H), 6.99-6.92 (m, 1H), 5.58-5.31 (m, 1H), 4.50-4.35 (m, 2H), 4.20-4.10 (m, 1H), 3.62-3.46 (m, 3H), 2.20-3.12 (m, 1H), 2.55-1.96 (m, 9H). MS (ESI, m / e) [M+H] + 639.5.
[0239] Example 15: 7-Fluoro-4-(8-fluoro-4-(((cis)-3-fluorocyclobutyl)amino)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0240]
[0241] Example 15 was prepared by a procedure analogous to that described in Example 1, substituting cis-3-fluorocyclobutylamine for cyclopropylamine, to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.51(s,1H),7.17–7.05(m,1H),6.95–6.78(m,1H),5.47–5.35(m,1H),4.61–4.19(m,3H),3 .90–3.69(m,3H),3.36–3.29(m,2H),2.96–2.84(m,2H),2.53–2.28(m,5H),2.26–2.16(m,2H),2.06–1.96(m,1H). MS(ESI,m / e)[M+H] + 627.6.
[0242] Example 16: 7-Fluoro-4-(8-fluoro-4-(((trans)-3-fluorocyclobutyl)amino)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0243]
[0244] Example 16 was prepared by a procedure analogous to that described in Example 1, substituting trans-3-fluorocyclobutylamine for cyclopropylamine, to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.55(s,1H),7.21-7.14(m,1H),7.00-6.92(m,1H),5.48-5.24(m,2H),5. 01-4.92(m,1H),4.51-4.36(m,2H),3.63-3.46(m,3H),3.28-3.16(m,1H),2.80-1.96(m,10H). MS(ESI,m / e)[M+H] + 627.4.
[0245] Example 17: 4-(4-((3,3-difluorocyclobutyl)amino)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0246]
[0247] Example 17 was prepared by a procedure analogous to that described in Example 1, substituting 3,3-difluorocyclobutane-1-amine for cyclopropylamine, to give the title product. 1H NMR(500MHz,CD3OD)δ8.57(s,1H),7.24–7.07(m,1H),7.02–6.91(m,1H),5.52–5.37(m,1H),4.65–4.30(m,3H),3.82 –3.50(m,3H),3.20–3.04(m,2H),2.96–2.78(m,2H),2.60–2.37(m,2H),2.37–2.26(m,1H),2.20(m,2H),2.03(m,1H). MS(ESI,m / e)[M+H] + 645.4.
[0248] Example 18: (cis)-3-((7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)amino)cyclobutane-1-carbonitrile
[0249]
[0250] Example 18 was prepared by a procedure analogous to that described in Example 1, substituting cis-3-aaminocyclobutanecarbonitrile for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.55(s,1H),7.26–7.10(m,1H),7.00–6.90(m,1H),5.54-5.37(m,1H),4.60–4.46(m,2H),3.77–3.61(m,3H),3.48–3.40 (m,1H),3.19–3.09(m,1H),3.00–2.91(m,2H),2.67–2.58(m,2H),2.60 –2.42(m,2H),2.36–2.29(m,1H),2.27–2.15(m,2H),2.08–2.00(m,1H). MS(ESI,m / e)[M+H] + 634.2.
[0251] Example 19: (trans)-3-((7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)amino)cyclobutane-1-carbonitrile
[0252]
[0253] Example 19 was prepared by a procedure analogous to that described in Example 1, substituting trans-3-aminocyclobutanecarbonitrile for cyclopropylamine, to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.59(s,1H),7.19-7.13(m,1H),7.00-6.91(m,1H),5.48-5.33( m,1H),4.54-4.40(m,2H),3.75-3.46(m,3H),3.28-3.23(m,2H),2.56-1.96(m,10H). MS(ESI,m / e)[M+H] + 639.5.
[0254] Example 20: ((cis)-3-((7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)amino)cyclobutyl)methanol
[0255]
[0256] Example 20 was prepared by a procedure analogous to that described in Example 1, substituting cis-3-amino-cyclobutanemethanol for cyclopropylamine to give the title product. 1 H NMR(500MHz,CD3OD)δ8.58(s,1H),7.26–7.12(m,1H),7.04–6.88(m,1H),5. 58-5.40(m,1H),4.76–4.50(m,3H),3.81–3.51(m,4H),2.64–1.95(m,11H). MS(ESI,m / e)[M+H] + 639.2.
[0257] Example 21: ((trans)-3-((7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)amino)cyclobutyl)methanol
[0258]
[0259] Example 21 was prepared by a procedure analogous to that described in Example 1, substituting trans-3-amino-cyclobutanemethanol for cyclopropylamine to give the title product. 1H NMR(500MHz,CD3OD)δ8.59(s,1H),7.22-7.14(m,1H),7.00-6.92(m,1H),5. 50-5.36(m,1H),4.54-4.40(m,2H),3.75-3.56(m,5H),2.56-1.96(m,11H). MS(ESI,m / e)[M+H] + 639.5.
[0260] Example 22: 7-Fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-(spiro[3.3]hept-2-ylamino)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0261]
[0262] Example 22 was prepared by a procedure analogous to that described in Example 1, substituting spiro[3.3]heptyl-2-amine for cyclopropylamine, to give the title product. 1 H NMR(500MHz,CD3OD)δ8.54(s,1H),7.25–7.08(m,1H),7.00–6.90(m,1H),5.48–5.30(m,1H),4.70–4.55(m,1H),4.50–4.30(m,2H),3 .69–3.39(m,3H),3.25–3.12(m,1H),2.61–2.51(m,2H),2.51–2.31(m,2H),2.30–2.08(m,7H),2.07–1.95(m,3H),1.95–1.80(m,2H). MS(ESI,m / e)[M+H] + 649.4.
[0263] Example 23: 4-(4-((2-oxaspiro[3.3]hept-6-yl)amino)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0264]
[0265] Example 23 was prepared by a procedure analogous to that described in Example 1, substituting 2-oxaspiro[3.3]hept-6-amine for cyclopropylamine, to give the title product. 1H NMR(500MHz,CD3OD)δ8.51(s,1H),7.25–7.07(m,1H),7.00–6.90(m,1H),5.49–5.33(m,1H),4.72–4.36(m,5H),3.72–3.42 (m,3H),3.25–3.12(m,1H),2.93–2.76(m,2H),2.55–2.33(m,4H),2.32–2.21(m,1H),2.20–2.08(m,2H),2.06–1.90(m,1H). MS(ESI,m / e)[M+H] + 651.4.
[0266] Example 24: 4-(4-(Bicyclo[1.1.1]pentan-1-ylamino)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0267]
[0268] Example 24 was prepared by a procedure analogous to that described in Example 1, substituting bicyclo[1.1.1]pentan-1-amine for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.48(s,1H),7.21–7.13(m,1H),6.97-6.94(m,1H),5.49-5.38( m,1H),4.52-4.44(m,2H),3.73-3.48(m,3H),3.29-3.21(m,1H),2.65-1.98(m,13H). MS(ESI,m / e)[M+H] + 621.5.
[0269] Example 25: 7-Fluoro-4-(8-fluoro-4-(((1S,3R)-3-fluorocyclopentyl)amino)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0270]
[0271] Example 25 was prepared by a procedure analogous to that described in Example 1, substituting (1S,3R)-3-fluorocyclopentan-1-amine for cyclopropylamine to provide the title product. 1H NMR(500MHz,CD3OD)δ8.62(s,1H),7.23–7.13(m,1H),6.98-6.94(m,1H),5.47-5.15(m,2H),4.77–4.69(m,1H),4 .56–4.40(m,2H),3.72–3.48(m,3H),3.28-3.18(m,1H),2.66–2.35(m,3H),2.31-2.23(m,2H),2.22–1.82(m,7H). MS(ESI,m / e)[M+H] + 641.5.
[0272] Example 26: (1S,2R)-2-((7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)amino)cyclopentane-1-carbonitrile
[0273]
[0274] Example 26 was prepared by a procedure analogous to that described in Example 1, substituting (1S,2R)-2-aminocyclopentane-1-carbonitrile for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.71(s,1H),7.25–7.13(m,1H),7.01-6.92(m,1H),5.50-5.33(m,1H),4.58–4.35(m,2H),3 .71–3.43(m,4H),3.27–3.15(m,1H),2.56–2.34(m,2H),2.33–2.21(m,3H),2.20–1.96(m,6H),1.86–1.71(m,1H). MS(ESI,m / e)[M+H] + 648.4.
[0275] Example 27: 4-(4-(cyclohexylamino)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0276]
[0277] Example 27 was prepared by a procedure analogous to that described in Example 1, substituting cyclohexylamine for cyclopropylamine, to provide the title product. 1H NMR(500MHz,CD3OD)δ8.57(s,1H),7.23–7.13(m,1H),7.01-6.92(m,1H),5.52-5.36(m,1H),4.60–4.44( m,2H),4.33–4.24(m,1H),3.80–3.54(m,3H),2.56–1.70(m,11H),1.59–1.50(m,4H),1.34–1.22(m,1H). MS(ESI,m / e)[M+H] + 637.4.
[0278] Example 28a (Common Intermediate): tert-Butyl (4-(6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-hydroxyquinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-yl)carbamate
[0279]
[0280] Step 1: 4-(Benzyloxy)-7-bromo-2,6-dichloro-8-fluoroquinazoline
[0281]
[0282] To a solution of benzyl alcohol (3.27 g, 30.27 mmol) in THF (200 mL) was added NaH (1.33 g, 33.3 mmol) dropwise at 0°C, and the mixture was stirred for another 30 minutes at 0°C. The mixture was cooled to -40°C, and 7-bromo-2,4,6-trichloro-8-fluoroquinazoline (10 g, 30.27 mmol) was added. The mixture was stirred at room temperature overnight. The mixture was diluted with water, filtered, and the solid was collected to give the title product (11 g, 91%). MS (ESI, m / e) [M+H] + =400.
[0283] Step 2: 4-(Benzyloxy)-7-bromo-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazoline
[0284]
[0285] 4-(Benzyloxy)-7-bromo-2,6-dichloro-8-fluoroquinazoline (11 g, 27.5 mmol), ((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizine-7a(5H)-yl)methanol (4.4 g, 27.5 mmol), RuPhos Pd G3 (2.3 g, 2.8 mmol) and Cs2CO3 (17.9 g, 55 mmol) were placed in dioxane (110 mL). The mixture was stirred for 16 hours and then cooled to room temperature. The solvent was removed and the residue was purified by column chromatography (hexane / EtOAc=2 / 1) to give the title product (9 g). MS (ESI, m / e) [M+H] + =524.3.
[0286] Step 3: tert-Butyl (4-(4-(benzyloxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-yl)carbamate
[0287]
[0288] 4-(Benzyloxy)-7-bromo-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazoline (9 g, 17.2 mmol), (2-((tert-butoxycarbonyl)amino)-7-fluorobenzo[d]thiazol-4-yl)boronic acid (8.1 g, 25.8 mmol), Pd(dppf)Cl2 (1.2 g, 1.7 mmol) and NaHCO3 (2.9 g, 34.4 mmol) were placed in dioxane (90 mL). The mixture was stirred at 80° C. for 4 hours and then cooled to room temperature. The solvent was removed and the residue was purified by column chromatography (hexane / EtOAc=1 / 2) to give the title product (8.8 g). MS (ESI, m / e) [M+H] + =712.4.
[0289] Step 4: tert-Butyl (4-(6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-oxo-3,4-dihydroquinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-yl)carbamate
[0290] Tert-butyl (4-(4-(benzyloxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-yl)carbamate (8.8 g, 12.4 mmol) was placed in EtOAc (100 mL), and the mixture was stirred at 50° C. for 16 hours. The solvent was removed, and the residue was purified by column chromatography (DCM / MeOH=10 / 1) to give the title product (4.6 g, 60%). MS (ESI, m / e) [M+H] + =622.3.
[0291] Example 28: 4-(6-chloro-4-(cyclopropylamino)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0292]
[0293] Example 28 was prepared by a procedure analogous to that described in Example 2, replacing tert-butyl (7-fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-oxo-3,4-dihydroquinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-yl)carbamate and (1S,2R)-2-fluorocyclopropane-1-amine with tert-butyl (4-(6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-oxo-3,4-dihydroquinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-yl)carbamate and cyclopropylamine to give the title product. 1 H NMR (500MHz, DMSO-d6) δ10.87(s,1H),8.64(s,1H),8.34(s,1H),7.91(s,2H),7.27-7.16(m,1H),7.10-7.01(m,1H),5.62-5.48(m,1H),4.62-4. 56(m,2H),3.90-3.72(m,3H),3.36-3.28(m,1H),3.18-3.10(m,1H),2.3 5-2.20(m,2H),2.23-2.08(m,2H),2.08-1.98(m,1H),0.89-0.70(m,4H). MS(ESI,m / e)[M+H] + 561.5.
[0294] Example 29: 4-(4-(((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)amino)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0295]
[0296] Example 29 was prepared by a procedure analogous to that described in Example 28, substituting (1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-amine for cyclopropylamine to provide the title product. 1 HNMR(500MHz,DMSO-d6)δ8.56(s,1H),8.27(s,1H),7.91(s,2H),7.28-7.16(m,1H),7.10-7.00(m,1H),5.49-5.28(m,1H),4.20-4.15(m,2 H),4.00-3.88(m,2H),3.79-3.63(m,2H),3.25-3.05(m,2H),2.98-2.84(m,2H),2.30-2.10(m,2H),2.11-1.98(m,3H),1.95-1.75(m,3H). MS(ESI,m / e)[M+H] + 603.5.
[0297] Example 30: 1-((1R,5S,6s)-6-((7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)amino)-3-azabicyclo[3.1.0]hexan-3-yl)ethan-1-one
[0298]
[0299] Example 30 was prepared by a procedure analogous to that described in Example 28, substituting 1-((1R,5S,6s)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl)ethan-1-one for cyclopropylamine to provide the title product. 1H NMR(500MHz,DMSO-d6)δ8.60(s,1H),8.26(s,1H),7.91(s,2H),7.31-7.17(m,1H),7.10-7.00(m,1H),5.47-5.23(m,1H),4.20-4.08(m,2H), 3.80-3.64(m,3H),3.47-3.36(m,1H),3.30-3.28(m,1H),3.23-3.00(m ,2H),2.87(s,1H),2.76(s,1H),2.25-2.00(m,4H),2.00-1.66(m,7H). MS(ESI,m / e)[M+H] + 644.5.
[0300] Example 31: 4-(6-chloro-4-(cyclobutylamino)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0301]
[0302] Example 31 was prepared by a procedure analogous to that described in Example 28, substituting cyclobutylamine for cyclopropylamine, to give the title product. 1 H NMR(500MHz,DMSO-d6)δ10.85(s,1H),8.83–8.75(m,1H),8.44(s,1H),7. 90(s,2H),7.24-7.21(m,1H),7.08–7.05(m,1H),5.65-5.45(m,1H),4.73- 4.68(m,1H),4.62-4.47(m,2H),3.90-3.74(m,3H),2.48-2.45(m,1H),2. 36-2.31(m,3H),2.19-2.17(m,4H),2.04-2.02(m,1H),1.84-1.72(m,2H). MS(ESI)m / e[M+1] + =575.4.
[0303] Example 32: 4-(4-(Bicyclo[1.1.1]pentan-1-ylamino)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0304]
[0305] Example 32 was prepared by a procedure analogous to that described in Example 28, substituting bicyclo[1.1.1]pentan-1-amine for cyclopropylamine to provide the title product. 1 H NMR(500MHz,DMSO-d6)δ9.10(s,1H),8.33(s,1H),7.91(s,2H),7.28-7.21(m,1H),7.08–7.00(m,1H),5.5 6-5.28(m,1H),4.50-4.00(m,2H),3.75-3.40(m,1H),3.20-2.85(m,3H),2.59(s,1H),2.32-1.80(m,12H). MS(ESI,m / e)[M+H] + 587.4.
[0306] Example 33: 4-(4-(azetidin-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0307]
[0308] Example 33 was prepared by a procedure analogous to that described in Example 2, substituting azetidine for (1S,2R)-2-fluorocyclopropane-1-amine, to give the title product. 1 H NMR(500MHz,CD3OD)δ8.07(s,1H),7.20-7.13(m,1H),6.98-6.91(m,1H),5.43-5.27(m,1H),4.79-4.52 (m,2H),4.43-4.25(m,2H),3.54-3.34(m,5H),3.18-3.09(m,1H),2.67-2.56(m,2H),2.44-1.87(m,6H). MS(ESI,m / e)[M+H] + 595.4.
[0309] Example 34: 7-Fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-(3-methylazetidin-1-yl)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0310]
[0311] Example 34 was prepared by a procedure analogous to that described in Example 2, substituting 3-methylazetidine for (1S,2R)-2-fluorocyclopropane-1-amine, to give the title product. 1 H NMR(500MHz,CD3OD)δ8.08(s,1H),7.20-7.12(m,1H),6.98-6.91(m,1H),5.47-5.25(m,1H),4 .40-4.25(m,2H),3.49-3.35(m,3H),3.18-2.98(m,3H),2.41-1.86(m,6H),1.43-1.38(m,3H). MS(ESI,m / e)[M+H] + 609.4.
[0312] Example 35: 7-Fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-(2-methylazetidin-1-yl)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0313]
[0314] Example 35 was prepared by a procedure analogous to that described in Example 1, substituting 2-methylazetidine for cyclopropylamine, to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.11(s,1H),7.25–7.15(m,1H),7.03–6.93(m,1H),5.61-5.47(m,1H),5.10-5.00(m,1H),4 .77–4.53(m,3H),4.03–3.79(m,3H),3.48-3.40(m,1H),2.88-2.76(m,1H),2.71–2.06(m,7H),1.74–1.66(m,3H). MS(ESI,m / e)[M+H] + 609.4.
[0315] Example 36: 4-(4-(2,2-dimethylazetidin-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0316]
[0317] Example 36 was prepared by a procedure analogous to that described in Example 1, substituting 2,2-dimethylazetidine for cyclopropylamine, to give the title product.1 H NMR(500MHz,CD3OD)δ8.13(s,1H),7.19-7.14(m,1H),6.98-6.91(m,1H),5.42-5.26(m,1H),4.85-4.76(m,3H) ,4.37-4.21(m,2H),3.51-3.34(m,3H),3.15-3.06(m,1H),2.45-2.38(m,2H),2.36-1.87(m,5H),1.82(s,6H). MS(ESI,m / e)[M+H] + 623.4.
[0318] Example 37: 7-Fluoro-4-(8-fluoro-4-(3-fluoroazetidin-1-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0319]
[0320] Example 37 was prepared by a procedure analogous to that described in Example 2, substituting 3-fluoroazetidine for (1S,2R)-2-fluorocyclopropane-1-amine, to give the title product. 1 H NMR(500MHz,CD3OD)δ8.07(s,1H),7.23-7.14(m,1H),7.02-6.92(m,1H),5.69-5.43(m,2H),5 .15-4.92(m,2H),4.80-4.54(m,4H),3.98-3.78(m,3H),3.46-3.37(m,1H),2.64-2.03(m,6H). MS(ESI,m / e)[M+H] + 708.4.
[0321] Example 38: 4-(4-(3,3-difluoroazetidin-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0322]
[0323] Example 38 was prepared by a procedure analogous to that described in Example 2, substituting 3,3-difluoroazetidine for (1S,2R)-2-fluorocyclopropane-1-amine to give the title product. 1H NMR(500MHz,CD3OD)δ8.03(s,1H),7.21-7.14(m,1H),6.99-6.93(m,1H),5.44-5.28(m,1H),5 .11-4.99(m,4H),4.45-4.32(m,2H),3.55-3.34(m,3H),3.17-3.09(m,1H),2.46-1.92(m,6H). MS(ESI,m / e)[M+H] + 631.4.
[0324] Example 39: 1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)azetidine-3-carbonitrile
[0325]
[0326] Example 39 was prepared by a procedure analogous to that described in Example 2, substituting azetidine-3-carbonitrile for (1S,2R)-2-fluorocyclopropane-1-amine, to give the title product. 1 H NMR(500MHz,CD3OD)δ8.03(s,1H),7.21-7.15(m,1H),7.00-6.93(m,1H),5.56-5.41(m,1H),5.03-4.90 (m,2H),4.62-4.48(m,2H),4.06-3.97(m,1H),3.88-3.64(m,3H),3.40-3.32(m,3H),2.61-2.01(m,6H). MS(ESI,m / e)[M+H] + 620.3.
[0327] Example 40: 2-(1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)azetidin-3-yl)acetonitrile
[0328]
[0329] Example 40 was prepared by a procedure analogous to that described in Example 1, substituting 2-(azetidin-3-yl)acetonitrile for cyclopropylamine, to provide the title product. 1H NMR(500MHz,CD3OD)δ8.08(s,1H),7.20-7.14(m,1H),6.98-6.91(m,1H),5.47-5.32(m,1H),4 .53-4.32(m,4H),3.68-3.42(m,4H),3.24-3.13(m,3H),2.99-2.93(m,2H),2.50-1.92(m,6H). MS(ESI,m / e)[M+H] + 634.6.
[0330] Example 41: 3-(1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)azetidin-3-yl)propanenitrile
[0331]
[0332] Example 41 was prepared by a procedure analogous to that described in Example 1, substituting 3-(azetidin-3-yl)propionitrile for cyclopropylamine to give the title product. 1 H NMR(500MHz,CD3OD)δ8.09(s,1H),7.21-7.14(m,1H),7.00-6.93(m,1H),5.49-5.32(m,1H),4.74-4.36 (m,4H),3.71-3.45(m,3H),3.25-3.15(m,3H),3.11-3.01(m,1H),2.61-2.53(m,2H),2.52-1.91(m,8H). MS(ESI,m / e)[M+H] + 648.5.
[0333] Example 42: 1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-3-methylazetidine-3-carbonitrile
[0334]
[0335] Example 42 was prepared by a procedure analogous to that described in Example 1, substituting 3-methylazetidine-3-carbonitrile for cyclopropylamine, to give the title product. 1H NMR(500MHz,CD3OD)δ8.03(s,1H),7.22–7.13(m,1H),7.02–6.92(m,1H),5.55–5. 41(m,1H),4.62–4.53(m,4H),3.83–3.67(m,3H),2.61–1.97(m,9H),1.83(s,3H). MS(ESI,m / e)[M+H] + 634.2.
[0336] Example 43: 1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-2-methylazetidine-3-carbonitrile
[0337]
[0338] Example 43 was prepared by a procedure analogous to that described in Example 1, substituting 2-methylazetidine-3-carbonitrile for cyclopropylamine to give the title product. 1H NMR (500 MHz, CD3OD) δ 8.01 (s, 1H), 7.22–7.13 (m, 1H), 7.02–6.93 (m, 1H), 5.60–5.40 (m, 1H), 5.26–5.03 (m, 2H), 4.68–4.51 (m, 2H), 4.20–4.11 (m, 1H), 3.92–3.70 (m, 3H), 3.43–3.35 (m, 1H), 2.66–2.02 (m, 6H), 1.87–1.78 (m, 3H). MS (ESI, m / e) [M+H] + 634.4.
[0339] Example 44: 7-Fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-(3-(methylsulfonyl)azetidin-1-yl)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0340]
[0341] Example 44 was prepared by a procedure analogous to that described in Example 1, substituting 3-(methylsulfonyl)azetidine for cyclopropylamine to give the title product. 1H NMR (500 MHz, CD3OD) δ 8.07 (s, 1H), 7.24-7.14 (m, 1H), 7.01-6.92 (m, 1H), 5.59-5.42 (m, 1H), 4.66-4.48 (m, 3H), 3.93-3.54 (m, 3H), 3.47-3.35 (m, 3H), 3.10 (s, 1H), 2.90-2.85 (m, 1H), 2.70-2.10 (m, 6H). MS (ESI, m / e) [M+H] + 673.5.
[0342] Example 45: 7-Fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-(3-methoxyazetidin-1-yl)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0343]
[0344] Example 45 was prepared by a procedure analogous to that described in Example 1, substituting 3-methoxyazetidine for cyclopropylamine, to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.09(s,1H),7.22–7.12(m,1H),7.02–6.91(m,1H),5.51-5.32(m,1H) ,4.62–4.23(m,5H),3.75–3.46(m,3H),3.41(s,3H),3.26–3.15(m,2H),2.56–1.90(m,6H). MS(ESI,m / e)[M+H] + 625.4.
[0345] Example 46: 1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-3-methylazetidin-3-ol
[0346]
[0347] Example 46 was prepared by a procedure analogous to that described in Example 1, substituting 3-methylazetidin-3-ol for cyclopropylamine, to provide the title product. 1H NMR(500MHz,CD3OD)δ8.07(s,1H),7.22–7.12(m,1H),7.02–6.91(m,1H),5.45-5.27(m,1H) ,4.75–4.25(m,6H),3.54–3.35(m,3H),3.20–3.05(m,1H),2.47–1.80(m,6H),1.61(s,3H). MS(ESI,m / e)[M+H] + 625.4.
[0348] Example 47: 1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-2-methylazetidin-3-ol
[0349]
[0350] Example 47 was prepared by a procedure analogous to that described in Example 1, substituting 2-methylazetidin-3-ol for cyclopropylamine, to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.06(s,1H),7.25–7.09(m,1H),7.02–6.91(m,1H),5.45-5.28(m,1H),5.22-5.03 (m,1H),4.63–4.24(m,3H),3.55–3.34(m,3H),3.20–3.06(m,1H),2.48–1.87(m,6H),1.70-1.54(m,3H). MS(ESI,m / e)[M+H] + 625.4.
[0351] Example 48: (1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)azetidin-3-yl)methanol
[0352]
[0353] Example 48 was prepared by a procedure analogous to that described in Example 1, substituting azetidin-3-ylmethanol for cyclopropylamine, to give the title product. 1H NMR(500MHz,CD3OD)δ8.11(s,1H),7.30–7.12(m,1H),7.02–6.91(m,1H),5.48-5.28(m,1H),4 .73–4.25(m,5H),3.88–3.75(m,2H),3.67–3.37(m,4H),3.23–3.00(m,2H),2.48–1.89(m,6H). MS(ESI,m / e)[M+H] + 625.4.
[0354] Example 49: ((2R)-1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)azetidin-2-yl)methanol
[0355]
[0356] Example 49 was prepared by a procedure analogous to that described in Example 1, substituting (R)-azetidin-2-ylmethanol for cyclopropylamine, to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.12(s,1H),7.22-7.12(m,1H),7.01–6.91(m,1H),5.49-5.34(m,1H),5.04-4.96(m,1H),4.83–4.76(m,1H),4 .72-4.64(m,1H),4.48-4.40(m,2H),4.24-4.17(m,1H),3.88-3.84(m,1H),3.69-3.43(m,3H),3.25-3.20(m,1H),2.70-1.94(m,8H). MS(ESI,m / e)[M+H] + 625.5.
[0357] Example 50: 7-Fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-(pyrrolidin-1-yl)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0358]
[0359] Example 50 was prepared by a procedure analogous to that described in Example 2, substituting pyrrolidine for (1S,2R)-2-fluorocyclopropane-1-amine, to provide the title product. 1H NMR(500MHz,CD3OD)δ8.47(s,1H),7.22-7.14(m,1H),6.99-6.92(m,1H),5.47-5.30(m,1H),4. 48-4.32(m,2H),4.09-3.98(m,4H),3.62-3.39(m,3H),3.22-3.12(m,1H),2.50-1.91(m,10H). MS(ESI,m / e)[M+H] + 609.4.
[0360] Example 51: 7-Fluoro-4-(8-fluoro-4-((R)-3-fluoropyrrolidin-1-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0361]
[0362] Example 51 was prepared by a procedure analogous to that described in Example 2, substituting (R)-3-fluoropyrrolidine for (1S,2R)-2-fluorocyclopropane-1-amine, to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.44(s,1H),7.21-7.15(m,1H),7.00-6.91(m,1H),5.55-5.25 (m,2H),4.41-4.01(m,6H),3.49-3.40(m,1H),3.10-3.02(m,1H),2.58-1.83(m,8H). MS(ESI,m / e)[M+H] + 627.4.
[0363] Example 52: 7-Fluoro-4-(8-fluoro-4-((S)-3-fluoropyrrolidin-1-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0364]
[0365] Example 52 was prepared by a procedure analogous to that described in Example 2, substituting (S)-3-fluoropyrrolidine for (1S,2R)-2-fluorocyclopropane-1-amine, to provide the title product. 1H NMR(500MHz,CD3OD)δ8.48(s,1H),7.23-7.15(m,1H),7.02-6.94(m,1H),5.57-5.41(m,2H),4 .68-4.53(m,2H),4.36-4.19(m,4H),3.98-3.68(m,3H),3.43-3.35(m,1H),2.66-2.02(m,8H). MS(ESI,m / e)[M+H] + 627.4.
[0366] Example 53: 4-(4-(3,3-difluoropyrrolidin-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0367]
[0368] Example 53 was prepared by a procedure analogous to that described in Example 2, substituting 3,3-difluoropyrrolidine for (1S,2R)-2-fluorocyclopropane-1-amine to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.38(s,1H),7.22-7.15(m,1H),6.99-6.93(m,1H),5.47-5.31(m,1H),4 .50-4.31(m,6H),3.61-3.38(m,3H),3.21-3.12(m,1H),2.70-2.58(m,2H),2.50-1.93(m,6H). MS(ESI,m / e)[M+H] + 645.4.
[0369] Example 54: 7-Fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-((R)-3-methylpyrrolidin-1-yl)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0370]
[0371] Example 54 was prepared by a procedure analogous to that described in Example 1, substituting (R)-3-methylpyrrolidine for cyclopropylamine, to provide the title product. 1H NMR(500MHz,CD3OD)δ8.44(s,1H),7.21-7.15(m,1H),6.98-6.91(m,1H),5.42-5.27(m,1H),4.42-4.25( m,2H),4.23-3.98(m,3H),3.65-3.34(m,3H),3.14-3.03(m,1H),2.55-1.68(m,10H),1.24-1.18(m,3H). MS(ESI,m / e)[M+H] + 623.5.
[0372] Example 55: 7-Fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-((R)-2-methylpyrrolidin-1-yl)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0373]
[0374] Example 55 was prepared by a procedure analogous to that described in Example 1, substituting (R)-2-methylpyrrolidine for cyclopropylamine, to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.46(s,1H),7.24–7.13(m,1H),7.02–6.91(m,1H),5.65–5.43(m,1H),4. 87–4.57(m,3H),4.31–3.82(m,5H),3.49–3.42(m,1H),2.74–1.81(m,10H),1.52-1.45(m,3H). MS(ESI,m / e)[M+H] + 623.5.
[0375] Example 56: 7-Fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-((S)-2-methylpyrrolidin-1-yl)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0376]
[0377] Example 56 was prepared by a procedure analogous to that described in Example 1, substituting (S)-2-methylpyrrolidine for cyclopropylamine, to provide the title product. 1H NMR(500MHz,CD3OD)δ8.47(s,1H),7.28–7.14(m,1H),7.03–6.93(m,1H),5.60–5.43(m,1H),4. 86–4.68(m,2H),4.30–3.85(m,5H),3.48–3.43(m,1H),2.72–1.85(m,10H),1.52-1.45(m,3H). MS(ESI,m / e)[M+H] + 623.5.
[0378] Example 57: 4-(4-(2,2-dimethylpyrrolidin-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0379]
[0380] Example 57 was prepared by a procedure analogous to that described in Example 2, substituting 2,2-dimethylpyrrolidine for (1S,2R)-2-fluorocyclopropane-1-amine to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.45(s,1H),7.21-7.15(m,1H),6.98-6.91(m,1H),5.41-5.25(m,1H) ,4.40-4.26(m,2H),4.26-4.20(m,2H),3.23-3.01(m,4H),2.43-1.84(m,10H),1.79(s,6H). MS(ESI,m / e)[M+H] + 636.9.
[0381] Example 58: 4-(4-((R)-2-ethylpyrrolidin-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0382]
[0383] Example 58 was prepared by a procedure analogous to that described in Example 1, substituting (R)-2-ethylpyrrolidine for cyclopropylamine, to provide the title product. 1H NMR(500MHz,CD3OD)δ8.39(s,1H),7.25–7.12(m,1H),7.02-6.91(m,1H),5.55–5.35(m,1H),4.70–4.42(m,3H),4. 24–4.05(m,2H),3.83–3.55(m,3H),2.63–2.41(m,2H),2.33–1.89(m,10H),1.72–1.58(m,1H),1.09-1.00(m,3H). MS(ESI,m / e)[M+H] + 637.5.
[0384] Example 59: 4-(4-((S)-2-ethylpyrrolidin-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0385]
[0386] Example 59 was prepared by a procedure analogous to that described in Example 1, substituting (S)-2-ethylpyrrolidine for cyclopropylamine, to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.41(s,1H),7.25–7.14(m,1H),7.02-6.93(m,1H),5.62–5.44(m,1H),4.70–4.60(m,3H),4.22–4.07( m,2H),4.04–3.81(m,3H),3.47–3.43(m,1H),2.70–2.53(m,2H),2.42–1.92(m,10H),1.72–1.57(m,1H),1.09-1.00(m,3H). MS(ESI,m / e)[M+H] + 637.5.
[0387] Example 60: 1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)pyrrolidine-3-carbonitrile
[0388]
[0389] Example 60 was prepared by a procedure analogous to that described in Example 2, substituting pyrrolidine-3-carbonitrile for (1S,2R)-2-fluorocyclopropane-1-amine, to give the title product. 1H NMR(500MHz,CD3OD)δ8.40(s,1H),7.21-7.14(m,1H),6.99-6.92(m,1H),5.42-5.25 (m,1H),4.44-4.15(m,6H),3.63-3.54(m,1H),3.15-3.04(m,1H),2.59-1.85(m,8H). MS(ESI,m / e)[M+H] + 634.4.
[0390] Example 61: 2-(1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)pyrrolidin-3-yl)acetonitrile
[0391]
[0392] Example 61 was prepared by a procedure analogous to that described in Example 2, substituting 2-(pyrrolidin-3-yl)acetonitrile for (1S,2R)-2-fluorocyclopropane-1-amine to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.43(s,1H),7.21-7.15(m,1H),6.98-6.91(m,1H),5.41-5.27(m,1H),4.43-4.07 (m,5H),3.85-3.77(m,1H),3.47-3.36(m,3H),3.13-3.03(m,1H),2.85-2.72(m,3H),2.45-1.86(m,8H). MS(ESI,m / e)[M+H] + 647.8.
[0393] Example 62: 4-(4-(2-azabicyclo[2.1.1]hex-2-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0394]
[0395] Example 62 was prepared by a procedure analogous to that described in Example 1, substituting 2-azabicyclo[2.1.1]hexane for cyclopropylamine, to provide the title product. 1H NMR(500MHz,CD3OD)δ8.41(s,1H),7.23-7.14(m,1H),7.01-6.91(m,1H),5.50-5.29(m,2H),4.42-4.27 (m,2H),4.21-4.09(m,2H),3.56-3.39(m,3H),3.19-3.10(m,2H),2.47-1.93(m,8H),1.62-1.53(m,2H). MS(ESI,m / e)[M+H] + 621.4.
[0396] Example 63: (3R)-1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)pyrrolidin-3-ol
[0397]
[0398] Example 63 was prepared by a procedure analogous to that described in Example 1, substituting (R)-pyrrolidin-3-ol for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.46(s,1H),7.25–7.13(m,1H),7.01–6.90(m,1H),5.50–5.32(m,1H),4.65–4.37 (m,3H),4.32–4.03(m,3H),3.99–3.91(m,1H),3.75–3.40(m,3H),3.27–3.12(m,1H),2.60–1.88(m,8H). MS(ESI,m / e)[M+H] + 625.3.
[0399] Example 64: (3S)-1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)pyrrolidin-3-ol
[0400]
[0401] Example 64 was prepared by a procedure analogous to that described in Example 1, substituting (S)-pyrrolidin-3-ol for cyclopropylamine to provide the title product. 1H NMR(500MHz,CD3OD)δ8.45(s,1H),7.25–7.11(m,1H),7.01–6.90(m,1H),5.48–5.32(m,1H),4.65–4.33 (m,3H),4.31–4.02(m,3H),3.99–3.91(m,1H),3.62–3.37(m,3H),3.21–3.07(m,1H),2.54–1.89(m,8H). MS(ESI,m / e)[M+H] + 625.4.
[0402] Example 65: ((3R)-1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)pyrrolidin-3-yl)methanol
[0403]
[0404] Example 65 was prepared by a procedure analogous to that described in Example 1, substituting (R)-pyrrolidin-3-ylmethanol for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.46(s,1H),7.23–7.13(m,1H),7.01–6.90(m,1H),5.47–5.30(m,1H),4.47–4.30(m,2H),4 .27–3.80(m,4H),3.76–3.60(m,2H),3.57–3.33(m,3H),3.18–3.10(m,1H),2.68–2.54(m,1H),2.48–1.87(m,8H). MS(ESI,m / e)[M+H] + 639.5.
[0405] Example 66: ((3S)-1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)pyrrolidin-3-yl)methanol
[0406]
[0407] Example 66 was prepared by a procedure analogous to that described in Example 1, substituting (S)-pyrrolidin-3-ylmethanol for cyclopropylamine to provide the title product. 1H NMR(500MHz,CD3OD)δ8.46(s,1H),7.25–7.09(m,1H),7.01–6.90(m,1H),5.47–5.30(m,1H),4.48–4.29(m,2H),4 .24–3.80(m,4H),3.76–3.60(m,2H),3.57–3.34(m,3H),3.20–3.06(m,1H),2.69–2.56(m,1H),2.49–1.85(m,8H). MS(ESI,m / e)[M+H] + 639.5.
[0408] Example 67: 7-Fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-(piperidin-1-yl)-6-(trifluoromethyl)quinazolin-7-yl)benzo[d]thiazol-2-amine
[0409]
[0410] Example 67 was prepared by a procedure analogous to that described in Example 2, substituting piperidine for (1S,2R)-2-fluorocyclopropane-1-amine to give the title product. 1H NMR (500 MHz, CD3OD) δ 8.12 (s, 1H), 7.22-7.15 (m, 1H), 6.99-6.93 (m, 1H), 5.46-5.30 (m, 1H), 4.46-4.27 (m, 2H), 4.00-3.89 (m, 4H), 3.56-3.35 (m, 3H), 3.19-3.10 (m, 1H), 2.48-1.90 (m, 6H), 1.88-1.79 (m, 6H). MS (ESI, m / e) [M+H] + 623.4.
[0411] Example 68: 1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)piperidine-4-carbonitrile
[0412]
[0413] Example 68 was prepared by a procedure analogous to that described in Example 2, substituting piperidine-4-carbonitrile for (1S,2R)-2-fluorocyclopropane-1-amine to give the title product. 1H NMR (500 MHz, CD3OD) δ 8.10 (s, 1H), 7.21-7.14 (m, 1H), 7.00-6.93 (m, 1H), 5.37-5.21 (m, 1H), 4.35-4.14 (m, 4H), 3.85-3.75 (m, 2H), 3.26-3.14 (m, 4H), 3.04-2.96 (m, 1H), 2.35-1.85 (m, 10H). MS (ESI, m / e) [M+H] + 648.4.
[0414] Example 69: 1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-4-methylpiperidine-4-carbonitrile
[0415]
[0416] Example 69 was prepared by a procedure analogous to that described in Example 1, substituting 4-methylpiperidine-4-carbonitrile for cyclopropylamine, to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.12(s,1H),7.23–7.13(m,1H),7.00-6.92(m,1H),5.40-5.21(m,1H),4.56–4.47(m,2H) ,4.36–4.22(m,2H),3.70–3.54(m,2H),3.28–3.15(m,3H),3.08–2.97(m,1H),2.39–1.79(m,10H),1.49(s,3H). MS(ESI,m / e)[M+H] + 662.6.
[0417] Example 70: 1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-4-fluoropiperidine-4-carbonitrile
[0418]
[0419] Example 70 was prepared by a procedure analogous to that described in Example 1, substituting 4-fluoropiperidine-4-carbonitrile for cyclopropylamine, to provide the title product. 1H NMR(500MHz,CD3OD)δ8.18(s,1H),7.25–7.13(m,1H),7.01-6.92(m,1H),5.51-5.31(m,1H),4. 58–4.40(m,2H),4.25–3.96(m,4H),3.74–3.41(m,3H),3.27–3.15(m,1H),2.59–1.95(m,10H). MS(ESI,m / e)[M+H] + 666.5.
[0420] Example 71: 2-(1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)piperidin-4-yl)acetonitrile
[0421]
[0422] Example 71 was prepared by a procedure analogous to that described in Example 1, substituting 2-(piperidin-4-yl)acetonitrile for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.12(s,1H),7.23–7.14(m,1H),7.01-6.92(m,1H),5.46-5.28(m,1H),4.66–4.52(m,2H),4 .45–4.28(m,2H),3.53–3.32(m,5H),3.19–3.05(m,1H),2.60–2.50(m,2H),2.47–1.89(m,9H),1.67–1.53(m,2H). MS(ESI,m / e)[M+H] + 662.4.
[0423] Example 72: 1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-3-fluoropiperidine-4-carbonitrile
[0424]
[0425] Example 72 was prepared by a procedure analogous to that described in Example 1, substituting 3-fluoropiperidine-4-carbonitrile for cyclopropylamine, to provide the title product. 1H NMR(500MHz,CD3OD)δ8.22(s,1H),7.23–7.14(m,1H),7.01-6.92(m,1H),5.59–5.39 (m,1H),5.14–5.00(m,1H),4.67–4.52(m,4H),3.91–3.45(m,6H),2.62–2.06(m,8H). MS(ESI,m / e)[M+H] + 666.5.
[0426] Example 73: 1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-3-methylpiperidine-4-carbonitrile
[0427]
[0428] Example 73 was prepared by a procedure analogous to that described in Example 1, substituting 3-methylpiperidine-4-carbonitrile for cyclopropylamine, to give the title product. 1 H NMR (500MHz, CD3OD) δ8.16-8.09(m,1H),7.22-7.16(m,1H),7.00-6.93(m,1H),5.47-5.32(m,1H),4.58-4. 25(m,3H),3.73-3.35(m,6H),3.24-3.06(m,2H),2.87-2.75(m,1H),2.54-1.90(m,8H),1.25-1.16(m,3H). MS(ESI,m / e)[M+H] + 662.6.
[0429] Example 74: 1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-trans-2-methylpiperidine-4-carbonitrile
[0430]
[0431] Example 74 was prepared by a procedure analogous to that described in Example 1, substituting trans-2-methylpiperidine-4-carbonitrile for cyclopropylamine, to provide the title product. 1H NMR(500MHz,CD3OD)δ8.07(s,1H),7.22-7.16(m,1H),7.00-6.93(m,1H),5.48-5.32(m,1H),5 .00-4.92(m,2H),4.55-4.36(m,3H),3.68-3.46(m,4H),2.44-1.85(m,8H),1.59-1.51(m,3H). MS(ESI,m / e)[M+H] + 662.5.
[0432] Example 75: 1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-trans-3-hydroxypiperidine-4-carbonitrile
[0433]
[0434] Example 75 was prepared by a procedure analogous to that described in Example 1, substituting trans-3-hydroxypiperidine-4-carbonitrile for cyclopropylamine, to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.26(s,1H),7.25–7.13(m,1H),7.02-6.93(m,1H),5.49-5.32(m,1H),4.55–4.34 (m,3H),4.26–4.95(m,2H),3.78–3.41(m,5H),3.26–3.14(m,1H),3.02–2.90(m,1H),2.56–1.92(m,8H). MS(ESI,m / e)[M+H] + 664.4.
[0435] Example 76: (3R)-1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)piperidine-3-carbonitrile
[0436]
[0437] Example 76 was prepared by a procedure analogous to that described in Example 1, substituting (R)-piperidine-3-carbonitrile for cyclopropylamine, to provide the title product. 1H NMR(500MHz,CD3OD)δ8.21(s,1H),7.27–7.15(m,1H),7.01–6.91(m,1H),5.52–5.32(m,1H),4.61–4.28( m,4H),4.18–4.10(m,1H),4.05–3.95(m,1H),3.83–3.74(m,1H),3.69–3.50(m,3H),2.56–1.84(m,10H). MS(ESI,m / e)[M+H] + 648.4.
[0438] Example 77: (3S)-1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)piperidine-3-carbonitrile
[0439]
[0440] Example 77 was prepared by a procedure analogous to that described in Example 1, substituting (3S)-piperidine-3-carbonitrile for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.23(s,1H),7.27–7.13(m,1H),7.01–6.91(m,1H),5. 63–5.47(m,1H),4.79–4.16(m,4H),4.05–3.78(m,5H),2.69–1.84(m,10H). MS(ESI,m / e)[M+H] + 648.4.
[0441] Example 78: 1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)piperidin-4-ol
[0442]
[0443] Example 78 was prepared by a procedure analogous to that described in Example 2, substituting piperidin-4-ol for (1S,2R)-2-fluorocyclopropane-1-amine, to provide the title product. 1H NMR(500MHz,CD3OD)δ8.14(s,1H),7.21-7.15(m,1H),7.00-6.93(m,1H),5.47-5.29(m,1H),4.47-426( m,4H),4.06-3.97(m,1H),3.75-3.64(m,2H),3.58-3.36(m,3H),3.22-3.12(m,1H),2.49-1.67(m,10H). MS(ESI,m / e)[M+H] + 639.4.
[0444] Example 79: (3S)-1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-3-methylpiperidin-3-ol
[0445]
[0446] Example 79 was prepared by a procedure analogous to that described in Example 1, substituting (S)-3-methylpiperidin-3-ol for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.44(s,1H),7.22-7.14(m,1H),7.00-6.92(m,1H),5.48-5.31(m,1H),4.50-4. 30(m,3H),4.20-4.12(m,1H),3.56-3.34(m,5H),3.20-3.12(m,1H),2.53-1.73(m,10H),1.27(s,3H). MS(ESI,m / e)[M+H] + 653.5.
[0447] Example 80: (3R)-1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-3-methylpiperidin-3-ol
[0448]
[0449] Example 80 was prepared by a procedure analogous to that described in Example 1, substituting (R)-3-methylpiperidin-3-ol for cyclopropylamine, to provide the title product. 1H NMR(500MHz,CD3OD)δ8.43(s,1H),7.22-7.14(m,1H),7.00-6.92(m,1H),5.46-5.28(m,1H),4.46-4. 30(m,3H),4.19-4.08(m,1H),3.58-3.38(m,5H),3.22-3.14(m,1H),2.47-1.68(m,10H),1.28(s,3H). MS(ESI,m / e)[M+H] + 653.5.
[0450] Example 81: 4-(4-(azepan-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine
[0451]
[0452] Example 81 was prepared by a procedure analogous to that described in Example 1, substituting azepane for cyclopropylamine, to give the title product. 1 H NMR(500MHz,CD3OD)δ8.32(s,1H),7.23–7.13(m,1H),7.00–6.92(m,1H),5.46–5.26(m,1H),4.45–4.28( m,2H),4.15–3.98(m,4H),3.54–3.32(m,3H),3.17–3.08(m,1H),2.45–1.88(m,10H),1.80–1.62(m,4H). MS(ESI,m / e)[M+H] + 637.5.
[0453] Example 82: 1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)azepane-4-carbonitrile
[0454]
[0455] Example 82 was prepared by a procedure analogous to that described in Example 1, substituting azepane-4-carbonitrile for cyclopropylamine, to give the title product. 1H NMR(500MHz,CD3OD)δ8.31(s,1H),7.27–7.11(m,1H),7.01–6.92(m,1H),5.46–5.29(m,1H),4. 48–4.30(m,2H),4.25–3.96(m,4H),3.60–3.35(m,3H),3.23–3.08(m,2H),2.50–1.87(m,12H). MS(ESI,m / e)[M+H] + 662.5.
[0456] Example 83: 1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizine-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)azepane-3-carbonitrile
[0457]
[0458] Example 83 was prepared by a procedure analogous to that described in Example 1, substituting azepane-3-carbonitrile for cyclopropylamine, to give the title product. 1 H NMR(500MHz,CD3OD)δ8.34(s,1H),7.28–7.14(m,1H),7.02–6.92(m,1H),5.50–5.29(m,1H),4.67–4.39( m,3H),4.36–3.98(m,3H),3.70–3.40(m,4H),3.24–3.10(m,1H),2.61–1.78(m,11H),1.65–1.45(m,1H). MS(ESI,m / e)[M+H] + 662.4.
[0459] Example 84: 1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)azepan-4-ol
[0460]
[0461] Example 84 was prepared by a procedure analogous to that described in Example 1, substituting azepan-4-ol for cyclopropylamine, to provide the title product. 1H NMR(500MHz,CD3OD)δ8.31(s,1H),7.24–7.13(m,1H),7.01–6.91(m,1H),5.48–5.29(m,1H),4. 49–4.28(m,2H),4.21–3.86(m,5H),3.58–3.35(m,3H),3.20–3.08(m,1H),2.48–1.68(m,12H). MS(ESI,m / e)[M+H] + 653.5.
[0462] Example 85: (1-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)azepan-4-yl)methanol
[0463]
[0464] Example 85 was prepared by a procedure analogous to that described in Example 1, substituting azepan-4-ylmethanol for cyclopropylamine, to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.32(s,1H),7.28–7.14(m,1H),7.01–6.91(m,1H),5.49–5.29(m,1H),4. 51–4.20(m,4H),4.02–3.86(m,2H),3.64–3.39(m,6H),3.24–3.10(m,1H),2.53–1.62(m,12H). MS(ESI,m / e)[M+H] + 667.5.
[0465] Example 86: 8-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one
[0466]
[0467] Example 86 was prepared by a procedure analogous to that described in Example 2, substituting 1-oxa-3,8-diazaspiro[4.5]decan-2-one for (1S,2R)-2-fluorocyclopropane-1-amine to give the title product. 1H NMR (500 MHz, CD3OD) δ 8.17 (s, 1H), 7.24–7.15 (m, 1H), 7.01–6.91 (m, 1H), 5.52–5.32 (m, 1H), 4.55–4.40 (m, 2H), 4.38–4.28 (m, 2H), 3.93–3.79 (m, 2H), 3.71–3.43 (m, 5H), 3.28–3.19 (m, 1H), 2.55–1.95 (m, 10H). MS (ESI, m / e) [M+H] + 694.5.
[0468] Example 87: 8-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one
[0469]
[0470] Example 87 was prepared by a procedure analogous to that described in Example 1, substituting 3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one for cyclopropylamine to give the title product. 1H NMR (500 MHz, CD3OD) δ 8.15 (s, 1H), 7.24–7.14 (m, 1H), 7.01–6.92 (m, 1H), 5.42–5.25 (m, 1H), 4.46–4.26 (m, 4H), 3.86–3.78 (m, 2H), 3.54–3.36 (m, 5H), 3.18–3.04 (m, 1H), 2.86 (s, 3H), 2.43–1.89 (m, 10H). MS (ESI, m / e) [M+H] + 708.6.
[0471] Example 88: 8-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-3-ethyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one
[0472]
[0473] Example 88 was prepared by a procedure analogous to that described in Example 1, substituting 3-ethyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one for cyclopropylamine, to give the title product. 1 HNMR(500MHz,CD3OD)δ8.15(s,1H),7.24–7.14(m,1H),7.01–6.92(m,1H),5.45–5.28(m,1H),4.50-4.31 (m,4H),3.96-3.78(m,2H),3.65-3.38(m,5H),3.19-3.10(m,1H),2.52-1.98(m,10H),1.23-1.14(m,3H). MS(ESI,m / e)[M+H] + 722.5.
[0474] Example 89: 2-(8-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-2-oxo-1-oxa-3,8-diazaspiro[4.5]decane-3-yl)acetonitrile
[0475]
[0476] Example 89 was prepared by a procedure analogous to that described in Example 1, substituting 2-(2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-3-yl)acetonitrile for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.37(s,1H),7.47–7.30(m,1H),7.27–7.10(m,1H),5.66-5.50(m,1H) ,4.87-4.67(m,3H),4.39(s,2H),4.15-3.85(m,5H),3.61-3.46(m,3H),2.78-2.09(m,10H). MS(ESI,m / e)[M+H] + 733.4.
[0477] Example 90: 8-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-3-(2,2-difluoroethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one
[0478]
[0479] Example 90 was prepared by a procedure analogous to that described in Example 1, substituting 3-(2,2-difluoroethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.17(s,1H),7.23-7.15(m,1H),7.02-6.92(m,1H),6.20-5.90(m,1H),5. 52-5.35(m,1H),4.56-4.32(m,4H),3.94-3.78(m,2H),3.74-3.51(m,8H),2.51-2.00(m,10H). MS(ESI,m / e)[M+H] + 758.5.
[0480] Example 91: 8-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-3-(2,2,2-trifluoroethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one
[0481]
[0482] Example 91 was prepared by a procedure analogous to that described in Example 1, substituting 3-(2,2,2-trifluoroethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.15(s,1H),7.24-7.14(m,1H),7.01-6.92(m,1H),5.43-5.26(m,1H),4.42-4. 32(m,4H),4.08-3.96(m,2H),3.91-3.82(m,2H),3.63(s,2H),3.20-3.12(m,1H),2.46-1.98(m,10H). MS(ESI,m / e)[M+H] + 776.5.
[0483] Example 92: 8-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-3-(cyclopropylmethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one
[0484]
[0485] Example 92 was prepared by a procedure analogous to that described in Example 1, substituting 3-(cyclopropylmethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.19(s,1H),7.24-7.15(m,1H),7.02-6.92(m,1H),5.59-5.42(m,1H),4.62-4.50(m,2H),4.43-4.32( m,2H),3.87-3.42(m,8H),3.21-3.14(m,2H),2.65-1.87(m,10H),1.06-0.97(m,1H),0.72-0.53(m,2H),0.34-0.21(m,2H). MS(ESI,m / e)[M+H] + 748.4.
[0486] Example 93: 8-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-3-(2-hydroxyethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one
[0487]
[0488] Example 93 was prepared by a procedure analogous to that described in Example 1, substituting 3-(2-hydroxyethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.17(s,1H),7.24-7.15(m,1H),7.02-6.92(m,1H),5.51-5.34(m,1H),4. 53-4.29(m,4H),3.92-3.83(m,2H),3.73-3.36(m,8H),3.21-3.10(m,2H),2.51-1.98(m,10H). MS(ESI,m / e)[M+H] + 738.5.
[0489] Example 94: 8-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-3-(2-methoxyethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one
[0490]
[0491] Example 94 was prepared by a procedure analogous to that described in Example 1, substituting 3-(2-methoxyethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.15(s,1H),7.23-7.15(m,1H),7.01-6.92(m,1H),5.45-5.28(m,1H),4. 47-4.29(m,4H),3.91-3.79(m,2H),3.65-3.37(m,12H),3.20-3.13(m,1H),2.47-1.90(m,10H). MS(ESI,m / e)[M+H] + 752.7.
[0492] Example 95: 8-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-2,8-diazaspiro[4.5]decan-1-one
[0493]
[0494] Example 95 was prepared by a procedure analogous to that described in Example 2, substituting 2,8-diazaspiro[4.5]decan-1-one for (1S,2R)-2-fluorocyclopropane-1-amine to provide the title product. 1 HNMR(500MHz,CD3OD)δ8.15(s,1H),7.24-7.15(m,1H),7.01-6.91(m,1H),5.45-5.28(m,1H),4 .51-4.32(m,4H),3.74-3.65(m,2H),3.51-3.36(m,5H),3.15-3.08(m,1H),2.48-1.61(m,12H). MS(ESI,m / e)[M+H] + 692.5.
[0495] Example 96: 8-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-2,8-diazaspiro[4.5]decan-3-one
[0496]
[0497] Example 96 was prepared by a procedure analogous to that described in Example 2, substituting 2,8-diazaspiro[4.5]decan-3-one for (1S,2R)-2-fluorocyclopropane-1-amine to provide the title product. 1 HNMR(500MHz,CD3OD)δ8.18(s,1H),7.24-7.15(m,1H),7.02-6.92(m,1H),4.65-4.54 (m,2H),4.16-4.05(m,2H),4.01-3.79(m,5H),3.48-3.37(m,3H),2.64-1.83(m,12H). MS(ESI,m / e)[M+H] + 692.5.
[0498] Example 97: 8-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-2-methyl-2,8-diazaspiro[4.5]decan-3-one
[0499]
[0500] Example 97 was prepared by a procedure analogous to that described in Example 2, substituting 2-methyl-2,8-diazaspiro[4.5]decan-3-one for (1S,2R)-2-fluorocyclopropane-1-amine to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.14(s,1H),7.23-7.15(m,1H),7.02-6.92(m,1H),5.47-5.30(m,1H),4.46-4. 34(m,2H),4.09-3.95(m,4H),3.53-3.37(m,5H),3.20-3.12(m,1H),2.87(s,3H),2.48-1.78(m,12H). MS(ESI,m / e)[M+H] + 706.5.
[0501] Example 98: 9-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
[0502]
[0503] Example 98 was prepared by a procedure analogous to that described in Example 2, substituting 1-oxa-4,9-diazaspiro[5.5]undecan-3-one for (1S,2R)-2-fluorocyclopropane-1-amine to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.18(s,1H),7.23-7.15(m,1H),7.02-6.92(m,1H),5.54-5. 37(m,1H),4.56-4.41(m,4H),4.23(s,2H),3.78-3.54(m,5H),2.53-1.86(m,10H). MS(ESI,m / e)[M+H] + 708.4.
[0504] Example 99: 9-(7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-1-oxa-3,9-diazaspiro[5.5]undecan-2-one
[0505]
[0506] Example 99 was prepared by a procedure analogous to that described in Example 1, substituting 1-oxa-3,9-diazaspiro[5.5]undecan-2-one for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ8.17(s,1H),7.24-7.15(m,1H),7.01-6.92(m,1H),5.49-5.32(m,1H),4. 53-4.38(m,4H),3.95-3.78(m,2H),3.65-3.37(m,5H),2.20-2.12(m,1H),2.53-1.98(m,12H). MS(ESI,m / e)[M+H] + 708.5.
[0507] Example 100a (common intermediate): 2-amino-7-fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-hydroxy-6-(trifluoromethyl)quinazolin-7-yl)benzo[b]thiophene-3-carbonitrile
[0508]
[0509] Step 1: tert-Butyl (4-(4-(benzyloxy)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-3-cyano-7-fluorobenzo[b]thiophen-2-yl)carbamate
[0510]
[0511] To a mixture of 4-(benzyloxy)-7-bromo-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazoline (578 mg, 1.04 mmol) in toluene (38 mL) was added tert-butyl (3-cyano-7-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[b]thiophen-2-yl)carbamate (1739 mg, 4.160 mmol), DephosPdCl2 (149 mg, 0.208 mmol) and Cs2CO3 (1016 mg, 3.120 mmol) at room temperature. The mixture was stirred at 100°C for 3 hours. The resulting mixture was concentrated to give a residue, which was further purified by flash chromatography to give the title product (123 mg).
[0512] Step 2: 2-Amino-7-fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-hydroxy-6-(trifluoromethyl)quinazolin-7-yl)benzo[b]thiophene-3-carbonitrile
[0513] To a solution of tert-butyl (4-(4-(benzyloxy)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-3-cyano-7-fluorobenzo[b]thiophen-2-yl)carbamate (123 mg, 0.160 mmol) in DCM (5 mL) was added TFA (5 mL) at room temperature and the mixture was stirred at 45 °C for 2 hours. The resulting mixture was concentrated to give a residue, which was further purified by reverse phase chromatography to give the title product (54 mg).
[0514] Example 100: (2R,4S)-1-(7-(2-amino-3-cyano-7-fluorobenzo[b]thiophene-4-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizine-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-4-yl)-2-methylpiperidine-4-carbonitrile
[0515]
[0516] To a mixture of 2-amino-7-fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-hydroxy-6-(trifluoromethyl)quinazolin-7-yl)benzo[b]thiophene-3-carbonitrile (50 mg, 0.086 mmol) in acetonitrile (5 mL) was added (2R,4S)-2-methylpiperidine-4-carbonitrile (42 mg, 0.26 mmol), BOP (114 mg, 0.258 mmol) and DIPEA (66 mg, 0.52 mmol). The mixture was stirred at 40 °C overnight. The resulting mixture was concentrated to give a residue, which was further purified by preparative HPLC to give the title product (75 mg). 1 H NMR (500MHz, CD3OD) δ8.10–8.00(m,1H),7.26–7.16(m,1H),7.03-6.99(m,1H),5.48-5.30(m,1H),4.99-4. 91(m,1H),4.48–4.34(m,3H),3.63–3.33(m,5H),3.20–3.12(m,1H),2.50–1.95(m,10H),1.60–1.49(m,3H). MS(ESI,m / e)[M+H] + 686.7.
[0517] Example 101a (common intermediate): 2-amino-4-(6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-hydroxyquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile
[0518]
[0519] Step 1: tert-Butyl (4-(4-(benzyloxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-7-yl)-3-cyano-7-fluorobenzo[b]thiophen-2-yl)carbamate
[0520]
[0521] To a 100 mL round-bottom flask were added 4-(benzyloxy)-7-bromo-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazoline (600 mg, 1.14 mmol), tert-butyl (3-cyano-7-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[b]thiophen-2-yl)carbamate (1.43 g, 3.42 mmol), Cs2CO3 (1.11 g, 3.42 mmol), PdCl2(DPEphos) (122 mg, 0.17 mmol) and toluene (40 mL), and the reaction mixture was stirred at 100°C for 4 hours. The resulting cooled mixture was concentrated and purified by flash column chromatography (DCM / MeOH=20 / 1) to give the title product (295 mg, 35%). MS (ESI, m / e) [M+H] + 736.3.
[0522] Step 2: 2-amino-4-(6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-hydroxyquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile
[0523] To a 50 mL round bottom flask was added tert-butyl (4-(4-(benzyloxy)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-7-yl)-3-cyano-7-fluorobenzo[b]thiophen-2-yl)carbamate (295 mg, 0.40 mmol) and TFA (20 mL), and the resulting mixture was stirred at 40 °C for 6 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by reverse flash chromatography (eluting with H2O (0.2% FA) / CH3CN) to give the title product (82 mg, 37%). MS (ESI, m / e) [M+H] + 546.1.
[0524] Example 101: (2R,4S)-1-(7-(2-amino-3-cyano-7-fluorobenzo[b]thiophen-4-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizine-7a(5H)-yl)methoxy)quinazolin-4-yl)-2-methylpiperidine-4-carbonitrile
[0525]
[0526] To a 50 mL round bottom flask was added 2-amino-4-(6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-hydroxyquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile (82 mg, 0.15 mmol), (2R,4S)-2-methylpiperidine-4-carbonitrile hydrochloride, BOP (99 mg, 0.22 mmol), DIEA (78 mg, 0.60 mmol) and CH3CN (8.0 mL), and the resulting mixture was stirred at 40°C for 24 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by reverse flash chromatography eluting with H2O (0.2% FA) / CH3CN to give the title product (45.1 mg, 46%). 1 H NMR(500MHz,CD3OD)δ7.76(s,1H),7.24–7.14(m,1H),7.10–6.96(m,1H),5.40–5.19(m,1H),4.37–4.13( m,3H),3.60–3.48(m,1H),3.27–3.10(m,4H),3.06–2.94(m,1H),2.39–1.80(m,10H),1.54–1.43(m,3H). MS(ESI,m / e)[M+H] + 652.4.
[0527] Example 102: (3S)-1-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)pyrrolidin-3-ol
[0528]
[0529] Step 1: (S)-3-Acetoxypyrrolidine-1-carboxylic acid benzyl ester
[0530]
[0531] To a solution of (S)-3-hydroxypyrrolidine-1-carboxylic acid benzyl ester (2.21 g, 10 mmol) in DCM (40 mL) was added acetyl chloride (1.02 g, 13 mmol) and DIPEA (3.58 g, 20 mmol). The mixture was stirred at room temperature overnight. The mixture was concentrated in vacuo, and the residue was purified by silica gel column chromatography (DCM / MeOH=7 / 3) to give the title compound (2.34 g, 88%). MS (ESI, m / e) [M+H] + 264.1.
[0532] Step 2: (S)-Pyrrolidin-3-yl acetate
[0533]
[0534] To a solution of (S)-3-acetoxypyrrolidine-1-carboxylic acid benzyl ester (2.21 g, 10 mmol) in THF (80 mL) was added Pd / C (10%, 468 mg) in one portion. The mixture was stirred at room temperature overnight. The solid was filtered off and the filtrate was concentrated in vacuo to give the title compound (1.18 g, crude), which was used in the next step without further purification. MS (ESI, m / e) [M+H] + 130.2.
[0535] Step 3: (S)-1-(7-bromo-2,6-dichloro-8-fluoroquinazolin-4-yl)pyrrolidin-3-yl acetate
[0536]
[0537] To a solution of 7-bromo-2,4,6-trichloro-8-fluoroquinazoline (2.5 g, 7.62 mmol) in DCM (30 mL) was added (S)-pyrrolidin-3-yl acetate (1.18 g, 9.15 mmol) and DIPEA (2 g, 15.2 mmol) in one portion. The mixture was stirred at room temperature overnight. The mixture was concentrated in vacuo and the residue was purified by silica gel column chromatography (DCM / MeOH=4 / 1) to give the title compound (2.96 g, 92%). MS (ESI, m / e) [M+H] + 422.0.
[0538] Step 4: (S)-1-(7-bromo-6-chloro-2,8-difluoroquinazolin-4-yl)pyrrolidin-3-yl acetate
[0539]
[0540] A mixture of 7-bromo-2,4,6-trichloro-8-fluoroquinazoline (2.96 g, 7.03 mmol) and KF (4.1 g, 70.3 mmol) in DMSO (30 mL) was stirred at 110 °C for 2 hours. The mixture was cooled to room temperature and poured into ice water (300 mL). The precipitate was filtered from the suspension and dried in vacuo to give the title compound (2.29 g, 80%). MS (ESI, m / e) [M+H] + 406.1.
[0541] Step 5: (S)-1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methylpyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)pyrrolidin-3-yl acetate
[0542]
[0543] A mixture of (S)-1-(7-bromo-6-chloro-2,8-difluoroquinazolin-4-yl)pyrrolidin-3-yl acetate (581 mg, 1.43 mmol), (6-(bis(4-methoxybenzyl)amino)-4-methylpyridin-2-yl)boronic acid (900 mg, 2.3 mmol), Pd(dppf)Cl2 (104.5 mg, 0.143 mmol) and K3PO4 (756 mg, 3.57 mmol) in THF / water (15 mL / 3 mL) was stirred at 65°C for 2 hours. The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE / EA=1 / 4) to give the title product (274 mg, 28%). MS (ESI, m / e) [M+H] + 674.5.
[0544] Step 6: (3S)-1-(7-(6-(bis(4-methoxybenzyl)amino)-3-iodo-4-methylpyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)pyrrolidin-3-yl acetate
[0545]
[0546] To a stirred solution of (S)-1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methylpyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)pyrrolidin-3-yl acetate (274 mg, 0.4 mmol) in DMF / AcOH (6 mL / 3 mL) was added NIS (274 mg, 1.22 mmol) dropwise at 0°C. The mixture was stirred at room temperature for 1.5 hours. The mixture was extracted with EtOAc (30 mL*3). The combined organic phases were washed with brine (40 mL), NaHCO3 solution (40 mL), and dried over Na2SO4. The mixture was concentrated in vacuo, and the residue was purified by silica gel column chromatography (DCM / MeOH=8 / 2) to give the title product (116 mg, 35%). MS (ESI, m / e) [M+H] + 800.4.
[0547] Step 7: (3S)-1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)pyrrolidin-3-yl acetate
[0548]
[0549] A mixture of (3S)-1-(7-(6-(bis(4-methoxybenzyl)amino)-3-iodo-4-methylpyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)pyrrolidin-3-yl acetate (116 mg, 0.145 mmol), CuI (275 mg, 1.45 mmol) and methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (139 mg, 0.725 mmol) in DMA (10 ml) was stirred at 120° C. for 2 hours. The reaction was cooled to room temperature, diluted with ice-cold water, and then extracted with EtOAc (30 mL*3). The combined organic phases were washed with brine (40 mL) and dried over Na2SO4. The residue was purified by silica gel column chromatography (PE / EA=1 / 4) to give the title product (80 mg, 48%). MS (ESI, m / e) [M+H] + 742.5.
[0550] Step 8: (3S)-1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)pyrrolidin-3-ol
[0551]
[0552] To a solution of ((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizine-7a(5H)-yl)methanol (35 mg, 0.221 mmol) in THF (10 mL) was added NaH (16 mg, 0.333 mmol) at 0°C, and the mixture was stirred at 0°C for 30 minutes. Then, (3S)-1-(7-(6-(bis(4-methoxybenzyl)amino)-3-iodo-4-methylpyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)pyrrolidin-3-yl acetate (82 mg, 0.111 mmol) was added. The mixture was stirred from 0°C to room temperature, and then stirred at room temperature for another 2 hours. The mixture was quenched with water (1 mL) and extracted with EtOAc (20 mL*2). The combined organic phases were washed with brine (20 mL), dried over Na2SO4, and concentrated in vacuo. The mixture was purified by silica gel column chromatography (DCM / MeOH=4 / 1) to give the title product (108 mg, crude product). MS (ESI, m / e) [M+H] + 742.5.
[0553] Step 9: (3S)-1-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)pyrrolidin-3-ol
[0554] A mixture of (3S)-1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)pyrrolidin-3-yl acetate (108 mg, 0.129 mmol) and TFA (5 mL). The mixture was stirred at 50 °C for 1 hour. The solvent was removed in vacuo to give the crude product, which was purified by preparative HPLC to give the title product (1.28 mg, 1.6%). 1 H NMR(500MHz,DMSO-d6)δ8.09(s,1H),6.86(s,2H),6.49(s,1H),5.49-5.28(m,1H),5.09(s ,1H),4.43(s,1H),4.35-3.67(m,6H),3.28-2.70(m,4H),2.37(s,3H),2.27-1.64(m,8H). MS(ESI,m / e)[M+H] + 599.4.
[0555] Example 103: 1-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)piperidine-4-carbonitrile
[0556]
[0557] Step 1: 1-(7-bromo-2,6-dichloro-8-fluoroquinazolin-4-yl)piperidine-4-carbonitrile
[0558]
[0559] To a solution of 7-bromo-2,4,6-trichloro-8-fluoroquinazoline (2.5 g, 7.62 mmol) in DCM (100 mL) was added piperidine-4-carbonitrile (0.924 g, 8.38 mmol) and DIPEA (3.24 g, 25.1 mmol). The mixture was stirred at room temperature overnight. The mixture was concentrated in vacuo, and the residue was purified by silica gel column chromatography (PE / EA=7 / 3) to give the title compound (390 mg, 13%). MS (ESI, m / e) [M+H] + 403.1.
[0560] Step 2: 1-(7-bromo-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile
[0561]
[0562] A mixture of 1-(7-bromo-2,6-dichloro-8-fluoroquinazolin-4-yl)piperidine-4-carbonitrile (385 mg, 0.958 mmol) and KF (278 mg, 4.79 mmol) in DMSO (10 mL) was stirred at 115 ° C for 3 hours. The mixture was cooled to room temperature and poured into ice water (150 mL). The filtered solid was a crude product, which was purified by silica gel column chromatography (PE / EA=19 / 1) to give the title compound (269 mg, 72%). MS (ESI, m / e) [M+H] + 387.1.
[0563] Step 3: 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methylpyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile
[0564]
[0565] A mixture of 1-(7-bromo-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile (982 mg, 2.54 mmol), (6-(bis(4-methoxybenzyl)amino)-4-methylpyridin-2-yl)boronic acid (1.75 g, 4.45 mmol), Pd(dppf)Cl2 (185 mg, 0.25 mmol) and K3PO4 (1.08 g, 5.08 mmol) in THF / water (30 mL / 6 mL) was stirred at 65° C. for 2 hours. The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE:EA=100%:0%-0%:100%) to give the title product (670 mg, 40%). MS (ESI, m / e) [M+H] + 655.5.
[0566] Step 4: 1-(7-(6-(bis(4-methoxybenzyl)amino)-3-iodo-4-methylpyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile
[0567]
[0568] To a solution of 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methylpyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile (570 mg, 0.871 mmol) in DMF / AcOH (20 mL / 10 mL) was added NIS (784 mg, 3.486 mmol). The mixture was stirred at room temperature for 1.5 hours. The mixture was extracted with EtOAc (50 mL*3). The combined organic phases were washed with brine (80 mL), Na2S2O3 solution (40 mL), and dried over Na2SO4. The mixture was concentrated in vacuo, and the residue was purified by silica gel column chromatography (DCM / MeOH=10 / 1) to give the title product (550 mg, 81%). MS (ESI, m / e) [M+H] + 781.5.
[0569] Step 5: 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile
[0570]
[0571] A mixture of 1-(7-(6-(bis(4-methoxybenzyl)amino)-3-iodo-4-methylpyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile (550 mg, 1.964 mmol), CuI (2.02 g, 9.82 mmol) and methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (746 mg, 3.93 mmol) in DMA (20 mL) was stirred at 120 ° C for 2 hours. The cooled reaction mixture was extracted with EtOAc (50 mL*3). The combined organic phases were washed with brine (50 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE / EA=1 / 1) to give the title product (455 mg, 89%). MS (ESI, m / e) [M+H] + 723.5.
[0572] Step 6: 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)piperidine-4-carbonitrile
[0573]
[0574] To a solution of ((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizine-7a(5H)-yl)methanol (150 mg, 0.943 mmol) in THF (10 mL) was added NaH (50 mg, 1.25 mmol) at 0°C. The mixture was stirred at 0°C for 30 minutes. Then, 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile (455 mg, 0.625 mmol) was added. The mixture was stirred from 0°C to room temperature and then stirred at room temperature for another 3 hours. The mixture was quenched with water (1 mL) and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE / EA=1 / 4) to give the title product (390 mg, 72%). MS (ESI, m / e) [M+H] + 862.7.
[0575] Step 7: 1-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)piperidine-4-carbonitrile
[0576] A mixture of 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)piperidine-4-carbonitrile (390 mg, 0.452 mmol) and TFA (5 mL). The mixture was stirred at 50 °C for 2.5 hours. The solvent was removed in vacuo to give the crude product, which was purified by preparative HPLC to give the title product (245 mg, 87%). 1 H NMR(500MHz,DMSO-d6)δ7.82(s,1H),6.86(s,2H),6.50(s,1H),5.50-5.22(m,1H),4.40-3.90(m ,4H),3.66-3.55(m,2H),3.28-3.10(m,3H),3.02-2.90(m,1H),2.37(s,3H),2.25-1.73(m,10H). MS(ESI,m / e)[M+H] + 622.5.
[0577] Example 104: 1-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)-trans-2-methylpiperidine-4-carbonitrile
[0578]
[0579] Step 1: 1-(7-bromo-2,6-dichloro-8-fluoroquinazolin-4-yl)-trans-2-methylpiperidine-4-carbonitrile
[0580]
[0581] To a solution of 7-bromo-2,4,6-trichloro-8-fluoroquinazoline (759 mg, 2.3 mmol) in DCM (25 mL) was added trans-2-methylpiperidine-4-carbonitrile (370 mg, 2.3 mmol) and DIPEA (890 mg, 6.9 mmol) at room temperature, and the mixture was stirred at room temperature for 1 hour. The resulting mixture was concentrated, and the residue was purified by silica gel chromatography (eluted with PE / EA=5 / 1) to give the title product (700 mg, 73%). MS (ESI, m / e) [M+H] + 417.0. Step 2: 1-(7-Bromo-6-chloro-2,8-difluoroquinazolin-4-yl)-trans-2-methylpiperidine-4-carbonitrile
[0582]
[0583] To a solution of 1-(7-bromo-2,6-dichloro-8-fluoroquinazolin-4-yl)-trans-2-methylpiperidine-4-carbonitrile (700 mg, 1.68 mmol) in DMSO (30 mL) was added KF (292 mg, 5.04 mmol) at room temperature, and the mixture was stirred at 100°C overnight. The resulting mixture was diluted with water (20 mL) and extracted with DCM (30 mL*3), and the combined organic layers were concentrated to give a residue, which was purified by silica gel chromatography (eluted with PE / EA=10 / 1) to give the title product (370 mg, 53%). MS (ESI, m / e) [M+H] + 401.0.
[0584] Step 3: 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methylpyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)-trans-2-methylpiperidine-4-carbonitrile
[0585]
[0586] To a solution of 1-(7-bromo-6-chloro-2,8-difluoroquinazolin-4-yl)-trans-2-methylpiperidine-4-carbonitrile (304 mg, 0.758 mmol) in dioxane (30 mL) was added (6-(bis(4-methoxybenzyl)amino)-4-methylpyridin-2-yl)boronic acid (743 mg, 1.895 mmol), Pd(dppf)Cl2 (124 mg, 0.15 mmol), K3PO4 (482 mg, 2.274 mmol) and water (6 mL) at room temperature, and the mixture was stirred at 100°C for 2 hours. The resulting mixture was concentrated, and the crude product was purified by silica gel chromatography (eluted with DCM / MeOH=20 / 1) to give the title product (344 mg, 38%). MS (ESI, m / e) [M+H] + 669.0.
[0587] Step 4: 1-(7-(6-(bis(4-methoxybenzyl)amino)-3-iodo-4-methylpyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)-trans-2-methylpiperidine-4-carbonitrile
[0588]
[0589] To a solution of 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methylpyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)-trans-2-methylpiperidine-4-carbonitrile (324 mg, 0.485 mmol) in DMF (10 mL) was added I2 (859 mg, 3.395 mmol) and Ag2SO4 (45 mg, 0.1455 mmol) at room temperature, and the mixture was stirred at room temperature for 2 hours. The resulting mixture was diluted with water (20 mL) and extracted with DCM (30 mL*3), and the combined organic layers were concentrated to give a crude product (304 mg). MS (ESI, m / e) [M+H] + 795.0.
[0590] Step 5: 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)-trans-2-methylpiperidine-4-carbonitrile
[0591]
[0592] To a solution of 1-(7-(6-(bis(4-methoxybenzyl)amino)-3-iodo-4-methylpyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)-trans-2-methylpiperidine-4-carbonitrile (304 mg, 0.382 mmol) in DMF (10 mL) was added methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (735 mg, 3.83 mmol) and CuI (728 mg, 3.83 mmol) at room temperature, and the mixture was stirred at 90° C. for 4 hours. The resulting mixture was concentrated, and the crude product was purified by silica gel chromatography (eluted with DCM / MeOH=20 / 1) to give the title product (107 mg, 38%). MS (ESI, m / e) [M+H] + 737.0.
[0593] Step 6: 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)-trans-2-methylpiperidine-4-carbonitrile
[0594]
[0595] To a solution of 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)-trans-2-methylpiperidine-4-carbonitrile (50 mg, 0.068 mmol) in THF (5 mL) was added ((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizine-7a(5H)-yl)methanol (27 mg, 0.17 mmol) and NaH (7 mg, 0.17 mmol) at room temperature, and the mixture was stirred at room temperature for 1 hour. The resulting mixture was quenched with ice water and extracted with DCM (30 mL*3), and the combined organic layers were concentrated to give a crude product (50 mg). MS (ESI, m / e) [M+H] + 842.0.
[0596] Step 6: 1-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)-trans-2-methylpiperidine-4-carbonitrile
[0597] To a solution of 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizine-7a(5H)-yl)methoxy)quinazolin-4-yl)-trans-2-methylpiperidine-4-carbonitrile (50 mg, 0.057 mmol) in DCM (1 mL) was added TFA (4 mL) at room temperature. The mixture was stirred at 50 °C for 1 hour. The resulting mixture was concentrated at room temperature and the pH was adjusted to 7 with Na2CO3, and the organic layer was concentrated to give a residue, which was further purified by preparative HPLC to give the title product (16.56 mg). 1 H NMR(500MHz,CD3OD)δ7.76(s,1H),6.60(s,1H),5.50–5.32(m,1H),4.97–4.88(m,1H),4.50–4.35(m,2H),4.34 –4.24(m,1H),3.65–3.43(m,4H),3.39–3.32(m,1H),3.24–3.15(m,1H),2.55–1.95(m,13H),1.58–1.39(m,3H). MS(ESI,m / e)[M+H] + 636.6.
[0598] Example 105: 6-(6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-((S)-3-methylmorpholino)quinazolin-7-yl)-4-methyl-5-(trifluoromethyl)pyridin-2-amine
[0599]
[0600] Step 1: (S)-4-(7-bromo-2,6-dichloro-8-fluoroquinazolin-4-yl)-3-methylmorpholine
[0601]
[0602] To a solution of 7-bromo-2,4,6-trichloro-8-fluoroquinazoline (1.60 g, 4.85 mmol) in dichloromethane (15 mL) at 0°C was added (S)-3-methylmorpholine (600 mg, 5.93 mmol) and 2 mL of N,N-diisopropylethylamine. The reaction was stirred at room temperature for 0.5 hours. The mixture was diluted with dichloromethane and water. The combined organic layers were dried over sodium sulfate and evaporated. The residue was purified by silica gel chromatography to give the title compound (1.20 g, 63%). MS (ESI, m / e) [M+H] + 393.5.
[0603] Step 2: (S)-4-(7-bromo-6-chloro-2,8-difluoroquinazolin-4-yl)-3-methylmorpholine
[0604]
[0605] To a solution of (S)-4-(7-bromo-2,6-dichloro-8-fluoroquinazolin-4-yl)-3-methylmorpholine (1.20 g, 3.03 mmol) in 30 mL of dimethyl sulfoxide was added potassium fluoride (1.21 g, 20.86 mmol). The reactants were stirred at 95 °C for 16 hours. The mixture was cooled to room temperature and diluted with dichloromethane and water. The combined organic layers were dried over sodium sulfate and evaporated. The residue was purified by silica gel chromatography to give the title compound (950 mg, 82%). MS (ESI, m / e) [M+H] + 377.5.
[0606] Step 3: (S)-6-(6-chloro-2,8-difluoro-4-(3-methylmorpholino)quinazolin-7-yl)-N,N
[0607] -Bis(4-methoxybenzyl)-4-methylpyridin-2-amine
[0608]
[0609] To a solution of (S)-4-(7-bromo-6-chloro-2,8-difluoroquinazolin-4-yl)-3-methylmorpholine (368 mg, 0.98 mmol) in 10 mL of 1,4-dioxane was added N,N-bis(4-methoxybenzyl)-4-methyl-6-(tributylstannyl)pyridin-2-amine (1.30 g, 2.04 mmol), copper(I) iodide (180 mg, 0.94 mmol), lithium chloride (180 mg, 4.29 mmol) and tetrakis(triphenylphosphine)palladium (350 mg, 0.30 mmol). The reactants were stirred at reflux for 8 hours and cooled to room temperature. The mixture was diluted with dichloromethane and water. The combined organic layers were dried over sodium sulfate and evaporated. The residue was purified by silica gel chromatography to give the title compound (180 mg, 27%). MS (ESI, m / e) [M+H] + 646.3.
[0610] Step 4: 6-(6-chloro-2,8-difluoro-4-((S)-3-methylmorpholino)quinazolin-7-yl)-5-iodo-N,N-bis(4-methoxybenzyl)-4-methylpyridin-2-amine
[0611]
[0612] To a solution of (S)-6-(6-chloro-2,8-difluoro-4-(3-methylmorpholino)quinazolin-7-yl)-N,N-bis(4-methoxybenzyl)-4-methylpyridin-2-amine (120 mg, 0.19 mmol) in 20 mL of N,N-dimethylformamide was added iodine (110 mg, 0.43 mmol), silver sulfate (20 mg, 0.06 mmol). The reactants were stirred at room temperature for 16 hours, and the mixture was diluted with dichloromethane and water. The combined organic layers were dried over sodium sulfate and evaporated. The residue was purified by silica gel chromatography to give the title compound (60 mg, 42%). MS (ESI, m / e) [M+H] + 772.5.
[0613] Step 5: 6-(6-chloro-2,8-difluoro-4-((S)-3-methylmorpholino)quinazolin-7-yl)-N,N-bis(4-methoxybenzyl)-4-methyl-5-(trifluoromethyl)pyridin-2-amine
[0614]
[0615] To a solution of 6-(6-chloro-2,8-difluoro-4-((S)-3-methylmorpholino)quinazolin-7-yl)-5-iodo-N,N-bis(4-methoxybenzyl)-4-methylpyridin-2-amine (60 mg, 0.08 mmol) in 5 mL of N-methyl-2-pyrrolidone was added methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (150 mg, 0.79 mmol) and copper (I) iodide (45 mg, 0.24 mmol). The reactants were stirred at 90 °C for 2 hours and then cooled to room temperature. The mixture was diluted with dichloromethane and water, and the combined organic layers were dried over sodium sulfate and evaporated. The residue was purified by preparative TLC to give the title compound (30 mg, 54%). MS (ESI, m / e) [M+H] + 714.3
[0616] Step 6: 6-(6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-((S)-3-methylmorpholino)quinazolin-7-yl)-N,N-bis(4-methoxybenzyl)-4-methyl-5-(trifluoromethyl)pyridin-2-amine
[0617]
[0618] To a solution of ((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizine-7a(5H)-yl)methanol hydrochloride (24 mg, 0.15 mmol) in 2 mL of tetrahydrofuran was added sodium hydride (60%, 6 mg, 0.15 mmol) at 0°C, and the mixture was stirred at room temperature for 0.5 hours. A solution of 6-(6-chloro-2,8-difluoro-4-((S)-3-methylmorpholino)quinazolin-7-yl)-N,N-bis(4-methoxybenzyl)-4-methyl-5-(trifluoromethyl)pyridin-2-amine (30 mg, 0.04 mmol) in 1 mL of tetrahydrofuran was added dropwise. After the addition, the reactants were stirred at room temperature for 0.5 hours, and the mixture was diluted with dichloromethane and water. The combined organic layers were dried over sodium sulfate and evaporated. The residue was purified by preparative TLC to give the title compound (18 mg, 50%). MS (ESI, m / e) [M+H] + 853.3
[0619] Step 7: 6-(6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-((S)-3-methylmorpholino)quinazolin-7-yl)-4-methyl-5-(trifluoromethyl)pyridin-2-amine
[0620] A solution of 6-(6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizine-7a(5H)-yl)methoxy)-4-((S)-3-methylmorpholino)quinazolin-7-yl)-N,N-bis(4-methoxybenzyl)-4-methyl-5-(trifluoromethyl)pyridin-2-amine (18 mg, 0.02 mmol) in trifluoroacetic acid (1 mL) was stirred at room temperature for 16 hours and then stirred at 40°C for 8 hours. The solvent was then evaporated and the pH was adjusted to 11 with aqueous sodium carbonate solution. The mixture was diluted with dichloromethane and water, and the combined organic layers were dried over sodium sulfate and evaporated. The residue was purified by preparative HPLC to give the title compound (5 mg, 38%). 1 H NMR(500MHz,CD3OD)δ7.81(s,1H),6.60(s,1H),5.39-5.23(m,1H),4.72-4.62(m,1H),4.33-4.06(m,3H),3 .99-3.92(m,1H),3.88-3.69(m,4H),3.06-2.99(m,1H),2.47(s,3H),2.28-1.85(m,6H),1.55-1.48(m,3H). MS(ESI,m / e)[M+H] + 613.4.
[0621] Example 106: 8-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one
[0622]
[0623] Step 1: 8-(7-Bromo-2,6-dichloro-8-fluoroquinazolin-4-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one
[0624]
[0625] A mixture of 7-bromo-2,4,6-trichloro-8-fluoroquinazoline (1.27 g, 3.9 mmol), 3-methyl-1-oxa-3,8-diazaspiro[4.5]decane-2-one hydrochloride (800 mg, 3.9 mmol) in DCM (50 mL) and DIPEA (6 mL) was stirred at 0°C to room temperature for 2 hours. After completion, the solvent was evaporated and the crude product was purified by silica column (eluted with PE / EtOAc=1 / 4) to give the title product (1.4 g). MS (ESI, m / e) [M+H] + 463.3.
[0626] Step 2: 8-(7-bromo-6-chloro-2,8-difluoroquinazolin-4-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one
[0627]
[0628] To a mixture of 8-(7-bromo-2,6-dichloro-8-fluoroquinazolin-4-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decane-2-one (1.4 g, 3.0 mmol) in DMSO (40 mL) was added KF (2 g), and the mixture was stirred at 100 ° C for 5 hours. After completion, the resulting mixture was cooled, poured into water and extracted with EtOAc. The organic layers were combined and concentrated. The residue was then further purified by silica gel column (eluted with PE / EA=1 / 9) to give the title product (1 g). MS (ESI, m / e) [M+H] + 447.2
[0629] Step 3: 8-(7-(6-(bis(4-methoxybenzyl)amino)-4-methylpyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one
[0630]
[0631] A mixture of 4-chloro-N,N-bis(4-methoxybenzyl)-4-methyl-6-(tributylstannyl)pyridin-2-amine (1.4 g, 2.2 mmol), 8-(7-bromo-6-chloro-2,8-difluoroquinazolin-4-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decane-2-one (500 mg, 1.1 mmol), Pd(PPh3)4 (387 mg, 0.3 mmol), CuI (225 mg), LiCl (170 mg) in dioxane (40 mL) was stirred at 110 ° C for 14 hours. After completion, the resulting mixture was directly concentrated. The crude product was then further purified by silica gel column (eluted with PE / EtOAc=1 / 4) to give the title product (500 mg). MS (ESI, m / e) [M+H] + 715.4.
[0632] Step 4: 8-(7-(6-(bis(4-methoxybenzyl)amino)-3-iodo-4-methylpyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one
[0633]
[0634] A mixture of 8-(7-(6-(bis(4-methoxybenzyl)amino)-4-methylpyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decane-2-one (500 mg, 0.7 mmol), Ag2SO4 (100 mg, 0.3 mmol), I2 (500 mg, 2 mmol) in DMF (50 mL) was stirred at room temperature for 1 hour. After completion, the resulting mixture was directly poured into water and extracted with EtOAc. The crude product was then further purified by silica gel column to give the title product (300 mg). MS (ESI, m / e) [M+H] + 841.3.
[0635] Step 5: 8-(7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one
[0636]
[0637] A mixture of 8-(7-(6-(bis(4-methoxybenzyl)amino)-3-iodo-4-methylpyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decane-2-one (300 mg, 0.36 mmol), CuI (300 mg, 1.6 mmol), methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (1.5 mL) in NMP (20 mL) was stirred at 90 ° C for 1 hour. After completion, the resulting mixture was directly poured into water and extracted with EtOAc. The crude product was then further purified by silica gel column to give the title product (150 mg). MS (ESI, m / e) [M+H] + 783.4.
[0638] Step 6: 8-(7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one
[0639]
[0640] To a solution of ((2S, 4R)-4-fluoro-1-methylpyrrolidin-2-yl)methanol (150 mg, 0.94 mmol) in THF (20 mL) was added NaH (50 mg), and the mixture was stirred at room temperature for 30 minutes. Then, 8-(7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-2,8-difluoroquinazoline-4-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decane-2-one (150 mg, 0.19 mmol) was added. The reaction mixture was stirred at 50 ° C for 4 hours. After completion, the reaction was quenched with H2O. The solvent was evaporated, and the crude product was purified by silica gel column (eluted with DCM / MeOH=4 / 1) to give the title product (120 mg). MS (ESI, m / e) [M+H] + 922.3.
[0641] Step 7: 8-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one
[0642] A mixture of 8-(7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one (120 mg, 0.13 mmol) in TFA (4 mL) was stirred at 50° C. for 3 hours. After completion, the resulting mixture was directly concentrated, and the pH of the residue was adjusted to 9 with DIPEA. The residue was then purified by C18 column (eluted with H2O / CH3CN=3 / 1) to give the title product (14 mg). 1 H NMR(500MHz,CD3OD)δ7.88(s,1H),6.60(s,1H),5.50-5.31(m,1H),4.49-4.35(m,2H),4.28-4.10(m,2H),3. 87-3.75(m,2H),3.65-3.38(m,5H),3.23-3.15(m,1H),2.89(s,3H),2.51-1.98(m,13H).MS(ESI,m / e)[M+H] + 682.6.
[0643] Example 107: 1-(7-(2-amino-6-methyl-5-(trifluoromethyl)pyrimidin-4-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)piperidine-4-carbonitrile
[0644]
[0645] Step 1: 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methoxypyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile
[0646]
[0647] A mixture of 1-(7-bromo-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile (400 mg, 1.036 mmol), 4-bromo-N,N-bis(4-methoxybenzyl)-6-methylpyrimidin-2-amine (884 mg, 2.072 mmol), Pd(PPh3)4 (120 mg, 0.104 mmol), Pd(PPh3)2Cl2 (72 mg, 0.104 mmol) and Bu6Sn2 (1.2 g, 2.07 mmol) was stirred at 100°C overnight. The mixture was concentrated in vacuo and the residue was purified by silica gel column chromatography (PE / EA=4 / 1) to give the title product (329 mg, crude product). MS (ESI, m / e) [M+H] + 656.6.
[0648] Step 2: 1-(7-(2-(bis(4-methoxybenzyl)amino)-5-iodo-6-methylpyrimidin-4-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile
[0649]
[0650] 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methylpyridin-2-yl)-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile (130 mg, 0.387 mmol) and NIS (261 mg, 1.161 mmol) were added to a 50 mL round-bottom flask, and the mixture was cooled to 0 ° C. Then, HOAc (10 mL) was added. The mixture was stirred at 0 ° C for 15 to 20 minutes. Then, the mixture was diluted with EtOAc, quenched with Na2S2O3 solution, and extracted with EtOAc. The combined organic layers were concentrated under vacuum and purified by silica column chromatography (PE / EA=4 / 1) to give the title product (40 mg, 33%). MS (ESI, m / e) [M+H] + 782.3.
[0651] Step 3: 1-(7-(2-(bis(4-methoxybenzyl)amino)-6-methyl-5-(trifluoromethyl)pyrimidin-4-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile
[0652]
[0653] A mixture of 1-(7-(2-(bis(4-methoxybenzyl)amino)-5-iodo-6-methylpyrimidin-4-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile (40 mg, 0.055 mmol), CuI (21 mg, 0.11 mmol) and methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (53 mg, 0.276 mmol) in DMA (5 mL) was stirred at 120 ° C for 2 hours. The reaction mixture was cooled to room temperature and the solvent was extracted with EtOAc (20 mL*3). The combined organic phases were washed with brine (50 mL) and dried over Na2SO4. The mixture was concentrated in vacuo to give the title product, which was used directly without further purification (90 mg, crude product). MS (ESI, m / e) [M+H] + 724.5.
[0654] Step 5: 1-(7-(2-(bis(4-methoxybenzyl)amino)-6-methyl-5-(trifluoromethyl)pyrimidin-4-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)piperidine-4-carbonitrile
[0655]
[0656] To a solution of ((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizine-7a(5H)-yl)methanol (20 mg, 0.124 mmol) in THF (10 mL) was added NaH (7.5 mg, 0.186 mmol) at 0°C. The mixture was stirred at 0°C for 30 minutes. Then, 1-(7-(2-(bis(4-methoxybenzyl)amino)-6-methyl-5-(trifluoromethyl)pyrimidin-4-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile (90 mg, 0.124 mmol) was added. The mixture was stirred from 0°C to room temperature and then stirred at room temperature for another 3 hours. The mixture was quenched with water (1 mL) and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE / EA=1 / 4) to give the title product (35 mg, 32%). MS (ESI, m / e) [M+H] + 863.7.
[0657] Step 6: 1-(7-(6-amino-4-methoxy-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)piperidine-4-carbonitrile
[0658] A mixture of 1-(7-(2-(bis(4-methoxybenzyl)amino)-6-methyl-5-(trifluoromethyl)pyrimidin-4-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)piperidine-4-carbonitrile (35 mg, 0.040 mmol) and TFA (3 ml) was stirred at 50° C. for 2 hours and then at 60° C. overnight. The solvent was removed in vacuo to give the crude product, which was purified by preparative HPLC to give the title product (3.63 mg). 1 H NMR(500MHz,DMSO-d6)δ7.85(s,1H),7.80-7.58(m,2H),5.38-5.17(m,1H),4.14-3.90(m,4H ),3.66-3.50(m,2H),3.24(s,1H),3.12-2.97(m,3H),2.87-2.79(m,1H),2.16-1.68(m,10H). MS(ESI,m / e)[M+H] + 623.4.
[0659] Example 108: 1-(7-(6-amino-4-methoxy-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)piperidine-4-carbonitrile
[0660]
[0661] Step 1: 6-Bromo-4-methoxy-N,N-bis(4-methoxybenzyl)pyridin-2-amine
[0662]
[0663] At 0°C, NaH (0.43 g, 10.8 mmol) was added dropwise to a solution of 6-bromo-4-methoxypyridin-2-amine (1 g, 4.92 mmol) in DMF (20 mL), and the mixture was stirred for another 30 minutes at 0°C. Then, PMBCl (1.7 g, 10.8 mmol) was added, and the mixture was stirred at room temperature overnight. The mixture was diluted with water, filtered and the solid was collected to give the title product (2 g, 92%). MS (ESI, m / e) [M+H] + 443.1.
[0664] Step 2: 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methoxypyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile
[0665]
[0666] A mixture of 1-(7-bromo-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile (0.4 g, 0.76 mmol), 6-bromo-4-methoxy-N,N-bis(4-methoxybenzyl)pyridin-2-amine (0.5 g, 1.14 mmol), Pd(PPh3)4 (87.8 mg, 0.076 mmol), Pd(PPh3)2Cl2 (53 mg, 0.076 mmol) and Bu6Sn2 (0.66 g, 1.14 mmol) was stirred at 90°C overnight. The reaction mixture was cooled to room temperature and filtered. The filtrate was concentrated, diluted with H2O (10 mL), and then extracted with EtOAc (20 mL×3). The combined organic layers were dried over Na2SO4, filtered and concentrated to give a crude product, which was purified by silica gel chromatography (PE:EA=20:1-1:1) to give the title product (0.5 g, 72%). MS (ESI, m / e) [M+H] + 671.2.
[0667] Step 3: 1-(7-(6-(bis(4-methoxybenzyl)amino)-3-iodo-4-methoxypyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile
[0668]
[0669] To a stirred solution of 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methoxypyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile (0.47 g, 0.7 mmol) in DMF / AcOH=4:1 (5 mL) at 0°C was added NIS (0.47 g, 2.1 mmol) dropwise. The mixture was stirred at room temperature for 2 hours. The solvent was removed by reduced pressure, and the residue was diluted with saturated NaHCO3 solution (100 mL) and extracted with EtOAc (20 mL*3). The combined organic phases were washed with brine (20 mL*2) and dried over Na2SO4. The solid was filtered off and concentrated to give the crude product, which was purified by silica gel chromatography (PE:EA=20:1-1:1) to give the title product (0.45 g, 81%). MS (ESI, m / e) [M+H] + 797.1.
[0670] Step 4: 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methoxy-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile
[0671]
[0672] A mixture of 1-(7-(6-(bis(4-methoxybenzyl)amino)-3-iodo-4-methoxypyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile (0.4 g, 0.5 mmol), CuI (0.8 g, 4.2 mmol) and methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (1.6 g, 8.3 mmol) in DMA (10 mL) was stirred at 120° C. for 2 hours. The reaction mixture was cooled to room temperature and the solvent was removed in vacuo to give a crude product, which was purified by silica gel chromatography (DCM:MeOH=50:1-10:1) to give the title product (0.2 g, 48%). MS (ESI, m / e) [M+H] + 739.2.
[0673] Step 5: 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methoxy-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)piperidine-4-carbonitrile
[0674]
[0675] To a solution of 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methoxy-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile (100 mg, 0.135 mmol) and ((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizine-7a(5H)-yl)methanol (21.6 mg, 0.135 mmol) in THF (10 mL) was added NaH (8 mg, 0.2 mmol) at 0°C. The mixture was stirred at room temperature for 3 hours. The mixture was diluted with ice water and filtered to collect the solid as a crude product, which was purified by silica gel chromatography (DCM:MeOH=50:1-10:1) to give the title product (100 mg, 90%). MS (ESI, m / e) [M+H] + 878.3.
[0676] Step 6: 1-(7-(6-amino-4-methoxy-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)piperidine-4-carbonitrile
[0677] To a mixture of 1-(7-(6-(bis(4-methoxybenzyl)amino)-4-methoxy-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizine-7a(5H)-yl)methoxy)quinazolin-4-yl)piperidine-4-carbonitrile (50 mg, 0.057 mmol) in CH2Cl2 (5 mL) was added TFA (1 mL) dropwise. The mixture was stirred at room temperature for 2 hours. The solvent was removed in vacuo to give the crude product, which was purified by preparative HPLC to give the title product (10 mg, 36%). 1 H NMR(500MHz,DMSO-d6)δ7.79(s,1H),6.85(s,2H),6.22(s,1H),5.37-5.17(m,1H),4.12-3.85(m,8H ),3.65-3.55(m,2H),3.28-3.18(m,1H),3.09-3.02(m,2H),2.90-2.75(m,1H),2.19-1.70(m,10H). MS(ESI)m / e[M+H] + =638.4.
[0678] Example 109: 7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-N,N-dimethylquinazolin-4-amine
[0679]
[0680] Step 1: 6-Bromo-3-methoxy-N,N-bis(4-methoxybenzyl)pyridin-2-amine
[0681]
[0682] At 0°C, NaH (1.0 g, 25 mmol) was slowly added to a solution of 6-bromo-3-methoxypyridin-2-amine (2.0 g, 15.2 mmol) in DMF (40 mL), and the reaction mixture was stirred at 0°C for 0.5 hours, and then PMBCl (3.3 g, 21 mmol) was added. The reaction mixture was warmed to room temperature for 16 hours. EtOAc (200 mL) was added, and the organic layer was washed with water and brine and dried over Na2SO4. The filtrate was concentrated and purified by column chromatography (hexane / EtOAc=4 / 1) to give the title product (3.7 g, 83%). MS (ESI, m / e) [M+H] + 443.2.
[0683] Step 2: 1-(7-(6-(bis(4-methoxybenzyl)amino)-5-methoxypyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile
[0684]
[0685] A mixture of 1-(7-bromo-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile (1.0 g, 2.6 mmol), 6-bromo-3-methoxy-N,N-bis(4-methoxybenzyl)pyridin-2-amine (1.5 g, 3.4 mmol), Pd(PPh3)2Cl2 (150 mg, 0.21 mmol), Pd(PPh3)4 and Bu6Sn2 (1.8 g, 3.1 mmol) in dioxane (25 mL) was stirred at room temperature for 1 hour and then heated to 100°C for 16 hours. The mixture was concentrated and purified by column chromatography (hexane / EtOAc=1 / 1) to give the title product (530 mg, 30%). MS (ESI, m / e) [M+H] + 617.6.
[0686] Step 3: 1-(7-(6-(bis(4-methoxybenzyl)amino)-3-iodo-5-methoxypyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile
[0687]
[0688] To a solution of 1-(7-(6-(bis(4-methoxybenzyl)amino)-5-methoxypyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile (500 mg, 0.75 mmol) in HOAc / DMF (2 mL / 10 mL) was added NIS (500 mg, 2.22 mmol) in portions at room temperature, and the mixture was stirred at room temperature for 6 hours. EtOAc (50 mL) was added, and the organic phase was washed with water (30 mL×2) and brine (30 mL×2), dried over Na2SO4, concentrated, and purified by column chromatography (hexane / EtOAc=1 / 2) to give the title product (160 mg, 27%). MS (ESI, m / e) [M+H] + 797.4.
[0689] Step 4: 1-(7-(6-(bis(4-methoxybenzyl)amino)-5-methoxy-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile
[0690]
[0691] A mixture of 1-(7-(6-(bis(4-methoxybenzyl)amino)-3-iodo-5-methoxypyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile (160 mg, 0.2 mmol), CuI (190 mg, 1.0 mmol) and methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (300 mg, 1.56 mmol) in DMA (6 mL) was heated to 140° C. for 2 hours. The reactant was cooled to room temperature, diluted with EtOAc (50 mL), washed with water (30 mL×2) and brine (30 mL×2), and the resulting organic phase was dried over Na2SO4, concentrated, and purified by column chromatography (hexane / EtOAc=1 / 2) to give the title product (50 mg, 34%). MS (ESI, m / e) [M+H] + 739.4.
[0692] Step 5: 1-(7-(6-(bis(4-methoxybenzyl)amino)-5-methoxy-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-yl)piperidine-4-carbonitrile
[0693]
[0694] To a solution of ((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizine-7a(5H)-yl)methanol (50 mg, 0.31 mmol) in THF was added NaH (10 mg, 0.25 mmol, 60%) in portions at 0°C, and the mixture was stirred at 0°C for 30 minutes. 1-(7-(6-(bis(4-methoxybenzyl)amino)-5-methoxy-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-2,8-difluoroquinazolin-4-yl)piperidine-4-carbonitrile (50 mg, 0.068 mmol) was added in portions to the mixture at 0°C. The mixture was stirred at room temperature for another 2 hours. The reaction was quenched with saturated aqueous NH4Cl solution and extracted 3 times with EtOAc. The combined organic phases were dried over Na2SO4, concentrated, and purified by column chromatography (DCM / MeOH=10 / 1) to give the title product (35 mg, 57%). MS (ESI, m / e) [M+H] + 878.5.
[0695] Step 6: 1-(7-(6-amino-5-methoxy-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)piperidine-4-carbonitrile
[0696] A mixture of 1-(7-(6-(bis(4-methoxybenzyl)amino)-5-methoxy-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)piperidine-4-carbonitrile (35 mg, 0.039 mmol) and TFA (3 mL) was stirred at 50° C. for 16 hours. Concentrated and purified by preparative HPLC to give the title product (7 mg, 28%). 1 H NMR(500MHz,DMSO-d6)δ7.82(s,1H),7.31(s,1H),6.80(s,2H),5.43-5.23(m,1H),4.20-4.10(m,2H ),4.05-3.95(m,5H),3.64-3.60(m,2H),3.30-3.10(m,4H),2.94-2.90(m,1H),2.22-1.82(m,10H). MS(ESI,m / e)[M+H] + 638.7.
[0697] Example 110a (common intermediate): 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-ol
[0698]
[0699] Step 1: 2,4,7-Trichloro-8-fluoropyrido[4,3-d]pyrimidine
[0700]
[0701] To a solution of 7-chloro-8-fluoropyrido[4,3-d]pyrimidine-2,4-diol (10 g, 39.8 mmol) in 200 mL POCl3 was added DIPEA (10.0 mL), and the mixture was stirred at 100 °C for 4 hours. Then, the mixture was cooled and concentrated to give a brown oil. The oil was dissolved in DCM, and the solution was washed twice with ice water. The organic layer was concentrated and purified by silica gel column (PE: EtOAc = 3: 1) to give the title compound (7 g, 60%). MS (ESI, m / e) [M + H] + 252.
[0702] Step 2: 4-(Benzyloxy)-2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidine
[0703]
[0704] To a solution of 2,4,7-trichloro-8-fluoropyrido[4,3-d]pyrimidine (7 g, 28 mmol) in 100 mL of 1,4-dioxane was added benzyl alcohol (6 g, 56 mmol), DIPEA (10.8 g, 84 mmol) and molecular sieves ( 10 g). The mixture was stirred at 60°C for 16 hours. Then, it was diluted with water, and the combined organic layer was dried over sodium sulfate. The solvent was evaporated, and the residue was purified by silica gel column chromatography to give the title compound (4 g, 78%). MS (ESI, m / e) [M+H] + 324.
[0705] Step 3: 4-(Benzyloxy)-7-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidine
[0706]
[0707] To a solution of 4-(benzyloxy)-2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidine (4 g, 12.38 mmol) in 100 mL of 1,4-dioxane was added ((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methanol (3.9 g, 24.76 mmol), DIPEA (4.8 g, 37.14 mmol) and molecular sieves ( 10 g). The mixture was stirred at 80 °C for 16 hours. The mixture was diluted with water and the combined organic layers were dried over sodium sulfate. The solvent was evaporated and the residue was purified by silica gel chromatography to give the title product (3.4 g, 62%). MS (ESI, m / e) [M+H] + 447.
[0708] Step 4: 3-(4-(Benzyloxy)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-chloro-4-(trifluoromethyl)aniline
[0709]
[0710] To a 250 mL round bottom flask was added 4-(benzyloxy)-7-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidine (3.4 g, 7.6 mmol), 3-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethyl)aniline (2.9 g, 9.1 mmol), K3PO4 (3.2 g, 15.2 mmol), mesylate (diadamantyl-n-butylphosphino)-2'-amino-1,1'-biphenyl-2-yl)palladium(II) dichloromethane adduct (95% minimum) and catalytic activity. Gen.3] (0.55 g, 0.76 mmol), THF (120 mL) and H2O (24 mL). The mixture was stirred at 70°C for 3 hours. The resulting cooled mixture was concentrated and purified by flash column chromatography (DCM / MeOH=30 / 1) to give the title product (2.8 g, 61%). MS (ESI, m / e) [M+H] + 606.
[0711] Step 5: 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-ol
[0712] To a 250 mL round-bottom flask was added 3-(4-(benzyloxy)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-chloro-4-(trifluoromethyl)aniline (2.8 g, 4.6 mmol) and TFA (50 mL), and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated and diluted with DCM. The pH of the solution was adjusted to 7 with DIPEA. The mixture was then purified by reverse flash chromatography to give the title product (1.3 g, 55%). MS (ESI, m / e) [M+H] + 516.2.
[0713] Example 110: 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-cyclopropyl-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-amine
[0714]
[0715] Step 1: 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-cyclopropyl-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-amine
[0716] To a mixture of 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-ol (25 mg, 0.0485 mmol) in acetonitrile (5 mL) was added cyclopropylamine (7.2 mg, 0.126 mmol), BOP (43 mg, 0.097 mmol) and DIPEA (37.5 mg, 0.291 mmol) stepwise. The mixture was stirred at 40 °C overnight. The resulting mixture was concentrated to give a residue, which was further purified by preparative HPLC to give the title product (5.67 mg). 1 H NMR(500MHz,MeOD)δ9.08(s,1H),6.90(s,1H),6.48(s,1H),5.50-5.35(m,1H),4.58-4.44(m,2H) ,3.67–3.43(m,3H),3.25–3.12(m,2H),2.57–1.96(m,6H),0.97-0.92(m,2H),0.81-0.75(m,2H). MS(ESI,m / e)[M+H] + 555.3.
[0717] Example 111: 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-cyclobutyl-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-amine
[0718]
[0719] Example 111 was prepared by a procedure analogous to that described in Example 110, substituting cyclobutylamine for cyclopropylamine, to give the title product. 1 H NMR(500MHz,CD3OD)δ9.17(s,1H),6.91(s,1H),6.49(s,1H),5.48-5.34(m,1H),4.50 -4.39(m,2H),3.64–3.42(m,3H),3.24–3.14(m,1H),2.51–2.25(m,7H),2.17–1.82(m,5H). MS(ESI,m / e)[M+H] +569.4.
[0720] Example 112: 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-(bicyclo[1.1.1]pentan-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-amine
[0721]
[0722] Example 112 was prepared by a procedure analogous to that described in Example 110, substituting bicyclo[1.1.1]pentan-1-amine for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ9.10(s,1H),6.90(s,1H),6.49(s,1H),5.47-5.36(m,1H),4.50–4 .37(m,2H),3.67–3.42(m,3H),3.24–3.15(m,1H),2.62–2.31(m,9H),2.28–1.96(m,4H). MS(ESI,m / e)[M+H] + 581.4.
[0723] Example 113: 3-Chloro-5-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-morpholinopyrido[4,3-d]pyrimidin-7-yl)-4-(trifluoromethyl)aniline
[0724]
[0725] Example 113 was prepared by a procedure analogous to that described in Example 110, substituting morpholine for cyclopropylamine, to provide the title product. 1 H NMR(500MHz,CD3OD)δ9.05(s,1H),6.94–6.88(m,1H),6.53–6.46(m,1H),5.48-5.34(m,1H),4.50-4.34 (m,2H),4.14-4.08(m,4H),3.87-3.85(m,4H),3.60–3.42(m,3H),3.23–3.14(m,1H),2.52–1.94(m,6H). MS(ESI,m / e)[M+H] + 585.3.
[0726] Example 114: 3-Chloro-5-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-((S)-3-methylmorpholino)pyrido[4,3-d]pyrimidin-7-yl)-4-(trifluoromethyl)aniline
[0727]
[0728] Example 114 was prepared by a procedure analogous to that described in Example 110, substituting (S)-3-methylmorpholine for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ9.02(s,1H),6.98–6.84(m,1H),6.54–6.47(m,1H),5.52-5.32(m,1H),4.95–4.92 (m,1H),4.55–4.38(m,3H),4.05–3.53(m,8H),3.29–3.24(m,1H),2.59–1.99(m,6H),1.65-1.55(m,3H). MS(ESI,m / e)[M+H] + 599.2.
[0729] Example 115: 3-Chloro-5-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-((R)-3-methylmorpholino)pyrido[4,3-d]pyrimidin-7-yl)-4-(trifluoromethyl)aniline
[0730]
[0731] Example 115 was prepared by a procedure analogous to that described in Example 110, substituting (R)-3-methylmorpholine for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ9.00(s,1H),6.95–6.84(m,1H),6.55–6.47(m,1H),5.42–5.32(m,1H),4.50–4.35 (m,3H),4.05–3.58(m,5H),3.46–3.36(m,3H),3.20–3.10(m,1H),2.48–1.89(m,6H),1.65–1.55(m,3H). MS(ESI,m / e)[M+H] + 599.4.
[0732] Example 116: 3-Chloro-5-(4-((S)-3-ethylmorpholino)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-4-(trifluoromethyl)aniline
[0733]
[0734] Example 116 was prepared by a procedure analogous to that described in Example 110, substituting (S)-3-ethylmorpholine for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ9.02(s,1H),6.95–6.86(m,1H),6.60–6.41(m,1H),5.50–5.32(m,1H),4.47–4.26 (m,3H),4.01–3.92(m,3H),3.82–3.49(m,6H),3.24–3.17(m,1H),2.50–2.01(m,8H),1.05–0.94(m,3H). MS(ESI,m / e)[M+H] + 613.2.
[0735] Example 117: 3-Chloro-5-(4-((R)-3-ethylmorpholino)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-4-(trifluoromethyl)aniline
[0736]
[0737] Example 117 was prepared by a procedure analogous to that described in Example 110, substituting (R)-3-ethylmorpholine for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ9.04(s,1H),6.93–6.89(m,1H),6.53–6.48(m,1H),5.57–5.41(m,1H),4.60–4.27 (m,3H),4.01–3.95(m,3H),3.82–3.62(m,6H),2.57–2.43(m,2H),2.36–2.05(m,6H),1.02–0.96(m,3H). MS(ESI,m / e)[M+H] + 613.2.
[0738] Example 118: 3-Chloro-5-(4-((3S,5S)-3,5-dimethylmorpholino)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-4-(trifluoromethyl)aniline
[0739]
[0740] Example 118 was prepared by a procedure analogous to that described in Example 110, substituting (3S,5S)-3,5-dimethylmorpholine for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ9.12(s,1H),6.95–6.89(m,1H),6.54–6.47(m,1H),5.54-5.40(m,1H),4.60-4.50 (m,2H),4.26-4.18(m,2H),4.12-4.04(m,2H),3.73–3.53(m,5H),2.63–2.00(m,6H),1.27–1.18(m,6H). MS(ESI,m / e)[M+1] + 613.5.
[0741] Example 119: 3-Chloro-5-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-(2-methylmorpholino)pyrido[4,3-d]pyrimidin-7-yl)-4-(trifluoromethyl)aniline
[0742]
[0743] Example 119 was prepared by a procedure analogous to that described in Example 110, substituting 2-methylmorpholine for cyclopropylamine, to provide the title product. 1 H NMR (500MHz, CD3OD) δ9.13–8.96(m,1H),7.05–6.84(m,1H),6.59–6.42(m,1H),5.53-5.36(m,1H),4.60–4.49(m,3H),4.48–4. 41(m,1H),4.07–3.98(m,1H),3.81–3.73(m,2H),3.63–3.56(m,3H),3.29–3.22(m,3H),2.56–1.99(m,6H),1.29–1.21(m,3H). MS(ESI,m / e)[M+H] + 599.2.
[0744] Example 120: ((2S)-4-(7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-8-fluoro-2-((2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)morpholin-2-yl)methanol
[0745]
[0746] Example 120 was prepared by a procedure analogous to that described in Example 110, substituting (S)-morpholin-2-ylmethanol for cyclopropylamine to give the title product. 1H NMR (500 MHz, CD3OD) δ 9.07 (s, 1H), 6.91 (s, 1H), 6.50 (s, 1H), 5.50-5.34 (m, 1H), 4.68-4.32 (m, 4H), 4.08-4.05 (m, 1H), 3.84-3.44 (m, 9H), 3.28-3.34 (m, 1H), 2.51-1.92 (m, 6H). MS (ESI, m / e) [M+H] + 615.5.
[0747] Example 121: 1-(7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)piperidine-4-carbonitrile
[0748]
[0749] Example 121 was prepared by a procedure analogous to that described in Example 110, substituting piperidine-4-carbonitrile for cyclopropylamine to give the title product. 1H NMR (500 MHz, CD3OD) δ 9.02 (s, 1H), 6.91 (s, 1H), 6.50 (s, 1H), 5.52-5.34 (m, 1H), 4.54-4.25 (m, 4H), 3.97-3.86 (m, 2H), 3.62-3.47 (m, 3H), 3.26-3.18 (m, 2H), 2.57-1.98 (m, 10H). MS (ESI, m / e) [M+H] + 608.2.
[0750] Example 122: 1-(7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3-fluoropiperidine-4-carbonitrile
[0751]
[0752] Example 122 was prepared by a procedure analogous to that described in Example 110, substituting 3-fluoropiperidine-4-carbonitrile for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ9.07(s,1H),6.92(s,1H),6.51(s,1H),5.53-5.36(m,1H),5.20-5 .02(m,1H),4.79–4.46(m,4H),4.00–3.85(m,1H),3.65–3.50(m,5H),2.54–2.01(m,8H). MS(ESI,m / e)[M+H] + 626.2.
[0753] Example 123: 1-(7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidine-4-carbonitrile
[0754]
[0755] Example 123 was prepared by a procedure analogous to that described in Example 110, substituting 3-methylpiperidine-4-carbonitrile for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ9.04(s,1H),6.91(s,1H),6.50(s,1H),5.58–5.40(m,1H) ,4.71–4.55(m,3H),3.75–3.60(m,6H),2.88–2.05(m,10H),1.30–1.18(m,3H). MS(ESI,m / e)[M+H] + 622.2.
[0756] Example 124: 1-(7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-2-methylpiperidine-4-carbonitrile
[0757]
[0758] Example 124 was prepared by a procedure analogous to that described in Example 110, substituting 2-methylpiperidine-4-carbonitrile for cyclopropylamine, to provide the title product. 1H NMR(500MHz,CD3OD)δ8.97(s,1H),6.98–6.86(m,1H),6.64–6.45(m,1H),5.58–5.41(m,1H),5.20–5.06( m,1H),4.65–4.48(m,3H),3.89–3.60(m,4H),3.39–3.33(m,2H),2.68–1.99(m,10H),1.56–1.50(m,3H). MS(ESI,m / e)[M+H] + 622.2.
[0759] Example 125: 2-(1-(7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)piperidin-4-yl)acetonitrile
[0760]
[0761] Example 125 was prepared by a procedure analogous to that described in Example 110, substituting 2-(piperidin-4-yl)acetonitrile for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ9.01(s,1H),6.91(s,1H),6.50(s,1H),5.53-5.37(m,1H),4.85-4.70(m,2H ),4.56-4.40(m,2H),3.80-3.38(m,6H),2.56-2.28(m,4H),2.26-1.95(m,7H),1.62-1.56(m,2H). MS(ESI,m / e)[M+H] + 622.5.
[0762] Example 126: 2-(1-(7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)piperidin-3-yl)acetonitrile
[0763]
[0764] Example 126 was prepared by a procedure analogous to that described in Example 110, substituting 2-(piperidin-3-yl)acetonitrile for cyclopropylamine to provide the title product. 1H NMR(500MHz,CD3OD)δ9.05(s,1H),6.91(s,1H),6.50(s,1H),5.54-5.37(m,1H) ,4.82–4.70(m,2H),4.60–4.45(m,3H),3.77–3.55(m,4H),2.64–1.50(m,14H). MS(ESI,m / e)[M+H] + 622.2.
[0765] Example 127: 1-(7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)piperidin-4-ol
[0766]
[0767] Example 127 was prepared by a procedure analogous to that described in Example 110, substituting piperidin-4-ol for cyclopropylamine, to provide the title product. 1 H NMR(500MHz,CD3OD)δ9.03(s,1H),6.92(s,1H),6.48(s,1H),5.59-5.42(m,1H),4.65–4.50(m,3H ),4.46–4.33(m,2H),4.10–4.00(m,1H),3.90–3.67(m,5H),2.65–2.02(m,8H),1.80–1.69(m,2H). MS(ESI,m / e)[M+H] + 599.2.
[0768] Example 128: (R)-1-(7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol
[0769]
[0770] Example 128 was prepared by a procedure analogous to that described in Example 110, substituting (3R)-3-methyl-piperidin-3-ol for cyclopropylamine to give the title product. 1H NMR(500MHz,CD3OD)δ9.21(s,1H),6.92(s,1H),6.50(s,1H),5.65-5.48(m, 1H),4.74–4.68(m,1H),4.66–4.58(m,2H),4.36–4.24(m,1H),4.06–3.84(m, 3H),3.65–3.56(m,1H),3.51–3.37(m,2H),2.78–2.54(m,2H),2.48–2.40(m ,1H),2.38–2.31(m,2H),2.22–2.08(m,2H),1.89–1.75(m,3H),1.29(s,3H). MS (ESI, m / e) [M+H] + 613.2.
[0771] Example 129: (S)-1-(7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol
[0772]
[0773] Example 129 was prepared by a procedure analogous to that described in Example 110, substituting (S)-3-methyl-piperidin-3-ol for cyclopropylamine to give the title product. 1 H NMR(500MHz,CD3OD)δ9.18(s,1H),6.91(s,1H),6.50(s,1H),5.57–5.38(m,1H),4.61–4.5 0(m,2H),4.48–4.40(m,1H),4.33–4.22(m,1H),3.75–3.53(m,4H),3.46–3.38(m,1H),3.29 -3.22(m,1H),2.59–2.38(m,2H),2.34–2.26(m,1H),2.24–1.99(m,4H),1.89–1.73(m,3H),1.28(s,3H). MS(ESI,m / e)[M+H] + 613.2.
[0774] Example 130: 1-(7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3-ethylpiperidin-3-ol
[0775]
[0776] Example 130 was prepared by a procedure analogous to that described in Example 110, substituting 3-ethylpiperidin-3-ol for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ9.20(s,1H),6.91(s,1H),6.50(s,1H),5.51-5.34(m,1H),4.64-4. 28(m,4H),3.69–3.39(m,5H),3.26–3.18(m,1H),2.53–1.50(m,12H),1.02-0.94(m,3H). MS(ESI,m / e)[M+H] + 627.4.
[0777] Example 131: 3-(7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3-azabicyclo[4.1.0]heptan-1-ol
[0778]
[0779] Example 131 was prepared by a procedure analogous to that described in Example 110, substituting 3-azabicyclo[4.1.0]heptan-1-ol for cyclopropylamine to provide the title product. 1 H NMR(500MHz,CD3OD)δ9.06(s,1H),6.91(s,1H),6.50(s,1H),5.53-5.36(m,1H),4.54-4.43(m,3H),4.20-4.17(m,1H),4.06–3 .97(m,1H),3.73-3.52(m,4H),3.29-3.21(m,1H),2.57-1.82(m,8H),1.47-1.38(m,1H),1.03-0.97(m,1H),0.64-0.58(m,1H). MS(ESI,m / e)[M+H] + 611.5.
[0780] Determination
[0781] Biochemical assays
[0782] KRAS WT and KRAS G12V probe replacement assay
[0783] The assay is used to identify compounds that bind to GDP-loaded KRAS proteins and are able to displace biotinylated probes that occupy KRAS binding sites. GST-labeled GDP-loaded WT KRAS (amino acids 1-169) and GST-labeled GDP-loaded KRAS G12V (amino acids 1-169) were expressed in Escherichia coli and purified in-house. All proteins and reaction solutions were prepared in an assay buffer containing 50mM HEPES pH7.5, 50mM NaCl, 1mM MgCl2, 1mM TCEP, 0.01% BSA, and 0.008% Brij-35. Purified WT KRAS (3nM final concentration) or KRAS G12V protein (2nM final concentration) was incubated with 3-fold serial dilutions of the compound in an assay plate (384-well microplate, black, Corning). The plate was incubated at 24°C for 1 hour. After incubation, biotinylated probe 1 for WT KRAS (60 nM final assay concentration) and biotinylated probe 2 for KRAS G12V (2.5 nM final assay concentration) were added to the assay plate, respectively. After incubation for 1 hour at 24°C, MabAnti-GST-Tb cryptate (Cisbio) and streptavidin-XL665 (Cisbio) were added and incubated for another 1 hour at 24°C. TR-FRET signals (ex337nm, em665nm / 620nm) were read on a BMG PHERAstar FSX instrument. The percentage of inhibition of KRAS protein binding to the biotinylated probe in the presence of increasing concentrations of compound was calculated based on the ratio of fluorescence at 665nm to fluorescence at 620nm. The data were fitted to a four-parameter logistic model by Dotmatics to calculate the IC for each compound. 50 value.
[0784] KRAS WT and KRAS G12D probe displacement assay
[0785] The assay is used to identify compounds that bind to GDP-loaded KRAS proteins and are able to displace biotinylated probes that occupy KRAS binding sites. GST-labeled GDP-loaded WT KRAS (amino acids 1-188) and GST-labeled GDP-loaded KRAS G12D (amino acids 1-188) were expressed in Escherichia coli and purified in-house. All proteins and reaction solutions were prepared in an assay buffer containing 50mM HEPES pH7.5, 50mM NaCl, 1mM MgCl2, 1mM TCEP, 0.01% BSA, and 0.008% Brij-35. Purified WT KRAS (3nM final concentration) or KRAS G12D protein (0.5nM final concentration) was incubated with 3-fold serial dilutions of the compound in an assay plate (384-well microplate, black, Corning). The plate was incubated at 24°C for 1 hour. After incubation, biotinylated probe 1 for WT KRAS (60 nM final assay concentration) and biotinylated probe 2 for KRAS G12D (4 nM final assay concentration) were added to the assay plate, respectively. After incubation for 1 hour at 24°C, Mab Anti-GST-Tb cryptate (Cisbio) and streptavidin-XL665 (Cisbio) were added and incubated for another 1 hour at 24°C. TR-FRET signals (ex337nm, em665nm / 620nm) were read on a BMG PHERAstar FSX instrument. The percentage of inhibition of KRAS protein binding to the biotinylated probe in the presence of increasing concentrations of compound was calculated based on the ratio of fluorescence at 665nm to fluorescence at 620nm. The data were fitted to a four-parameter logistic model by Dotmatics to calculate the IC for each compound. 50 value.
[0786] KRAS G12V pERK assay
[0787] The SW620 cell line was used in this study. The cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (Thermo Fisher), 50 units / mL penicillin and streptomycin (Thermo Fisher) and maintained at 37°C in a humidified atmosphere with 5% CO2 in the air. The cells were revived from frozen cells within 30 passages of the purchased original cells. 40,000 cells per well were seeded in a 96-well plate and incubated overnight. The cells were treated with a 10-point dilution series. The final compound concentration was 0 μM to 10 μM. After 2 hours of compound treatment, the cells were lysed and the pERK1 / 2 (THR202 / TYR204) levels in the cell lysates were detected by the HTRF kit (Cisbio). In brief, a total of 16 μL of cell lysate from each well of the 96-well plate was transferred to a 384-well white assay plate. Lysate from each well was incubated with 2 μL of Eu3+-cryptate (donor) labeled anti-phospho-ERK1 / 2 and 2 μL of D2 (acceptor) labeled anti-phospho-ERK1 / 2 antibody (Cisbio) at room temperature in the dark overnight. When the donor and acceptor are in close proximity, laser excitation of the donor triggers fluorescence resonance energy transfer (FRET) toward the acceptor, which then fluoresces at a wavelength of 655 nm. The FRET signal was measured using a PHERAstar FSX reader (BMG Labtech). IC50 determinations were performed by fitting a curve of percent inhibition versus the logarithm of the inhibitor concentration using Dotmatics.
[0788] KRAS G12D pERK assay
[0789] AsPC-1 cell line was used in this study. Cells were maintained in RPMI-1640 supplemented with 10% fetal bovine serum (Thermo Fisher), 50 units / mL penicillin and streptomycin (Thermo Fisher) and maintained at 37°C in a humidified atmosphere containing 5% CO2 in the air. Cells were revived from cryopreserved cells within 30 passages of the purchased original cells. 30,000 cells per well were seeded in a 96-well plate and incubated overnight. Cells were treated with a 10-point dilution series. The final compound concentration was 0 μM to 10 μM. After 2 hours of compound treatment, cells were lysed and pERK1 / 2 (THR202 / TYR204) levels in cell lysates were detected by HTRF kit (Cisbio). In brief, a total of 16 μL of cell lysate from each well of a 96-well plate was transferred to a 384-well white assay plate. Lysate from each well was incubated with 2 μL of Eu3+-cryptate (donor) labeled anti-phospho-ERK1 / 2 and 2 μL of D2 (acceptor) labeled anti-phospho-ERK1 / 2 antibody (Cisbio) at room temperature overnight in the dark. When the donor and acceptor are in close proximity, excitation of the donor with a laser triggers fluorescence resonance energy transfer (FRET) toward the acceptor, which then fluoresces at a wavelength of 655 nm. The FRET signal was measured using a PHERAstar FSX reader (BMG Labtech). IC was performed by fitting a curve of percent inhibition versus the logarithm of the inhibitor concentration using Dotmatics 50 Determination.
[0790] Active Table
[0791] Each compound in Table 1, Table 2, and Table 3 was tested in one or more of the biochemical assays provided herein and found to be active therein.
[0792] Table 1.
[0793]
[0794] Table 2
[0795]
[0796]
[0797] Table 3.
[0798]
[0799] As shown by the data in Tables 1 to 3, the present inventors surprisingly and unexpectedly discovered that the exemplary compounds in Tables 1 to 3 can modulate or inhibit the activity of KRAS G12V.
[0800] A number of references have been cited, the disclosures of which are incorporated herein by reference in their entireties.
Claims
1. A compound of formula (I): or a pharmaceutically acceptable salt, tautomer, stereoisomer or enantiomer thereof, in: Ring A is X is N or CR 2 ; Y is N or C-CN; Z is N or CR 3 ; W is N or CR 5 ; V is N or CR 7 ; R 1 Yes - NR 1a R 1b ; R 2 is halogen, or unsubstituted or substituted alkyl; R 3 is halogen, or unsubstituted or substituted alkyl; R 4 It is halogen, -NO 2 , or unsubstituted or substituted alkyl; R 5 is hydrogen, halogen or -CN; R 7 is hydrogen, halogen or -CN; R 8 , R 9 and R 10 Each of is independently hydrogen, halogen, unsubstituted or substituted alkyl or -OH; R 1a and R 1b are each independently hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocyclylalkyl, provided that R 1a and R 1b not all hydrogen; or R 1a and R 1b Together with the nitrogen atom to which they are attached they form an unsubstituted or substituted heterocyclic group.
2. The compound according to claim 1, Wherein ring A is 3. The compound of claim 2, wherein Y is N.
4. The compound of claim 2, wherein Y is C-CN.
5. The compound of claim 2, wherein X is CR 2 .
6. A compound as described in any one of claims 2 to 5, wherein R 2 is halogen, or unsubstituted or substituted alkyl; preferably Cl or CF 3 CF is more preferred 3 .
7. A compound as described in any one of claims 2 to 6, wherein R 1 Yes - NHR 1a .
8. The compound of claim 7, wherein R 1a is an unsubstituted or substituted cycloalkyl group, or an unsubstituted or substituted heterocyclic group, wherein R 1a At least one ring of is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; preferably cyclopropyl.
9. The compound according to claim 1, Wherein ring A is 10. The compound of claim 9, wherein X is CR 2 .
11. A compound as described in any one of claims 2 to 6, wherein R 1a and R 1b Together with the nitrogen atom to which they are attached, they form an unsubstituted or substituted monocyclic heterocyclic group or an unsubstituted or substituted spiro heterocyclic group containing 0 or 1 or 2 additional heteroatoms selected from oxygen, nitrogen or optionally oxidized sulfur, preferably R 1 is an unsubstituted or substituted heterocyclic group selected from the group consisting of an unsubstituted or substituted azetidinyl group, an unsubstituted or substituted pyrrolidinyl group, an unsubstituted or substituted piperidinyl group, an unsubstituted or substituted azepanyl group, an unsubstituted or substituted Unsubstituted or substituted Unsubstituted or substituted Unsubstituted or substituted or unsubstituted or substituted 12. The compound according to claim 1, Wherein ring A is 13. The compound of claim 12, wherein X is CR 2 .
14. The compound of claim 13, wherein R 2 is halogen, or unsubstituted or substituted alkyl; preferably Cl or CF 3 ; More preferably Cl.
15. The compound of claim 14, wherein ring A is 16. A compound as described in any one of claims 12 to 15, wherein R 1a and R 1b Together with the nitrogen atom to which they are attached, they form an unsubstituted or substituted monocyclic heterocyclic group or an unsubstituted or substituted spiro heterocyclic group containing 0, 1 or 2 additional heteroatoms selected from oxygen, nitrogen or optionally oxidized sulfur; preferably, R 1 is an unsubstituted or substituted heterocyclic group selected from the group consisting of an unsubstituted or substituted azetidinyl group, an unsubstituted or substituted pyrrolidinyl group, an unsubstituted or substituted piperidinyl group, an unsubstituted or substituted morpholinyl group, or an unsubstituted or substituted 17. A compound as described in any one of claims 12 to 14, wherein R 1 yes 18. The compound according to claim 17, Wherein ring A is 19. The compound of claim 12, wherein X is N.
20. The compound of claim 19, wherein ring A is 21. A compound as described in any one of claims 19-20, wherein R 1 Yes - NHR 1a .
22. The compound of claim 21, wherein R 1a is an unsubstituted or substituted cycloalkyl group, or an unsubstituted or substituted heterocyclic group, wherein R 1a At least one ring of is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; preferably cyclopropyl.
23. A compound as described in any one of claims 19-20, wherein R 1a and R 1b Together with the nitrogen atom to which they are attached, they form an unsubstituted or substituted monocyclic heterocyclic group or an unsubstituted or substituted spiro heterocyclic group containing 0 or 1 or 2 additional heteroatoms selected from oxygen, nitrogen or optionally oxidized sulfur, preferably R 1 At least one ring of is piperidinyl or morpholinyl.
24. The compound of claim 23, wherein R 1 Optionally one or more C 1-4 Alkyl, halogen, -CN or -OH, wherein the C 1-4 Each of the alkyl groups is independently optionally substituted with one or more halogen, -CN or -OH.
25. The compound of claim 19, wherein R 1 yes 26. The compound of claim 25, wherein ring A is 27. A compound as described in any one of claims 1 to 26, wherein R 1a and R 1b Together with the nitrogen atom to which they are attached they form an unsubstituted or substituted monocyclic heterocyclyl, an unsubstituted or substituted bicyclic heterocyclyl, an unsubstituted or substituted tricyclic heterocyclyl or an unsubstituted or substituted spirocyclic heterocyclyl.
28. A compound as described in any one of claims 1 to 26, wherein R 1 Not unsubstituted or substituted piperazinyl.
29. A compound as described in any one of claims 1 to 26, wherein R 1 Not unsubstituted or substituted Unsubstituted or substituted Unsubstituted or substituted Unsubstituted or substituted Unsubstituted or substituted Unsubstituted or substituted or unsubstituted or substituted 30. A compound as described in any one of claims 1-26, wherein R 1 is not unsubstituted or substituted 3,8-diazabicyclo[3.2.1]octan-3-yl, or unsubstituted or substituted 31. The compound of any one of claims 1-26, wherein the compound is selected from Table 1, Table 2, and Table 3.
32. A pharmaceutical composition comprising an effective amount of a compound as described in any one of claims 1 to 31, or a pharmaceutically acceptable salt, tautomer, isotopomer, stereoisomer or prodrug thereof, and a pharmaceutically acceptable carrier, excipient or vehicle.
33. A method for inhibiting the activity of a KRAS mutant protein in a cell, the method comprising contacting the cell with an effective amount of a compound according to any one of claims 1 to 31 or a pharmaceutically acceptable salt, tautomer, isotopologue, stereoisomer or prodrug thereof, optionally wherein the KRAS mutant protein is a KRAS G12D and / or G12V mutant protein.
34. A method for treating or preventing cancer, the method comprising administering to a subject in need thereof an effective amount of a compound as described in any one of claims 1 to 31 or a pharmaceutically acceptable salt, tautomer, isotopomer, stereoisomer or prodrug thereof, optionally wherein the cancer is mediated by a KRAS mutation; preferably a KRAS G12D and / or G12V mutation.
